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ABSTRACT 
The so-called “party drug” 3,4-Methylenedioxymethamphetamine (MDMA, or 
ecstasy) may share many of the addictive properties common to other CNS 
stimulants.  In humans MDMA is primarily consumed orally in one more pills per 
session.  However, animal research has mostly focused on examining the effects of 
MDMA as a function of other routes of administration.  Route of administration can 
have profound effects on the subjective and reinforcing properties of drugs of 
abuse.  This thesis assessed the locomotor-activating and reinforcing properties of 
MDMA when delivered orally.  MDMA-induced hyperlocomotion was used to 
examine magnitude of response and onset of action as a function of ip, sc and oral 
administration.  Significant route-dependant effects were found with ip producing 
higher locomotor activity than sc and oral respectively.  Onset of action was slower 
for subcutaneous administration compared with both ip and oral administration.  The 
reinforcing properties of MDMA were examined by use of the self-administration 
procedure.  Oral MDMA self-administration was firstly examined using simple 
schedules of reinforcement as a function of two different vehicle substrates, water 
(under water deprivation) and saccharin.  Oral MDMA maintained responding and 
reliable dose-response curves were obtained under both water and saccharin 
vehicle conditions.  However, both saccharin and water vehicle conditions also 
acted as strong reinforcers in these studies.  Further studies utilising a behavioural 
economic approach were conducted in order to delineate the reinforcing effects of 
MDMA from that of its parent vehicle.  In addition, demand-curve analysis using 
both the Linear-Elasticity model (Hursh et al., 1988, 1989) and the Exponential 
Model of Demand (Hursh & Silberberg, 2008) were compared in order to evaluate 
each model and assess the relative reinforcing efficacy of oral MDMA.  Demand 
curves for the oral self-administration of MDMA revealed that responding for MDMA 
was more elastic (lower Pmax) than responding for saccharin-alone indicating that 
saccharin functioned as stronger reinforcer than did MDMA+saccharin.  The results 
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of these studies provide evidence for the positive-reinforcing effects of MDMA when 
it is delivered via the oral route of administration, however, the relative reinforcing 
efficacy of orally delivered MDMA appears to be low.      
3 
 
ASSESSMENT OF THE REINFORCING PROPERTIES OF ORALLY ADMINISTERED MDMA 
(„ECSTASY‟) IN RATS  
 
The popular club drug 3,4-methylenedioxymethamphetamine (MDMA) or „ecstasy‟ is 
a prominent drug that continues to be abused around the world.  The United Nations 
Office on Drugs and Crime (UNODC) estimated that in 2008 there were between 
10.5 and 25.8 million users of ecstasy and related compounds (MDA, MDEA, MDA) 
accounting for approximately 0.2 to 0.6% worldwide prevalence in the 15-64 age 
bracket (World Drug Report 2010, UNODC).  MDMA use in New Zealand appears 
to be of particular concern as the Oceania region accounts for the highest 
percentage prevalence rates of ecstasy-group drug use in the world with 3.6% to 
4% of people aged 15-64 estimated to have used ecstasy in the past year (World 
Drug Report, 2010, UNODC).  From 1998 to 2006 MDMA use in New Zealand 
increased with the percentage of people reporting previous use increasing from 3.1 
to 8.0%.  Users reporting MDMA use in the past year rose from 1.5 to 3.9% across 
the same time span (Wilkins & Sweetsur, 2008).  The continued increase in 
popularity of MDMA as a drug of abuse has resulted in parallel increases in 
research into the addictive and long-term consequences of MDMA use (Green, 
2004).   
Never intended as a recreational drug, MDMA was first synthesized by 
pharmaceutical company Merck in 1912.  MDMA was originally patented as part of 
a group of chemical intermediates in the syntheses for a novel clotting agent 
(Freudenmann, Öxler & Bernschneider-Reif, 2006).  It was not till the early 1970‟s 
that MDMA re-emerged as a therapeutic agent (as an adjunct to psychotherapy), 
and also for it‟s non-therapeutic recreational effects (Grinspoon & Bakalar, 1986).  
MDMA is one of a number of „club drugs‟ also including GHB, flunitrazepam 
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(„roofies‟), ketamine and LSD, so called due to their high frequency of use at night 
clubs and all night dance parties known as „raves‟ (Teter & Guthrie, 2001).  MDMA 
further rose to prominence in the 1980‟s and 1990‟s as a drug associated primarily 
with the rave scene (Parrott, 2001).  MDMA was originally known as „empathy‟ due 
its related psychoactive properties, though it later acquired the name the „ecstasy‟, 
it‟s most common name (Parrott, 2001).  In addition, MDMA has also been known 
by various other names including, E, X, XTC, adam and the „love drug‟ (Freye, 
2009; Smith, Larive & Romanelli, 2002).           
In 1985 the US Drug Enforcement Agency used its emergency powers to classify 
MDMA as a Schedule I drug reserved for those drugs that have high abuse liability 
and no confirmed therapeutic actions (Green, Mechan, Elliott, O‟Shea & Colado, 
2003; Green, 2004; Parrott, 2001).  In New Zealand MDMA is classified as a Class 
B drug with high risk of harm (Misuse of Drugs Act, 1975).  Despite this, MDMA use 
continues to grow worldwide.                      
Ecstasy is primarily consumed in one or more oral doses most often in pill form, 
though it also available in capsules or as powder (Smith et al., 2002; Teter & 
Guthrie, 2001).  The main active ingredient in ecstasy is MDMA and a typical pill 
contains approximately 80-150mg, though purity, doses and presence of other 
active ingredients can vary by pill type (Teter & Guthrie, 2001; Green et al., 2003).      
Generally, MDMA has been considered a „safe‟ drug not only by users but also the 
general public (Timár, Gyarmati, Szabó & Fürst, 2003).  Part of this misconception 
may stem from the relatively low reports of MDMA-related death, for example, 
despite an estimated 500,000 people taking Ecstasy in the UK on any given 
weekend estimates for MDMA-related deaths are estimated to be just 12 per year 
(Green et al., 2003).  Using a sample collected directly from a nightclub rave, 
Yacoubian and colleagues found that ecstasy non-users were more likely to 
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perceive risk associated both long-term and short-term use of MDMA than were 
past-year MDMA users (Yacoubian, Boyle, Harding & Loftus, 2003).      
The perception of safety related to MDMA use is in stark contrast to the scientific 
evidence indicating that MDMA can cause long-term damage to serotonin neurons 
in a variety of experimental species including rats (Broening, Bowyer & Slikker, 
1995; Scanzello, Hatzidimitriou, Martello, Katz & Ricaurte, 1993; Schenk, Hely, 
Lake, Daniela, Gittings & Mash, 2007), guinea pigs (Saadat, Elliott, Colado & 
Green, 2004) and non-human primates (Scheffel et al. 1998; Hatzidimitrou, McCann 
& Ricaurte, 1999).  Studies conducted using rodents have indicated some recovery 
of function of the serotonin system over time with levels returning to near baseline 
levels after 52 weeks (Scanzello et al., 1993).  However, deficits in non-human 
primates have been shown to persist for as long as seven years raising concerns 
about the severity of MDMA-induced serotonin neurotoxicity in humans 
(Hatzidimitriou et al., 1999).  The evidence for MDMA-induced serotonin 
neurotoxicity in humans is less clear (Curran, 2000; Steele, McCann & Ricaurte, 
1994), however studies conducted with positron emission tomography (PET) have 
shown decreased serotonin transporter binding in MDMA users compared with 
controls (McCann, Szabo, Scheffel, Dannals & Ricaurte, 1998).  
 
Pharmacology of MDMA 
MDMA is a ring-substituted amphetamine derivative that is structurally similar to 
CNS stimulants like methamphetamine, and hallucinogens such as mescaline 
(Schmidt, Leven & Lovenberg, 1987; Steel et al., 1994; Green et al., 2003, Farré et 
al., 2004).  However, due to the unique properties of MDMA it cannot be classified 
as either “a true hallucinogen nor a potent stimulant” (Stone, Stahl, Hanson & Gibb, 
1986, p.41).  Instead the term „entactogen‟ has been proposed as a new class of 
6 
 
drug to describe the effects of MDMA (Nichols, 1986; Oberlender & Nichols, 1988; 
Vollenweider, Gamma, Liechti & Huber, 1998; Morgan, 2000; Liechti & 
Vollenweider, 2001).  Nichols reports that the term „entactogen‟ relates to its ability 
to produce “a touching from within” (Nichols, 1986, p.308), a desirable trait initially 
reported to be of interest for therapeutic use.   
Depending on drug doses and metabolism the acute effects of MDMA generally 
manifest between 30-60 minutes after ingestion and the peak effects are seen 
approximately 60-120 minutes after ingestion (Kolbrich et al., 2008b).  The effects of 
a typical single oral dose of 80-150 mg of MDMA last for approximately 3-5 hours 
(Liechti & Vollenweider, 2001; Green et al., 2003). 
Subjective effects of MDMA include a feeling of „closeness‟ to others (Peroutka, 
Newman & Harris, 1988) and an increased state of well-being, happiness, 
extroversion and sociability (Liechti, Gamma & Vollenweider, 2001).  MDMA also 
has euphoric properties producing a „high‟, like many other CNS stimulants (Liechti 
& Vollenweider, 2001).  MDMA does not produce classic hallucinations like other 
psychotropic drugs; rather users report an altered emotional consciousness.  
However, some individuals experience visual hallucinations, though these 
hallucinations are typically not well formed (as compared with other prominent 
psychotropic drugs).  These hallucinations tend to manifest as flashes of light, 
colours and patterns serving to provide increased vividness and distortion for the 
user (Peroutka et al.; Liechti et al. 2001).   
Physiological effects of MDMA include increases in heart rate, body temperature, 
and in both systolic and diastolic blood pressure.  (Kolbrich et al., 2008b; 
Vollenweider et al. 1998).  While modest effects on body temperature have been 
found in controlled human studies, the effects on temperature are almost certainly 
impacted by the conditions in which MDMA is generally taken; most usually hot 
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nightclubs or „raves‟ with non-stop dancing, concurrent use of other drugs/alcohol 
and often-times poor access to hydration (Green, O‟Shea & Colado, 2004).  
Tachycardia, jaw clenching and teeth grinding (bruxism), lack of appetite, difficulty 
concentrating, impaired balance, insomnia, forgetfulness and dry month/thirst have 
also been commonly reported symptoms of MDMA ingestion (Peroutka et al., 1988; 
Vollenweider et al. 1998).   
 
Cellular mechanisms of MDMA action   
MDMA is a potent indirect monoamine agonist and reuptake inhibitor that results 
primarily in the release of 5-HT and dopamine in the brain (Parrot, 2001).  The 
primary acute effects of MDMA are thought to be mediated through MDMA‟s affinity 
with the presynaptic serotonin transporter (SERT), resulting in reversal of the SERT 
and MDMA/5-HT exchange, thus causing a 5-HT efflux (Rudnick & Wall, 1992).  
Increased synaptic 5-HT has been shown to correlate with the mood altering and 
physiological effects of MDMA as shown by attenuation of those effects after 
blockade of the SERT with the 5-HT reuptake inhibitor citalopram (Liechti, Bauman, 
Gamma & Vollenweider, 2000; Liechti & Vollenweider, 2001).  In addition, MDMA 
has moderate direct affinity for post-synaptic 5-HT2 receptors (Battaglia, Brooks, 
Kulsakdinun & De Souza, 1988) that have been implicated in the hallucinogenic 
properties of MDMA (Liechti & Vollenweider, 2001).  Activation of the 5-HT2 
receptors has also been implicated in dopamine efflux through a modulatory effect 
(Green et al., 2003).   
Though to a lesser extent than serotonin, MDMA is also a potent indirect dopamine 
agonist both in vitro (Johnson, Hoffman & Nichols, 1986) and in vivo (Yamamoto & 
Spanos, 1988).  Antagonism of the dopamine D2 receptor with haloperidol was 
shown to attenuate the euphoric effects of MDMA implicating dopamine‟s role in the 
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„high‟ experienced after MDMA administration (Liechti & Vollenwieder, 2000; 2001).  
Dopamine release has also been linked with the stimulant-related effects of MDMA 
such as its locomotor activating (Spanos & Yamamoto, 1989) and reinforcing effects 
(Daniela, Brennan, Gittings, Hely & Schenk, 2004).      
The second phase of MDMA‟s action results from an interaction between the 
depletion of vesicular 5-HT and deactivation of the enzyme tryptophan hydroxylase 
(TPH) (Schmidt & Kehne, 1990).  Reversal of the SERT results in the massive acute 
release of vesicular 5-HT into the synapse, but also prevents deactivation via 
reuptake into the presynaptic terminal.  Further depletion of 5-HT and its 
metabolites occurs due to deactivation of 5-HT‟s rate-limiting enzyme, TPH, 
therefore preventing further synthesis of 5-HT.  The resulting depletion of 5-HT and 
its metabolites may be a factor in the subacute symptoms found after MDMA 
administration, such as drowsiness, muscle aches, difficulty concentrating and 
depression (Peroutka et al., 1988) as well as lack of appetite, lethargy, thirst and 
insomnia (Vollenweider et al., 1998). 
 
Abuse Potential of MDMA 
DSM-IV criteria for drug dependence contains features including the development of 
tolerance, manifestation of withdrawal symptoms, maintenance or escalations of 
drug use, increased drug-seeking behaviours and a lose of control of drug intake 
(Bickel, Madden & Petry, 1998).  MDMA use (like that of other drugs of abuse) has 
been shown to meet the criteria for dependence and abuse according to DSM-IV 
criteria.  For example, Cottler, Womack, Compton and Ben-Abdallah (2001) studied 
ecstasy use in adolescents and young adults and found that 30% of their sample 
had used ecstasy more than 5 times (the inclusion criteria for the study).  Of those 
individuals 43% met the DSM-IV criteria for dependence and 34% met the criteria 
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for abuse.  Crucially, all of the respondents reported either tolerance (35%) or 
withdrawal (59%) after MDMA use.   
A key feature of a drug having abuse potential lies in its ability to act as a reinforcer 
(i.e. maintain behaviours that lead to its delivery).  Primarily the subjective effects of 
drugs of abuse can act as positive reinforcers, but note that drug use may also be 
maintained by negative reinforcement contingencies such as removing unwanted 
withdrawal symptoms (Koob & Le Moal, 1997).          
Tancer and Johanson (2003) measured the reinforcing subjective effects of MDMA 
by using a multiple choice procedure (MCP) in humans by asking participants to 
choose between the current dose of MDMA they had administered and a range of 
dollar values.  MDMA produced dose-dependent increases in the dollar amount 
needed to switch from drug to money (the crossover point) compared with placebo.  
Participants in Tancer and Johanson‟s study also reported „liking‟ MDMA more than 
both amphetamine and mCPP (a 5-HT agonist).   
Greenwald (2008) re-evaluated the results Tancer and Johanson (2003) as part of a 
wider reanalysis of MCP data in terms of Behavioural Economic demand curves.  
Briefly, behavioural economics applies aspects of consumer demand theory to the 
experimental analysis of behaviour (Lea, 1978; Hursh, 1980, 1984; Greenwald, 
2008).  Demand for a good (reinforcer) reflects the price (effort required) in order to 
obtain that good.  Demand curves plot consumption (reinforcers earned) as a 
function of price (effort required per unit of consumption) and typically produce a 
non-linear function that exhibits decreased consumption as a function of increased 
price.  Demand curves (when plotted in logarithmic space) allow for the analysis of 
elasticity of demand or the sensitivity of consumption to changes in price.  Elasticity 
of demand spans a continuum from inelastic demand, where prices rises are met 
with increased effort or expenditure in order to maintain access to the commodity, to 
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elastic demand where consumption decreases more than the proportional change in 
price.  Importantly, different commodities (including drugs of abuse) differ in 
elasticity of demand.  In essence those commodities that are defended more 
strongly represent greater inelasticity and stronger reinforcers relative to those with 
lower elasticity.  For a more comprehensive discussion of Behavioural Economics 
see Chapter 4.  Greenwald compared demand functions for several opiates and 
found that rank order inelasticity was highest for fentanyl followed by 
hydromorphone (in heroin users), methadone and hydromorphone (in heroin 
abstainers), respectively.  When comparing psychostimulant drugs rank order 
inelasticity was d-amphetamine, MDMA, followed by MDMA + fluoxetine indicating 
that d-amphetamine required higher dollar amounts to be offered before switching 
preference from drug to money.  The difference between MDMA and MDMA + 
fluoxetine conditions suggests that the addition of fluoxetine decreased the 
subjective value of the MDMA and subjects were likely to choose lesser dollar 
amounts before switching preference from drug to money. 
Similarly, Sumnall and colleagues investigated hypothetical drug purchases in 
polysubstance drug abusers (Sumnall, Tyler, Graham & Cole, 2004; Goudie, 
Sumnall, Field, Clayton & Cole, 2007).  They found that drug purchases for cocaine, 
amphetamine and ecstasy were elastic, while only demand for alcohol was inelastic.  
The authors suggest that alcohol was the preferred drug of choice of the polydrug 
user population they sampled as evidenced by inelastic demand.  That is, demand 
for alcohol was defended by higher expenditure as price increased.  Interestingly, 
when the price of ecstasy was increased, cocaine choices increased suggesting 
that cocaine acts as a substitute to MDMA when prices increase (and vice versa).  
The polydrug user population studied by Sumnall et al. indicated that MDMA and 
cocaine substitute for one another suggests that MDMA likely produces reinforcing 
effects similar to cocaine, a drug with well-known abuse potential.  In a follow up 
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study Goudie et al. manipulated perceived quality of drugs and income levels 
(amount of money available to buy drugs for a hypothetical night out), while keeping 
prices fixed at or near prices for drugs on the street (in keeping with the real world 
higher quality drug commanded higher relative prices).  Alcohol, cocaine, cannabis 
and ecstasy produced income elastic choices for poor quality drugs, that is despite 
restricted income participants continued to choose lower (and average for some 
drugs) quality drugs.  Choices were income elastic for all high quality drugs except 
for alcohol.  In effect higher quality drugs were chosen when income was high, but 
not when income was set to a low value representing the fact that high quality drugs 
are a luxury good.                      
While the reinforcing subjective effects of MDMA appear to mirror the similar effects 
of other prominent drugs of abuse, MDMA does not appear to produce drug craving 
or physical dependence often associated with the addictive potential of other more 
prominent drugs of abuse (Parrott, 2001).  But MDMA, like other drugs of abuse 
such as cocaine and amphetamine does produce tolerance and dosage escalation 
(Parrott, 2001).  Patterns of use of MDMA seem to change as a function of 
experience with the drug.  While first time users typically start with a single or even 
half a tablet experienced users will often take multiple tablets in a binge session 
(Hammersley, Ditton, Smith & Short, 1999).  Binging can be achieved either via 
„stacking‟ (i.e. taking multiple doses at once) or „boosting‟ (first taking a single pill, 
and another several hours after the first) or a combination of both (Hammersley et 
al.; Parrott, 2005).  In a referral-type sample of ecstasy users, Hammersley et al. 
found significant variation in MDMA use allowed for subjects to be categorised as 
„light‟, „medium‟ or „heavy‟ users.  Light users reported MDMA use „less than 
monthly‟, medium users reported „more than monthly but less than weekly‟, while 
heavy users reported „more than weekly but less than daily‟.  Heavy users were 
more likely to engage in binging than light users were with 76% of heavy users 
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reporting binging on MDMA compared with just 16% of light users.  The incidence of 
increased binge dosing and escalation suggests that tolerance to the drug is 
occurring.  Indeed, users self-reports have suggested than the positive effects of 
MDMA decline with increased usage, while the negative effects become more 
prominent (Petrouka et al., 1988).  Irvine et al., (2006) found evidence for tolerance 
to MDMA‟s sympathomimetic and behavioural effects in a study that collected 
pharmacokinetic and physiological data before and after subjects attended a „dance 
party‟.  Those who were experienced users showed blood concentrations of MDMA 
in the range of „toxic to lethal‟, however, reported little to no adverse side effects.    
While direct evidence for the abuse potential of MDMA in humans remains tentative, 
substantial evidence for its abuse potential comes from animal models, particularly 
drug self-administration (Schenk, 2009).  The self-administration procedure provides 
drug reinforcers (typically delivered through intravenous catheters) contingent upon 
operant responding.  Acquisition and maintenance of drug self-administration 
reflects the ability of the drug to act as a reinforcer and has been demonstrated 
across a wide variety of abused drugs (Spealman & Goldberg, 1978).  The 
reinforcing effects of MDMA have been demonstrated by the self-administration 
procedure where it has been shown to initiate and maintain lever responding in a 
variety of species including, non-human primates, rats and mice (for details, see 
Chapter 3, Table 3.1).  
In addition, MDMA has been shown to reliably produce conditioned place 
preference (CPP) (Cole, Sumnall, O‟Shea & Marsden, 2003; Meyer, Mayerhofer, 
Kovar & Schmidt, 2002; Schechter, 1991; see Tzschentke, 1998, 2007 for a 
comprehensive review on CPP).  MDMA administration also lowers the reward 
threshold for electrical brain stimulation; a model of the euphoria inducing effects of 
drugs of abuse (Hubner, Bird, Rassnick & Kornetsky, 1988).  
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The similarities between MDMA and other more prominent drugs of abuse suggest 
that MDMA has significant abuse potential.  However few studies have attempted to 
quantify the relative abuse potential of MDMA using animal models.  Animal models 
allow for assessment of abuse potential by comparing the strength of a drug 
reinforcer with that of other reinforcers, a measure known as relative reinforcer 
efficacy.  Drugs can then be ranked as a function of their relative reinforcer efficacy; 
with those drugs that rank higher having more potential for abuse and thus more 
likely to lead to potential addiction.      
This thesis addressed several gaps in the current literature concerning the study of 
MDMA.  To date the reinforcing effects of MDMA as an oral drug have often been 
overlooked in the literature.  Animal models used for assessing the reinforcing 
effects of MDMA have almost exclusively been studied using parenteral routes of 
administration such as intravenous (iv) (in self-administration studies), 
intraperitoneal (ip) or subcutaneous (sc) injection (in conditioned place preference).      
In particular, the differences between iv and oral administration have the potential to 
produce markedly different profiles of the reinforcing effects of MDMA (see Chapter 
2).  As MDMA is consumed almost exclusively in pill form in humans, studies of the 
effects of oral doses are prudent in order to better understand the human condition 
with regard to MDMA‟s reinforcing and addictive properties.  The first goal of this 
thesis was to establish a paradigm with which the oral effects of MDMA can be 
studied.  Methods generally used for the study of alcohol reinforcement in rats were 
adapted in order to accomplish this goal.  The second objective of this thesis was to 
examine the abuse liability of MDMA through quantitative methods.  Relative 
reinforcing efficacy of a drug can be considered synonymous with its potential for 
abuse.  Relative reinforcing efficacy can be studied by utilizing an economic 
framework and examining changes in consumption (reinforcers consumed) as a 
function of changes in price (response requirement).  The field of behavioural 
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economics provides two theoretical models with which relative reinforcing efficacy 
can be quantified.     
  
15 
 
Chapter 2  ROUTE OF ADMINISTRATION 
 
While all psychoactive compounds have their primary effects in the Central Nervous 
System (CNS) the route with which those compounds reach the CNS can produce 
profound differences in the effects of those compounds (Farré & Camí, 1991).  
Route of administration affects the speed and the efficacy of a drug during its 
passage across the blood brain barrier into the brain.  The most common routes of 
administration human drug use are intravenous (iv), inhalation, intranasal (e.g. 
snorting of cocaine) and ingestion (oral or po).  It is common for most drugs to be 
confined to a single route of administration but several drugs are known to be used 
via multiple routes leading to very different abuse and efficacy profiles (e.g. 
methamphetamine can be taken orally, injected intravenously, snorted or smoked all 
producing distinct pharmacological and pharmacokinetic effects (de la Torré et al., 
2004). 
A drug‟s effectiveness is a function of the combination of its pharmacodynamic and 
pharmacokinetic parameters, however, route of administration can also serve to 
modulate the pharmacokinetic parameters for a given drug (Farré & Camí, 1991; 
Smith, Jones & Walker, 1996).  The route of administration is an important 
determinant of a drug‟s effect as it will change not only the rate of absorption, but 
also the metabolism of that drug based on the site of absorption (Strang et al., 
1998).  This in turn will affect the drug‟s bioavailability or the proportion of the active 
drug circulating in the systemic system.  For example, first pass metabolism in the 
liver and gut after oral ingestion will decrease bioavailability relative to iv 
administration that results in almost instantaneous absorption and a fast onset of 
action (Farré & Camí, 1991).  Route of administration can also have dramatic 
effects on the onset of action of a drug and will affect the time taken to reach peak 
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plasma concentration (Tmax) and peak plasma concentration (Cmax) (e.g. Baumann et 
al., 2009).             
MDMA Pharmacokinetics 
MDMA is metabolised through two major pathways.  Firstly, MDMA is metabolised 
to HHMA by the enzyme CYP2D6 in humans or the similar enzyme CYP2D1 in rats 
(Baumann et al., 2009).  HHMA is then subsequently metabolised to HMMA by the 
enzyme COMT.  The minor secondary pathway involves metabolism of MDMA to its 
active metabolite MDA and subsequent metabolism to HHA and HMA by CYP2D6 
and COMT respectively (Baumann et al., 2009; de la Torré et al., 2000; Lim & Foltz, 
1988).  The major metabolism pathways for MDMA in rats and humans are shown 
in Figure 2.1 (Baumann et al., 2009).  Oral administration of MDMA in human 
participants results in detectable plasma levels 15-30 minutes after ingestion 
(Kolbrich et al., 2008a).  Studies have consistently found increased area under the 
concentration time/curve (AUC) more than the proportional increase in dose 
suggesting that  MDMA exhibits non-linear pharmacokinetics in humans (de la Torré 
et al., 2000; Farré et al., 2004; Kolbrich et al., 2008b), non-human primates 
(Mechan et al., 2006) and rats (Baumann et al., 2009).  For example, 
de la Torre et al. (2000) tested a range of MDMA doses from 50 to 150mg in human 
volunteers and found that maximum concentration (Cmax) and AUC for MDMA 
increased as a function of dose.  Despite the three fold difference between the 50 
and 150mg doses the authors report an increase in AUC greater than 10 fold.  In 
addition, Kolbrich and colleagues (2008b) found that 82% of participants had 
detectable levels of MDMA 47 hours after receiving a high dose (1.6mg/kg) of 
MDMA; in those same subjects only 23.5% showed detectable levels of MDMA after 
a low dose (1.0mg/kg) after the same duration.  Time to maximum concentration 
(Tmax) for MDMA was 2.4 hours and was similar across both high and low doses.  
However, Cmax was significantly higher for the high dose than it was for the low 
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dose.  It has been suggested that the non-linear pharmacokinetics of MDMA are a 
result of auto-inhibition of the enzyme CYP2D6 by MDMA at high doses; which in 
turn results in decreased metabolism of MDMA and MDA (Baumann et al, 2009; de 
la Torré et al, 2000; Kolbrich et al, 2008b).  The auto-inhibition of CYP2D6 by 
MDMA is thought to occur via formation of a metabolic inhibitory complex that starts 
within an hour of ingestion.  The deficit in levels of the enzyme CYP2D6 may be 
long lasting with up to 10 days required before a return to basal levels of CYP2D6 
(Yang et al., 2006).  The inhibition of the metabolism of MDMA may have direct 
consequences for those who use MDMA regularly, particularly those who are 
frequent users or those who „stack‟ or „boost‟ multiple doses of MDMA.  Farré et al. 
(2004) examined the effects of repeated doses of MDMA on the pharmacokinetics 
of MDMA in human participants.  Subjects were given two 100mg doses of MDMA 
separated by 24 hours.  Results showed that plasma concentrations were increased 
by 77% and Cmax was increased by 29% compared to the first dose, suggesting 
inhibition of MDMA metabolism, rather than just simple accumulation of drug in the 
system.  Similarly, Mechan et al. (2006) studied the effects of multiple oral doses of 
MDMA in squirrel monkeys and found evidence for non-linear pharmacokinetics of 
MDMA after both single doses as well as multiple doses of MDMA delivered three 
hours apart.  
Baumann and colleagues have recently systematically characterised the effect of 
route of administration on the pharmacokinetics of MDMA in rats.  Baumann et al. 
(2009) administered either a low (2 mg/kg) or high (10 mg/kg) dose of MDMA to rats 
via either the ip, sc or po routes of administration.  Results indicated non-linear 
pharmacokinetics for all three routes of administration due to larger than 
proportional increases in Cmax for the high dose compared with the low dose.  Cmax 
values varied as a function of route of administration with ip producing greater Cmax 
values than sc and po respectively.  In addition, both low- and high-dose oral 
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administration showed significantly decreased AUC compared with the ip and sc 
routes of administration.  Tmax varied as a function of route of administration with sc 
administration producing the slowest time to maximum concentration compared with 
the ip and po routes.  The authors suggest that oral MDMA is likely subject to 
decreased absorption as well as first pass metabolism in the liver or gut which 
results in decreased blood levels of MDMA.  The decrease in circulating MDMA will 
result in less centrally active MDMA and thus produce marked differences in its 
action when delivered via the oral route.  It has been suggested that in rats MDMA 
survives mostly untouched after enzymatic degradation in the liver, such that the 
majority reaches the bloodstream (Finnegan et al., 1988). 
 
 
Despite delays in onset of action and decreased absorption of MDMA evident in 
pharmacokinetic analysis of blood metabolites there still appears to be significant 
behavioural and pharmacological effects resulting from administration of oral 
 
Figure 2.1: Metabolism of 3,4-methylenedioxymethamphetamine in humans and rats 
(Baumann et al., 2009). 
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MDMA.  For example, Finnegan et al. (1988) found that MDMA produced equivalent 
depletions of 5-HT in the hippocampus regardless of whether either the oral or 
subcutaneous route of administration was used.  However, using primates Ricaurte 
and colleagues showed that the oral route of administration resulted in decreased 5-
HT depletion relative to sc administration (Ricaurte, DeLanney, Irwin & Langston, 
1988).  Baumann et al. (2009) found no effects on either cortical or striatal 5-HT 
levels two weeks after either a high (10 mg/kg) or low (2 mg/kg) doses of MDMA 
given to rats, irrespective of the route of administration used (either ip, sc, or po).   
A limited number of studies have used behavioural assays in order to examine 
effects across a range of routes of administration.  Measurement of locomotor 
activity permits the analysis of MDMA‟s efficacy as function of route of 
administration as well as the timecourse of MDMA‟s locomotor activating effects.  
Many studies have shown that administration of MDMA results in dose-dependent 
increases in locomotor activity (for examples see, Gold & Koob, 1988; Spanos & 
Yamamoto, 1989; McNamara, Kelly, & Leonard, 1995; Daniela, Brennan, Gittings, 
Hely & Schenk, 2004).  However, relatively few studies have tested MDMA-induced 
hyperactivity as a function of route of administration.  De Souza and colleagues 
found that oral MDMA produced dose dependant increases in locomotor activity 
after oral administration (De Souza, Kelly, Harkin & Leonard, 1997).  The highest 
locomotor activity scores were noted for 20 mg/kg MDMA with subsequent 
decreases in locomotor activity after 40 and 80 mg/kg doses.  This result may reflect 
increased occurrences of serotonin syndrome symptoms apparent after high MDMA 
dose administration (Spanos & Yamamoto, 1989); most notably low body posture 
and head weaving that may be mutually exclusive with the forward locomotion 
associated with stimulant-type induction of hyperactivity.  In addition, De Souza and 
colleagues showed significant increases in temperature and lethality as a function of 
increasing oral doses of MDMA indicating that MDMA has significant 
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pharmacological actions even when delivered orally.  However, the dose range 
used is their study was extremely high (20 – 320 mg/kg MDMA po) and no 
comparisons were made between the oral route and other common routes of 
administration typically used in animal models.  Crean, Davis and Taffe (2007) 
measured the effect of high (5 mg/kg) and low doses (1.78 mg/kg) of MDMA 
delivered via either the im or po routes of administration on homecage activity in 
rhesus monkeys.  They found homecage activity was decreased in the high dose im 
condition.  Activity was decreased after high dose oral administration, but to a lesser 
extent than that of the intramuscular route suggesting that there are route 
dependent effects of MDMA on locomotion in non-human primates.  However, the 
results from Crean et al.‟s study showed a decrease in locomotor activity in contrast 
with increased locomotion seen in rat studies; although it must be noted that the 
procedure for measuring locomotion in rats and primate studies vary substantially.  
The rhesus monkeys studied by Crean et al. were confined to their homecages 
during testing and had transmitters surgically implanted in order to measure gross 
motor movements.  In contrast, rats are typically tested in novel open field 
chambers and locomotion is measured via the use of infrared beam breaks.  
Despite differences in the behavioural assay across species Crean et al. showed 
that oral MDMA was less effective than intramuscular administration across the 
same dose range indicating that despite the contrasting behavioural effects across 
species the MDMA was less efficacious when delivered via the oral route.       
The pharmacokinetic effects of route of administration on MDMA and its metabolites 
have recently been systemically studied (Baumann et al., 2009), however locomotor 
activity has not as yet been examined in this context.  The following study was 
designed to test the effects of route of administration on MDMA-induced hyper-
locomotion.  The effects of MDMA administered via either the intraperitoneal, 
subcutaneous or oral route were examined in order to measure total activity, time to 
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peak activity and the time course for each route of administration.  Although this 
initial study did not assess the reinforcer effects of MDMA, the open field locomotor 
paradigm provided a rapid method which to quantify the magnitude and time course 
of the effects produced by MDMA as a function of route of administration.                  
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Experiment 2.1: Effect of Oral, Subcutaneous and Intraperitoneal Administration of 
MDMA on Locomotor Activity 
Method 
Subjects: 
Subjects were 91 naïve male Sprague-Dawley rats weighing between 250-300 
grams bred in the Victoria University Animal Facility.  Animals were housed in 
polycarbonate cages with cage tops made of wire mesh with free access to food 
and water, except during experimental sessions.  Animals were maintained in a 
temperature controlled environment with ambient temperature 21°C and 70% 
humidity and a 12:12 hour light/dark cycle, lights on at 7am.  Research was 
approved and animals were treated in accordance with ethical guidelines set forth 
by the Victoria University of Wellington Animals Ethics Committee.   
Apparatus/materials:  
Equipment: 
Experiments were run in eight ENV-515 Open Field Test chambers (Med-
Associates Inc, Vermont, USA) used to measure rat locomotor activity.  Chambers 
were 45 cm x 45 cm with white acrylic floors and clear Perspex walls 30 cm high.  
Each chamber was housed in a sound and light attenuating cubicle.  Infrared light 
beams equally spaced and positioned 1.5 cm above the floor formed a 16 by 16 
lattice.  Experiments were controlled by Activity Monitor 5 software using the 
following parameters, box size 3; resolution 100ms; resting delay 1000ms (Med 
Associates, Vermont, USA).  During behavioural tests a white-noise generator 
external to the cubicles was used to mask any ambient noise.    
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Solutions: 
+/-3,4-methylenedioxymethamphetamine hydrochloride (ESR, Porirua, New 
Zealand) for injections were made at doses of 0, 10, and 20mg/ml in a vehicle of 
sterile 0.9% physiological saline.  Injections were administered either sc or ip at 
1ml/kg of bodyweight.  MDMA HCl for oral gavage was prepared at doses of 0, 10 
and 20mg/ml in a vehicle of dH2O.  Gavage was administered po at 1ml/kg of 
bodyweight.  All drug doses refer to the salt. 
Procedure: 
In order to decrease distress related to administration method animals‟ were 
habituated to oral gavage or injection in the home cage with vehicle administration 
five days prior to commencing behavioural testing.  Vehicle administration continued 
for three days. 
On the test day, animals were transported to the testing room and placed inside the 
locomotor activity chambers.  Animals were left in the chambers for a habituation 
period of 30-minutes during which time the activity monitoring software was active 
and white-noise generator was on.  At the end of the habituation period each animal 
was given either an injection (ip or sc) or oral gavage before being placed back into 
the chamber.  Following injections/gavage behaviour was recorded for a further 
60 minutes.   
Animals were randomly assigned to one of nine different drug-administration 
groups.  Groups and subject numbers are detailed in Table 2.1. 
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Table 2.1: Experiment 2.1 conditions 
Route of Administration 
 
 
Dose (mg/kg) Subjects numbers (n) 
Oral (po)  20.0 12 
  10.0 6 
 
 0.0 6 
Intraperitoneal (ip)  20.0 10 
  10.0 9 
 
 0.0 12 
Subcutaneous (sc)  20.0 12 
  10.0 12 
 
 0.0 12 
 
Data Analysis: 
Locomotor activity data were collected and analysed in 5-minute time bins.  Briefly, 
animals were considered ambulatory if they moved at least three beam breaks away 
from their current position in less than specified resting delay (1000 ms).  An 
ambulatory episode continued until such time as the animal failed to meet the above 
criteria.  Ambulatory counts represent the sum of all X and Y beam breaks during 
ambulatory episodes.  Binned activity data was calculated as ambulatory counts for 
that time bin averaged across all animals.  Total activity scores represent the group 
average of the summed ambulatory counts across all time bins.  Time to peak 
activity for each condition was determined by averaging the time at which peak 
ambulatory counts occurred for each subject.  Obtained values represent the 
average time bin from which peak activity was recorded.  The habituation period 
that consisted of the first 30 minutes of each session prior to drug treatment was 
discarded and not used in the subsequent analysis.   
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Results and Discussion 
Figure 2.2 shows locomotor activity data for all conditions broken down as a 
function of route of administration.  Figure 2.2 indicates that both 20 and 10mg/kg 
MDMA and all three routes of administration produced MDMA-induced hyper-
locomotion.  As expected the highest rates of locomotor activity were found for 
20mg/kg MDMA for each of the three routes of administration tested (Figure 2.2 top 
panel).  In general, total activity counts were dose dependent with higher doses 
producing higher total activity than lower doses, with the exception of the ip route of 
administration which produced similar behaviour for both the 20 and 10mg/kg doses 
of MDMA.  Figure 2.2 (bottom panel) shows that 20mg/kg MDMA produced a similar 
increase in activity for both the ip and sc routes of administration, which were in turn 
higher than activity for the same dose when delivered via the po route.  Overall the 
intraperitoneal route was the most effective at producing MDMA-induced hyper-
locomotion at the doses tested, followed by the subcutaneous and oral routes of 
administration.  A two-way ANOVA was conducted using factors of dose (3 levels: 
0, 10 and 20mg/kg) and route of administration (3 levels: ip, sc and po) and found a 
significant interaction (F (4, 82) = 3.494, p = 0.011).  However, the interaction was 
no longer significant when the each of the vehicle conditions was removed from the 
analysis, F (2, 55) = 0.636, p = 0.533).  With the vehicle conditions removed the 
main effect of dose failed to reach significance (F (2, 55) = 3.393, p = 0.71), but 
there was however a significant main effect of route of administration (F (2, 55) = 
12.310, p < 0.01).  Tukey post-hoc analysis revealed that the oral route of 
administration produced significantly less locomotor activity than did either the 
subcutaneous or intraperitoneal routes of administration (p < 0.01).  There was no 
significant difference between the ip and sc routes of administration.       
 Figure 2.3 shows the timecourse analysis as a function of MDMA dose for the ip 
(top panel), sc (middle panel) and po (bottom panel) routes of administration.  
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Figure 2.4 shows the timecourse of MDMA-induced locomotion as a function of 
dose.  Figure 2.4 indicates that both the 20mg/kg ip (top panel) and 10mg/kg ip 
doses (middle panel) produced the highest peak activity and the highest time to 
peak activity (Tmax) (see Table 2.2).  The sc route of administration produced lower 
peak activity relative to the ip route but higher than the po route of administration; 
however, though overall activity was lower for po than it was for sc, the po route 
showed a lower Tmax indicating a faster onset of action.  Time to peak activity (Tmax) 
data is shown in Table 2.2.  A two-way ANOVA revealed a significant main effect of 
route of administration (F, (2, 55) = 3.766, p = 0.029) but not of dose (F (2, 55) = 
0.385, p = 0.538) on Tmax.  The interaction term was not significant (F (2, 55) = 
1.371, p = 0.262).  Post-hoc analysis indicated that the subcutaneous route 
produced significantly slower time to peak activity than did the oral or intraperitoneal 
routes.  
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Figure 2.2: (top panel) Effect of route of administration on MDMA-induced hyper-locomotion in 
rats. Bars represent average total ambulatory counts (+SEM) as a function of dose for ip, sc 
and po routes of administration respectively. (bottom panel) Comparison of route of 
administration on MDMA-induced hyper-locomotion for vehicle, 10 and 20mg/kg MDMA doses.   
Error bars represent standard error of the mean.    
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Figure 2.3: Timecourse for MDMA-induced locomotor activity for intraperitoneal (ip) (top 
panel), subcutaneous (sc) (middle panel) and oral (po) (bottom panel) as a function of 
MDMA dose.  Drug injections were delivered at timepoint zero.  Error bars represent 
standard error of the mean.     
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Figure 2.4: Timecourse for MDMA-induced locomotor activity for 20mg/kg (top panel), 
10mg/kg (middle panel,) and vehicle administration (bottom panel) as a function of route of 
administration.  Drug injections were delivered at timepoint zero.  Error bars represent 
standard error of the mean.     
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Table 2.2: Time to maximum activity (Tmax) as a function of three routes of administration. 
Route of Administration 
 
 
Dose (mg/kg)   Tmax   SE 
 
Oral (po) 
 
 
20.0 
 
36.25 
 
4.97 
  
10.0 31.67 8.43 
Intraperitoneal (ip)  20.0 28.00 2.26 
  10.0 29.44 4.03 
Subcutaneous (sc)  20.0 35.42 2.98 
  10.0 45.42 4.37 
 
As expected both the route of administration and dose of MDMA had prominent 
effects on the locomotor activating effects of MDMA.  The intraperitoneal route of 
administration produced both the highest overall locomotor activity counts as well as 
the highest peak locomotor activity.  In addition, the ip route exhibited the fastest 
onset of action as measured by Tmax.  The subcutaneous route produced moderate 
locomotor activating effects, typified by a slower onset of action (Tmax) that gradually 
increased over the timecourse measured (relative to the to the ip route).  Though 
slower to reach peak activity the 20mg/kg sc dose of MDMA produced similar levels 
of total activity compared with the 20mg/kg ip dose of MDMA.  This was not the 
case for the 10mg/kg dose of MDMA where the sc dose produced not only a slower 
onset of action but also lower total locomotor activity counts.  The decreased 
locomotor activity for the 10mg/kg sc dose is consistent with a decrease in central 
bioavailability due to slower absorption and increased systemic metabolism.  
Notably this was not case for the 20mg/kg MDMA condition where both ip and sc 
routes produced similar activity levels suggesting a ceiling effect for the MDMA-
induced hyperlocomotion at that dose.           
The oral administration of MDMA resulted in dose dependent increases in locomotor 
activity when administered orally, however MDMA-induced hyperlocomotion was 
low when delivered orally compared with the ip and sc routes of administration.  
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High dose MDMA treatment (20mg/kg) produced modest increases in locomotor 
activity approximately 40-45 percent lower than either the ip or sc routes of 
administration.  The 10mg/kg MDMA dose produced significant route-dependent 
effects with ip producing more total activity counts than the sc route and the oral 
routes respectively.  The lower activity counts after oral administration are 
consistent with decreased bioavailability due to increased metabolism and 
absorption found in oral administration relative to the subcutaneous and 
intraperitoneal routes of administration.  This decrease in central bioavailability 
results in less dopamine release resulting in lower overall MDMA-induced 
hyperlocomotion.      
It was expected that the oral route of administration would result in the slowest 
onset of action due to slow passage from the stomach to the large intestine (the 
primary absorption site).  Thus it was expected that the oral route would show the 
highest time to peak activity (Tmax).  However, this was not the case and in fact the 
subcutaneous route showed the highest Tmax value, followed by the oral and ip 
routes respectively.  Though it produced an attenuated effect on total activity counts 
compared with the subcutaneous route, the oral route was faster to reach its peak 
effects.  This result corresponds with the research of Baumann et al. (2009) who 
found that the Tmax value for MDMA plasma concentration was higher for the 
subcutaneous route than it was for po and ip routes for both high (10mg/kg) and low 
(2 mg/kg) doses.  In addition, they found that Cmax and AUC values for both high 
and low doses were highest for ip, followed by sc with po producing the lowest 
values for both parameters.  Though the current research did not attempt to 
correlate the behavioural and neurochemical parameters, together with the results 
of Baumann et al.‟s study, these data suggest that the behavioural data closely 
matches the pharmacokinetic profiles for the different routes of administration. 
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The results from the current study are also consistent with findings from others 
stimulant drugs, such as cocaine and methylphenidate.  Dow-Edwards and 
colleagues (Dow-Edwards, Fico, Osman, Gamagaris & Hutchings, 1989) found that 
subcutaneous cocaine produced a two-fold increase in locomotor activity compared 
with the same 40mg/kg dose delivered orally, though both po and sc administration 
resulted in sensitization to the cocaine locomotor activating effects over the course 
of 15 days of treatment.  Plasma levels of cocaine were tested 15 or 45-minutes 
post-cocaine administration and the authors found that cocaine concentration 
remained similar or increased at each time point for subcutaneous administration, 
however oral cocaine showed decreased plasma concentration when tested after 
45-minutes.  The increasing plasma concentration for the sc administration 
suggests that peak effects had not yet occurred, while the decreasing plasma 
concentration for the oral route suggests that peak effects have already occurred 
prior to testing at 45-minutes.  Similarly, Gerasimov et al. (2000) found that po 
administration of methlyphenidate (MP) to rats showed both slower onset and lower 
total locomotor activity than the same dose delivered ip.  In addition the authors 
showed that the increased locomotor activity corresponded closely to measured 
dopamine release in the nucleus accumbens. 
In the current study some dose and route combinations (most notably the 20mg/kg 
dose delivered via the sc or ip routes) used in the current experiment approximated 
equal locomotor effects despite the differences in the route with which it was 
administered.  These results were not anticipated or planned, thus the current 
results do not enable dose equivalence to be determined, at least not across all 
routes used.  For oral administration of MDMA doses higher than 20mg/kg higher 
may have resulted in a larger MDMA-induced locomotor response.  However, 
De Souza et al. (1997) found that a single oral dose of 20mg/kg MDMA actually 
produced overall higher locomotor activity than did 40mg/kg MDMA and that the 
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latter dose produced lethality in 1 out of the 12 rats tested suggesting that other 
factors may prevent further dose-dependent increases in hyperactivity.  De Souza 
and colleagues also showed that additional increases in dose further decreased 
locomotor activity (80mg/kg po) and lethality (80-320mg/kg po).  However, future 
studies might serve to test a greater range of doses in order to calculate equivalent 
doses for MDMA as a function of differing routes of administration using locomotor 
activity.  Though even with the use of equivalent doses in future experiments care 
must be given to conclusions generated.  For example, Porrino (1993) tested 
equivalent doses of cocaine on locomotor activity across intravenous (1mg/kg) and 
intraperitoneal (10mg/kg) administration.  Despite producing similar effects on 
locomotor activity scores, the differing routes of administration produced markedly 
different patterns of local cerebral glucose utilization across brain regions 
suggesting that cocaine produced differential activation of neuronal circuits based 
on alternative routes of administration.  Local cerebral glucose utilization has also 
been mapped after exposure to MDMA and the results suggest that MDMA 
produces a similar pattern of glucose utilization to that of other drugs of abuse such 
as cocaine, d-amphetamine and phencyclidine (Wilkerson & London, 1989; Quate, 
McBean, Ritchie, Olverman & Kelly, 2004).  Though never directly tested, it remains 
a distinct possibility that route of administration may promote changes in neuronal 
circuit activation for equivalent doses of MDMA in much the same way as the results 
reported by Porrino for cocaine.                          
The results of this study show a clear decrease in the efficacy of MDMA when 
delivered orally with regard to its locomotor activating effects.  However, it must be 
noted that the current study used gavage for assessing the effects of oral MDMA 
while using injection methods for both subcutaneous and intraperitoneal routes of 
administration.  Though unlikely, it remains possible that the differing methods of 
administration were the cause or at least contributed to the differences noted in the 
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experiment above.  Oral gavage has been shown to induce stress and is associated 
with a number of other consequences such as breathing interference as a 
consequence of the intubation tube (often metal), stomach distension and 
accidental tracheal placement instead of the stomach (Balcombe, Barnard & 
Sandusky, 2004).  Brown, Dinger and Levine (2000) conducted a study into the 
effect of gavage of various compounds with rats.  They found that gavage with corn 
oil, but not 1% methylcelluose/0.2% tween 80 or water produced volume dependent 
increases in plasma corticosterone one hour after gavage.  Sham gavage for each 
of the compounds produced plasma corticosterone within normal values suggesting 
that the gavage itself did not produce large scale changes in stress-induced 
corticosterone levels.  However elevated corticosterone levels have been shown to 
modulate dopamine release and increase the reinforcing efficacy and locomotor 
activating effects of drugs of abuse (Piazza & Le Moal, 1996).  However it seems 
unlikely that gavage would have produced a significant change in corticosterone 
levels in the current study as the volumes were small (1ml/kg) and the animals were 
habituated to gavage prior to the experiment.  Additionally, examination of the 
control (0.0mg/kg) conditions revealed no effects of the gavage procedure, and 
locomotor activity was ostensibly identical to that of both sc and ip injection. 
It remains unclear to what extent the dose and route dependency of the locomotor 
activating effects of MDMA correspond with changes in the reinforcing efficacy of 
the drug itself.  While dose has been established as a major factor in the self-
administration of MDMA (see Chapter 3 for details), route of administration has 
mostly been neglected.  It seems likely however that route of administration will 
modulate the reinforcing properties of MDMA primarily through differences in 
metabolism (decrease in potency) and onset of action (delay between response and 
reinforcer).  Faster onset of action, but not duration of action appears to be a better 
predictor of relative reinforcer efficacy (Winger, Hursh, Casey and Woods, 2002; Ko, 
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Terner, Hursh, Woods & Winger, 2002; Lile et al., 2003).  Specifically if rapid onset 
of effects (neurologically or behaviourally) corresponds to reinforcing efficacy of a 
drug then it may be that po MDMA may still act as a reinforcer, albeit a relatively 
weak one.  The following chapter explores the issue of the reinforcing effects of 
MDMA when tested via the oral route of administration.     
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Chapter 3 ORAL ADMINISTRATION OF DRUGS OF ABUSE 
 
Much of the behavioural evidence for the reinforcing properties of drugs of abuse 
comes from the literature concerning self-administration of drugs of abuse in animal 
subjects.  In the self-administration model animals are trained to make operant 
responses in order to obtain access to various pharmacologically active 
compounds.  By allowing the animal access to the drug compound contingent upon 
operant responses (i.e., lever presses) the consumption of that compound is wholly 
dependent on the animals‟ behaviour.  Those compounds that support operant 
responding are considered to have some „hedonic‟ or reinforcing properties, while 
those that do not maintain responding are either not reinforcing, or provide some 
other  effect that may instead suppress responding. 
Weeks‟ (1962) pioneer procedure for drug self-administration involved the 
implantation of chronic indwelling intravenous (iv) catheters through which drug 
solutions could be infused.  Adapted to study drugs of abuse across a wide range of 
drug classes including psychomotor stimulants, opiates, sedatives and hypnotics 
(Spealman & Goldberg, 1978) this method of drug delivery is still the primary 
method used today in self-administration studies in non-human primates, rats and 
mice.    
The face validity of self-administration of drugs of abuse is evidenced by the fact 
that almost all pharmacological compounds abused by humans are also self-
administered by animals, with the general exception of the hallucinogens (Griffiths 
Bigelow & Henningfield, 1980; Self & Nestler, 1995).  Many of the properties of the 
drug used are also observed in both humans and animals and thus animal models 
can serve as a viable alternative to the study of drugs in humans where polydrug 
use is prevalent and doses consumed vary widely.   
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The self-administration procedure allows for the direct reinforcing effects of drugs to 
be measured and also for the relative reinforcing efficacy of drugs to be compared.  
In addition, pharmacological manipulations such as administration of agonists or 
antagonists can help us to better understand the neurological mechanisms through 
which drugs of abuse produce their effects.      
 
Self-administration of MDMA        
MDMA has generally been considered a low-efficacy reinforcer (Schenk, 2009).  
This is backed up by research using the self-administration paradigm that shows 
that MDMA is a weaker reinforcer compared to other typical stimulant drugs like 
cocaine (Lamb & Griffiths, 1987; Lile, Ross & Nader, 2005; Ratzenboeck, Saria, 
Kriechbaum & Zernig, 2001), methamphetamine (Wang & Woolverton, 2007) or 
amphetamine (Dalley, et al., 2007).  Early reports on the self-administration of 
MDMA showed that both rhesus monkeys (Beardsley, Balster & Harris, 1986) and 
baboons (Lamb & Griffiths, 1987) would continue to respond when MDMA was 
substituted in the place of cocaine suggesting that it functioned as a reinforcer.  
Later attempts have shown that in addition to non-human primates both mice (Trigo 
et al., 2006) and rats (see Schenk (2009) for a review) will readily self-administer 
MDMA even without prior training or experience with other drugs of abuse.  Table 
3.1 summarises current literature published on MDMA self-administration over the 
course of the last 25 years; in the case of studies that have tested multiple self-
administered drugs the results from those conditions have been omitted from the 
table unless a direct comparison was merited.  MDMA self-administration has most 
commonly been shown using fixed ratio (FR) schedules of reinforcement.  In 
addition, progressive ratio (Lile et al., 2005; Trigo et al., 2006; Wang & Woolverton, 
2007; Schenk et al., 2007), concurrent choice (Banks et al., 2008a,b,c) and runway 
(Wakonigg et al., 2003) procedures have also provided evidence for the reinforcing 
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effects of MDMA.  Drug seeking has been measured using reinstatement of 
previously extinguished MDMA reinforced responding with non-contingent drug 
priming injections or with non-drug stimuli previously paired contingently with MDMA 
infusions (Ball, Walsh & Rebec, 2007; Banks et al., 2008a; Schenk, Hely, Gittings, 
Lake & Daniela, 2008).  MDMA has also been shown to be self-administered in the 
home cage when available as a drinking solution (Reinhard & Wolffgramm, 2005, 
2006) and is self-administered directly into the brain when delivered by the icv route 
of administration (Braida & Sala, 2002).  The pharmacology of the reinforcing effects 
of MDMA and its individual stereoisomer‟s (Fantegrossi et al. , 2002, 2004; Wang & 
Woolverton, 2007) has been examined as well as the effects of various antagonists 
on MDMA maintained self-administration (Fantegrossi et al., 2002; Braida & Sala, 
2002; Daniela et al., 2004; Brennan, Carati, Lea, Fitzmaurice & Schenk, 2009).  The 
effects of ambient temperature have been shown to modulate the reinforcing 
strength of MDMA such that high ambient temperature will increase responding for 
MDMA (Cornish et al., 2003) and low ambient temperature can attenuate the 
reinforcing strength of MDMA (Banks et al., 2008a). 
In a recent review on rodent self-administration studies De La Garza and colleagues 
(2007) note that different laboratories have produced vastly different results with 
regard to MDMA intake despite it producing reinforcing effects across a range of 
laboratories and paradigms.  Table 3.1 includes estimates of the maximum MDMA 
intake found in each study across the range of MDMA self-administration papers 
published to date.  In some studies, such as those employing a progressive ratio, it 
was impossible to calculate intake levels from the reported parameters so intake 
levels for those studies have been omitted.  In other cases, such as the runway 
procedure employed by Wakonigg et al. (2003), the intake of MDMA was 
constrained such that levels of intake did not functionally vary making comparisons 
to other studies invalid.  Values in the table are by necessity estimates as often 
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times authors fail to report MDMA intake levels consumed during studies, instead 
opting to plot reinforcers obtained or responses as a function dose.  The values in 
the table represent maximum estimates based on the highest total dose of MDMA 
earned in a session irrespective of the dose it was obtained from.  For simplicity‟s 
sake, I have opted to use the maximum intake value rather than an average across 
all doses as in many cases dose-response figures were inverted U-shaped 
functions that also include some doses that no not support MDMA self-
administration to high levels, thus including those values in averages would provide 
underestimates of the maximum intake and inhibit direct comparison. 
A brief examination of Table 3.1 reveals different results across species and 
paradigms.  When exclusively examining rat studies the results can be broadly 
divided into three categories; those studies that show low levels of intake (i.e. less 
than 4 mg/kg) (e.g. Ratzenboeck et al., 2001; Ball et al., 2007; De La Garza et al., 
2007); those studies that show mid level intakes (i.e. 6-8mg/kg) (e.g. Cornish et al, 
2003; Reveron, Maier & Duvauchelle, 2006, 2009; Feduccia, Kongovi & 
Duvauchelle, 2010); and finally those that maintain high levels of intake (i.e. more 
than 20mg/kg) (e.g. Schenk, Gittings, Johnstone & Daniela, 2003; Schenk et al.,  
2008; Daniela et al., 2004; Daniela, Gittings & Schenk, 2006; Brennan et al., 2009).  
It is clear that there are vastly different results across laboratories that have 
reported MDMA self-administration.  It is unclear why such large differences exist, 
though different strains of rats and training protocols likely contribute to these 
differences (Schenk, 2009).  Individual variability between subjects may also 
contribute heavily to these differences.  For example, Banks et al. (2008b) reported 
a range of individual subject intake values that ranged from 4 to 22 mg/kg in a study 
of four Rhesus monkeys.  It is possible that the non-linear pharmacokinetics of 
MDMA has a substantial effect on the reinforcing properties of MDMA.  Increased 
exposure to high levels of MDMA may lead to sensitisation to the reinforcing effects 
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of MDMA or alternatively to the development of tolerance, particularly to the 5-HT 
mediated effects.  Schenk (2009) suggests that 5-HT neurotoxicity may be a 
significant factor in MDMA‟s reinforcing effects, by reducing serotonin release 
relative to dopamine release.  Thus MDMA may become a more efficacious 
reinforcer contingent upon high levels of exposure to MDMA.  
Of interest for the present study, Reinhard and Wolffgramm (2005, 2006) found that 
rats consumed an extremely low amount of MDMA when the drug was made 
available orally with cumulative doses reaching an average of 4.433mg/kg (SE = 
1.212) after 49 weeks of access to the drug.  Over half of that cumulative dose was 
said to be consumed during the first 12 weeks of the study.  Of particular note is the 
fact that rats failed to consume high levels of MDMA when it was freely available to 
them; indeed, the authors report that consumption decreased almost to the point of 
complete cessation by the end of the 49 week study.  It is unclear from their study 
whether the decrease in consumption was related to taste of the unadulterated 
MDMA solution or to a lack of reinforcing effects.  However, the use of MDMA in 
humans when consumed orally suggests that it retains reinforcing properties under 
those conditions.  Ergo, it is logical to conclude that MDMA should also function as 
a reinforcer in animal subjects when delivered orally.  There is substantial support 
for the reinforcing effects of pharmacologically active compounds when delivered 
orally (Meisch, 2001; Ator & Griffiths, 2003).  While the majority of this research has 
focussed on alcohol, it has also been established with other drugs of abuse such as 
cocaine (Falk,ma & Lau, 1991; Miles, Everitt & Dickenson, 2003), amphetamine, 
ketamine (Carroll & Stotz,1983), pentobarbital (Meisch & Lemaire, 1988) and PCP 
(Carroll & Meisch, 1980; Carroll, 1982).  The majority of research utilising oral 
administration has been tested using rhesus monkeys, though rats and mice have 
been used to a lesser extent (Meisch, 2001).  The following section will examine 
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research and paradigms used for testing the reinforcing qualities of orally 
administered drugs.             
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Table 3.1: A summary of research related to MDMA self-administration in animals. 
Authors 
 
Species Methods Dose of 
MDMA 
Estimated 
M.D.C
1
 
R.O.A.
2
 Findings 
Beardsley et al. 
(1986) 
Rhesus 
monkey (n=4) 
FR10 
MDMA/saline 
substitution from 
cocaine baseline  
3-300 
μg/kg/inj 
7.8 mg/kg IV MDMA substituted for cocaine and was self-administered by at least 3 of the 
4 subjects for at least one tested dose.  In most cases MDMA was obtained 
at a rate much lower than cocaine.       
Lamb & Griffiths 
(1987) 
Baboons (n=3) FR160 – 3hr TO 
MDMA substitution 
from cocaine 
baseline. 
0.1-3.2 
mg/kg/inj 
9.6 mg/kg IV MDMA substituted for cocaine and maintained dose dependent 
consumption and response rates.  All except the lowest dose produced 
responding higher than vehicle responses.  MDMA self-administration was 
maintained at levels lower than that of cocaine.    
Ratzenboeck et al. 
(2001) 
Long Evans 
rats (n=19) 
FR1, 150 TO 0.032-10 
mg/kg/inj 
3.5 mg/kg IV No difference in MDMA S.A. between animals who experienced cocaine 
S.A. before MDMA.  MDMA produced lower rates of responding than 
cocaine.  MDMA S.A. higher during a second dose response determination. 
Fantegrossi et al. 
(2002) 
Rhesus 
monkeys 
(n=5) 
FR10:60 sec TO 
FR30:45 sec TO 
Substitution from 
cocaine 
0.001-0.3 
mg/kg/inj 
SR(+/-) 
MDMA 
S(+) MDMA 
R(-) MDMA 
4.8 mg/kg 
Racemate 
only 
IV Racemic MDMA and both of its isomers maintained similar biphasic dose 
response functions though peak responding was shown at different doses.  
Response rates were lower than both Methamphetamine and cocaine.  5-
HT2  Antagonist ketanserin and 5-HT2A antagonist MDL 100907 attenuated 
responding for (+) MDMA while both abolished responding for (-) MDMA.   
Braida & Sala 
(2002) 
Wistar rats 
(n=18) 
FR1 0.01-2.0 
μg/inj 
80 μg/kg ICV Subjects responded for ICV MDMA dose-dependently with a biphasic 
function with 1.0 μg/inj producing the highest response rate and 2.0 μg/inj 
the lowest.      
                                               
1 Maximum Daily Consumption: This value is an estimate of the maximum intake of MDMA consumed during self-administration sessions.  Values have been estimated using number of 
responses/infusions and doses and corresponds to the peak amount consumed irrespective of dose (in cases of multiple doses tested only the highest figure is presented.  Estimated values have 
been reconstructed from presented tables and figures and are approximate values only.  W here possible actual values from published results have been reported and are noted as such above.        
2 Route of administration. 
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Authors 
 
Species Methods Dose of 
MDMA 
Estimated 
M.D.C
1
 
R.O.A.
2
 Findings 
Schenk  et al. 
(2003) 
Sprague-
Dawley rats 
(n=11) 
FR1  
2,6 or 24 hr session 
length 
0.25-2.0 
mg/kg/inj  
21 mg/kg IV Demonstrated acquisition of MDMA in naïve rats that subsequently showed 
increased responding when drug dose was decreased (from 1.0 to 0.5 
mg/kg/inj) and extinction when MDMA was substituted with saline.  
Additionally rats produced dose dependent responding across the range of 
doses tested and subjects continued to respond throughout a 24-hr test 
session though most responding occurred primarily at the beginning of the 
session.    
Cornish  et al. 
(2003) 
Hooded Wistar 
rats (n=40) 
FR1, 20s TO 
Measured at 
normal 21°C and 
High 30°C ambient 
temperature 
0.1-1.0 
mg/kg/inj 
7.5 mg/kg 
normal temp 
only 
IV Rats freely administered MDMA in a dose dependent manner and to a 
lesser extent than cocaine controls.  Reponses for MDMA (and cocaine) 
were significantly increased in the high temperature condition.  There was a 
contingent decrease in hyperactivity at the high temperature indicating that 
increased locomotion was not responsible for the increased responding for 
MDMA.   
Wakonigg et al. 
(2003) 
Long Evans 
rats (n=5) 
Sprague-
Dawley rats 
(n=6) 
Runway procedure 1.0 mg/kg/inj -- IV MDMA produced shorter average runtime than saline controls for both 
strains suggesting positive reinforcing effects. 
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Authors 
 
Species Methods Dose of 
MDMA 
Estimated 
M.D.C
1
 
R.O.A.
2
 Findings 
Daniela et al.  
(2004) 
Sprague-
Dawley rats 
(n=6) 
FR1 plus DA D1  
receptor 
antagonism 
 
0.25-2.0 
mg/kg/inj 
22 mg/kg IV Antagonism with the D1 receptor antagonist shifted the dose response curve 
for MDMA self-administration to the right implicating dopaminergic 
mechanisms in the self-administration of MDMA.  
Fantegrossi et al. 
(2004) 
Rhesus 
monkey 
(n=4)  
FR10:60 sec TO 
Cocaine/saline 
substitution 
0.03-0.3 
mg/kg/inj 
SR(+/-) 
MDMA 
S(+) MDMA 
R(-) MDMA 
1.26 mg/kg 
Racemate 
only
3
 
IV Dose response curves were determined several times over the course of 18 
months of cocaine and MDMA administration.  Results showed that 
responding for racemic and (-) MDMA were attenuated between the first and 
last dose effect determinations.  Results were less mixed for (+) MDMA with 
at least one animal showing attenuation and another increased responding 
between determinations.  The effect was specific to MDMA and suggests 
long term changes in reinforcing effects may be apparent after long term 
dosing.            
Lile et al. (2005) Rhesus 
Monkey (n=4) 
Progressive Ratio 
MDMA substitution 
from cocaine 
baseline 
 
0.01-0.56 
mg/kg/inj 
-- IV Subjects initially trained on cocaine, various doses of MDMA substituted for 
cocaine self-administration under PR schedules.  MDMA maintained lower 
peak BP‟s than cocaine over a lesser dose range .  Authors suggest  MDMA 
is a lower efficacy reinforcer  than cocaine    
Reinhard & 
Wolffgramm  
(2005, 2006) 
Wistar rats 
(n=16) 
Free-choice two 
bottle test 
50mg/L 4.433 mg/kg
4
 PO The only study to have examined oral administration of MDMA in respect to 
its reinforcing abilities.  Subjects strongly preferred water to the MDMA 
containing solution.  Stable pattern of low level consumption of MDMA over 
a 49 week period with subjects decreasing intake over the course of the 
study.  Consumption resumed after a 12 week abstinence period, but rats 
failed to defend access strongly when MDMA was adulterated with aversive 
quinine.        
                                               
3 Data reported, averaged across all doses tested 
4 Data reported, represents ccumulative intake over 49 weeks of testing.  
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Authors 
 
Species Methods Dose of 
MDMA 
Estimated 
M.D.C
1
 
R.O.A.
2
 Findings 
Trigo et al. (2006) Mice  FR1 nosepoke 
Progressive Ratio 
0.06-1.0 
mg/kg/inj 
4.25 mg/kg IV Established MDMA self-administration in naïve mice making the procedure 
suitable for the study of K.O. strains.  Dose-dependant effects found for both 
acquisition and responding.  Progressive ratio found dose dependent 
decreases in B.P with increased dose.     
Daniela et al. 
(2006) 
Sprague-
Dawley rats 
(n=30) 
FR1, FR2, FR5 
 
0.5-1.0 
mg/kg/inj 
22 mg/kg IV Subjects compensated to increases in response requirement and 
maintained similar rates of drug intake despite increased economic strain.  
Responding ceased when put into extinction and resumed after 
reinstatement of the drug reinforcer.  Additionally subjects required more 
sessions to extinguish when a light stimulus previously paired with MDMA 
was present during extinction.  Removal of both the light and the drug 
however resulted in rapid extinction.  Responding also decreased in the 
drug present/light absent condition suggesting that the conditioned 
reinforcing properties of the light may be important for the self-administration 
of MDMA.         
Reveron et al. 
(2006) 
Sprague-
Dawley rats 
(n=12) 
FR1  
Acquisition phase, 
days 1-10 
Maintenance phase 
days 11-20 
0.5-1.0 
mg/kg/inj 
6.5 mg/kg IV During the acquisition phase rats received 1.0 mg/kg/inj MDMA.  
Responding and drug intake increased during the maintenance phase.  
Subjects showed experience dependent changes in temperature 
(hypothermic-normal) and locomotor activity (normal to potentiated) as a 
function of increased exposure to MDMA.    
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Schenk et al. 
(2007) 
Sprague-
Dawley rats 
(n=23) 
FR1 
Progressive Ratio 
0.25-1.0 
mg/kg/inj 
-- IV Acquisition was tested with 0.25 and 1.0 mg/kg/inj MDMA over 6-hour daily 
sessions and approximately 60% of the animals acquired MDMA self-
administration over the 15 day test period compared with 100% of the 
cocaine comparison group.  There were no real differences in the latency to 
acquire MDMA self-administration as a function of dose.  MDMA produced 
dose-dependant increases in BP as a function of increased dose.       
Ball et al. (2007) Sprague-
Dawley rats 
(n=14) 
FR5:6 sec TO-
extinction –
reinstatement 
0.3 mg/kg/inj 2.5 mg/kg
5
 IV Tested acquisition across 14 daily sessions followed by extinction by 
removal of drug plus light/tone stimuli.  After extinction (average 5 days) 
reintroduction to the light/tone stimulus resulted in reinstatement of the 
previously extinguished responding showing that stimuli paired with self-
administered MDMA can lead to reinstatement/relapse.  However, a 
5.0mg/kg injection failed to reinstate responding.     
Dalley et al. 
(2007) 
Lister Hooded 
rats 
(n=6) 
FR1 0.5 μg/kg/inj 
(as the free 
base) 
23.3 μg/kg  Rats acquired MDMA self-administration at a slower rate than both 
Methamphetamine and d-amphetamine though responding was 
approximately equal across drugs after the 21-day testing period.  Enduring 
deficits in attention were found after a 6 weeks withdrawal period in 
response to challenges as measured with a 5 choice serial reaction time 
task.       
Wang & 
Woolverton  
(2007) 
Rhesus 
monkey (n=6) 
Progessive ratio 
Substitution from 
cocaine/saline BL 
0.025-0.8 
mg/kg/inj of 
MDMA,  
(+)-MDMA or 
(-)-MDMA 
6 mg/kg 
Racemate 
only 
 Progressive ratios were used to test relative reinforcing efficacy of MDMA or 
its individual isomers.  Both (+/-), and (+)-MDMA functioned as a reinforcer 
with the (+) isomer producing more responding (albeit not significantly).  The 
(-) isomer (primarily 5-HT release) did not function as a reinforcer in 3 of the 
5 animals tested.  Cocaine and Methamphetamine both produced higher 
numbers of drug infusions suggesting that MDMA is a weaker reinforcer 
than those two more prominent drugs.  
Trigo et al. (2007) Wild type mice  
SERT K.O. 
mice 
FR1 nosepoke 0.03-0.25 
mg/kg/inj 
-- IV WT mice steadily acquired MDMA self-administration but SERT K.O. mice 
did not acquire self-administration at any dose. 
                                               
5 Average reported data for the last 5 days of self-administration testing. 
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De La Garza et al. 
(2007) 
Wistar rats 
(n=20) 
FR2 or FR1 0.185-1.5 
mg/kg/inj 
2.7 mg/kg
6
 IV Experiment 1 showed low rates of responding though one rat (of 5) did show 
dose dependent responding.  In a second experiment subjects showed 
greater responding for MDMA during the dark cycle (active phase) than 
during the light cycle.  However, when doses were changed to a lower dose 
or saline responding for MDMA did not recover.    
Schenk et al. 
(2008) 
Sprague-
Dawley rats 
(n=9) 
FR5-extinction-
reinstatement 
0.5 mg/kg/inj 24 mg/kg IV Subjects maintained high rates of responding for MDMA prior to extinction.  
After extinction both priming injections of MDMA or cocaine dose-
dependently reinstated previously extinguished responding despite only 
being given infusions of vehicle.  Reinstatement was also observed after the 
return of the light stimulus, though to a much lesser extent.  
Banks et al. 
(2008a) 
Rhesus 
monkeys (n=5) 
Concurrent FR30 
(MDMA) : FR30 
(Food) 
Both 30 sec TO 
0.03-0.3 
mg/kg/inj 
2.25 mg/kg
5
 
±0.43  
IV Examined the effects of ambient temperature using a concurrent choice 
procedure between MDMA and food.  At room temperature subjects 
preferred MDMA over food for all doses except the lowest.  At the high 
ambient temperature subjects also showed a preference for the lowest dose 
over food, suggesting an increase in relative reinforcing efficacy.  At low 
ambient temperatures only the high dose of MDMA showed a clear 
preference indicating the relative reinforcing efficacy may have decreased.  
MDMA given non-contingently dose dependently increased responding 
when saline was substituted for MDMA however this reinstatement was not 
effected by changes in ambient temperature.          
Banks et al. 
(2008b) 
Rhesus 
monkeys (n=4) 
Concurrent FR30 
(MDMA) : FR30 
(Food) 
Both 30 sec TO 
0.03-0.3 
mg/kg/inj 
4-22 mg/kg
7
 
 
IV Subjects self-administered MDMA for a period of at least 6 months.  After 
which PET scans were taken and to examine SERT availability.  It was 
found that subjects in the MDMA group showed no differences in SERT 
availability than control subjects.  In comparison a cocaine control group 
found up regulation of the SERT.  It is unclear why do deficits were found 
though the possible remains that either the process of self-administering the 
drug or more likely the total amount of drug consumed was not sufficient to 
produce detectable deficits.       
                                               
6 Data reported. 
 
7 Range of the weekly average reported. 
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Banks et al. 
(2008c) 
Rhesus 
monkeys 
(n=4)* 
reanalysis of 
data obtained 
from (Banks et 
al., 2008a) 
Concurrent FR30 
(MDMA) : FR30 
(Food) 
Both 30 sec TO 
0.03-0.3 
mg/kg/inj 
--  MDMA produced a dose dependent decrease in overall response rate.  In 
addition MDMA caused a dose dependent decrease in RR for both drug and 
food.  In comparison cocaine did not produce a decrease in RR for food.  
Running RR for individual drug levers did not vary as a function of dose 
suggesting that RR is independent of reinforcing strength.     
Reveron et al. 
(2010) 
Sprague-
Dawley rats 
(n=9) 
FR1-20 sec TO 0.5-
1.0mg/kg/inj 
6.6 mg/kg IV Responding for MDMA increased gradually during an initial 10-day 
acquisition phase at 1.0mg/kg/inj.  Responding and MDMA intake were 
significantly higher during a second 10-day maintenance phase when the 
dose was decreased to 0.5mg/kg/inj.  MDMA subjects showed decreased 
core body temperature during the acquisition phase and higher locomotor 
activity during part of the acquisition and all of the maintenance phase 
compared with saline controls.   
Brennan et al. 
(2009) 
Sprague-
Dawley rats 
(n=7) 
FR1 plus DA D2 
receptor 
antagonism 
0.5-2.0 
mg/kg/inj 
22 mg/kg IV Measured the effects of the D2 receptor antagonist eticlopride.  Eticlopride 
increased responding fro MDMA partially implicating the D2 receptor in the 
rewarding effects of MDMA.      
Feduccia et al. 
2010 
Sprague-
Dawley rats 
(n = 16) 
FR1-20 sec TO  
High ambient temp 
32°C 
Normal room temp 
23°C 
 
0.5-
1.0mg/kg/inj 
5.75 mg/kg 
total intake 
days 1-10 ≈ 
35 mg/kg 
total intake 
days 11-20 ≈ 
45mg/kg 
 
IV No effect of ambient temperature on intake of MDMA.  Subjects showed 
increased intake during the maintenance phase (MDMA 0.5mg/kg/nj, days 
11-20) compared with the acquisition phase (MDMA 1.0mg/kg/inj days, 1-
10).  Subjects showed increased core temp in the high ambient temp 
condition, but only during the maintenance phase.  Locomotor activity was 
enhanced for both high and normal temp conditions during maintenance 
phase.  High ambient temp significantly increased extracellular levels of 5-
HT in the NAcc compared with room temperature but temperature had no 
effect on extracellular DA in NAcc. 
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Oral self-administration of MDMA 
The benefits of an oral model of MDMA self-administration include the ability to 
more closely replicate the human condition in which MDMA is almost exclusively 
taken orally.  Also an oral method would bypass issues regarding catheter 
patency and allow for long-term parametric studies to be conducted (Meisch, 
2001).  In addition, it would be possible to examine the long-term effects of 
continued MDMA administration over longer time spans than is currently 
possible with iv self-administration in rodents.  Long-term studies may also help 
to elucidate the effects of tolerance upon MDMA self-administration and enable 
the study of the occurrence of other deleterious health sequelae such as 
MDMA–induced serotonin deficits.   
Typically an oral drug is perceived only to be reinforcing if the intake of a 
particular compound exceeds the consumption of that compound‟s vehicle 
solution (Meisch, 2001).  In general this means that the animal indicates a 
preference for the drug over vehicle solutions.  Much like drugs tested using the 
iv administration procedure, drugs that are delivered orally will commonly 
produce inverted u-shaped dose-response functions.  The inverted u-shaped 
dose-response curve consists of both an ascending and a descending limb.  In 
the former responding increases as a function of increases in dose, where as in 
the latter the inverse is true.  Under generally unrestricted drug access, subjects 
consume approximately the same total amount of drug per session regardless of 
the dose of drug, this is known as self-regulation or titration (Griffiths et al., 
1980).  Regulation of drug intake is evidenced in the descending portion of the 
dose-response curve where subjects increase or decrease responding in order 
to maintain relative similar levels of drug intake across doses, for example as 
doses increases the subject can regulate drug intake by decreasing responding 
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during a sessions and thus obtaining less reinforcers, but approximately the 
same level of drug intoxication.         
Meisch (2001) outlines several major factors that can hinder studies of oral self-
administration and must be overcome for successful oral self-administration.  
Firstly, consumption of oral compounds is often low due to factors such as the 
aversive taste, even in experienced animals.  Secondly, if consumption of a drug 
is too low then subjects may not experience the pharmacological effects of the 
drug in question.  Finally, a delay in onset of action of up to 5 minutes caused by 
oral administration is thought to decrease the likelihood that operant conditioning 
will occur (Meisch, 2001).  Conditioned stimuli have been shown to have an 
important role in the development and maintenance of self-administration.  For 
example, in iv self-administration removal of a conditioned stimulus (e.g. a light) 
paired with drug infusions will result in a decrease in responding (Daniela et al., 
2006; Schenk & Partridge, 2001).  In addition, presence of a conditioned 
stimulus is integral to studies of second-order schedules that can maintain self-
administration over large response requirements by response contingent 
presentation of conditioned reinforcers to maintain responding in the absence of 
frequent drug reinforcement (Schindler, Panlilio & Goldberg, 2002).  In spite of 
the delay in onset of action for oral drugs the taste of the solution can come to 
serve as a conditioned stimulus for the presence of the drug despite a lengthy 
delay between responding its central effects (Meisch, 2001).  So while the drug 
taste itself may start as potentially aversive it may actually come to signal the 
presence of up coming drug effects.   
Strategies have been developed in order to overcome the initial reluctance to 
consume oral drugs including substitution and fading procedures.  Substitution 
procedures rely on animals that have already developed self-administration of 
another drug (often alcohol).  Different drugs can then either be substituted 
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wholly for the previous solution or they can be mixed initially and the original 
solution faded by decreasing its concentration over time.  In a fading procedure 
(e.g. Samson, 1986) high rates of drinking are maintained by another fluid 
(usually sucrose or saccharin).  Gradually, doses of the drug are added to the 
solution in increasing concentrations over several, sometimes many, sessions.  
When intake is relatively stable the concentration of the adulterant solution is 
gradually decreased until only the drug remains.  This has proven to be a 
reliable way of demonstrating self-administration of oral drugs.                                              
Another common method used to establish oral self-administration is to employ 
a procedure that produces schedule-induced polydipsia (SIP) (Falk, 1961).  SIP 
is the excessive intake of water that can be induced when animals are exposed 
to intermittent schedules of food reinforcement.  Typically with this method 
animals are placed in a chamber that is programmed to deliver food pellets at a 
Fixed Time (FT) duration (for example FT60 seconds).  In addition to the 
presentation of food; animals are also given access to two water bottles; one 
containing a drug solution and the other its vehicle (usually water).  As animals 
increase their consumption of liquid (above levels normally seen) exposure to 
the drug solution increases.  Over time a long-lasting preference can develop for 
the drug solution (Falk & Lau, 1995).   
Critically important in SIP is the learning history of the animal.  In a study by Falk 
and colleagues it was shown that prior history with an adulterated drug solution 
that was then subsequently faded was necessary for the animals to reliably 
choose a cocaine solution to water.  After training almost all animals showed a 
clear preference for the cocaine solution over water.  The presumed mechanism 
for this effect is that the preferred vehicle becomes paired with the gustatory 
response to the drug resulting in the development of a strong conditioned 
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reinforcing effect even after fading of the vehicle solution (Falk, Neal & Lau, 
1997). 
The following experiments were designed to assess the reinforcing effects of 
MDMA when consumed orally.  In Experiment 3.1 a method similar to that of 
Reinhard and Wolffgramm (2005, 2006) was adopted whereby animals were 
given free access to both water and a solution containing MDMA in the home 
cage to see whether animals would readily consume MDMA when it was freely 
available.  Experiment‟s 3.2 and 3.3 used operant methods to measure the 
reinforcing efficacy of MDMA when the drug was delivered orally rather than 
intravenously, as has been the case in rodent studies up until now.  Finally, 
Experiment 3.4 systematically replicated the procedure of Daniela et al. (2004) 
to determine whether oral MDMA self-administration is mediated through 
dopaminergic mechanisms through concurrent administration of the DA D1-like 
antagonist SCH 23390. 
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Experiment 3.1A: Two choice free access in the home cage: Preference 
between MDMA and water  
  
Preference between drug and non-drug containing solutions has been 
previously used to determine whether a drug compound acts as a reinforcer.  
Experiment 3.1 was designed to test preference between water and MDMA-
containing solutions.  This was done by monitoring daily MDMA intake in the 
home cage when subjects had free access to both MDMA and water 
simultaneously.  Of additional interest was the amount of MDMA consumed 
when animals have free access to the drug in the home cage as a comparison 
with rates of intake in the operant paradigm used in Experiments 3.2, 3.3 and 
3.4.  
Experiment 3.1 was a partial replication of Reinhard and Wolffgramm (2005, 
2006), such that this study focused solely on the choice between water and 
MDMA in the home cage (in the original study the authors were interested in 
concurrent availability of MDMA and THC). The dose used in the current study 
differed from that used by Reinhard & Wolffgramm but was chosen based on 
pilot studies of an operant self-administration task in which MDMA solutions 
served as the reinforcer (see Experiment 3.2 for further details on this task).  
The dose used for the free-access choice procedure was selected on the basis 
that it was the dose that promoted the highest response rate during the oral self-
administration operant pilot studies. 
To date the studies conducted by Reinhard and Wolffgramm are the only studies 
to have tested MDMA‟s effects as a reinforcer when delivered orally.  Reinhard 
and Wolffgramm (2006) found that consumption of MDMA was highest through 
the first several weeks of the study but decreased to almost nothing by the end 
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of the 49 weeks of access.  They concluded that subjects held a strong 
preference for water over the drug containing solution when both solutions were 
concurrently available.  As noted in Table 3.1, the subjects consumed an 
average of 4.433 mg/kg of MDMA over 49 weeks.  However, the drug was 
available in a 50mg/L solution suggesting that the subjects very rarely 
consumed much fluid from the drug-containing bottle.  Wolffgramm and 
colleagues have previously shown that some drugs, including alcohol, the opiate 
etonitazene and d-amphetamine, will produce addiction-like profiles using this 
paradigm (Heyne & Wolffgramm, 1998).  Initially drinking behaviour is said to be 
“controlled” where consumption can be modulated by external circumstances 
such as changes in housing conditions, etc. These changes will have effects on 
the level of drug consumption, for example, increasing or decreasing intake.  
Whereas an “addicted” profile is indicative of a loss of control over drug 
consumption indicated by marked increases in intake and inflexibility of drug 
consumption (Wolffgramm, Galli, Thimm & Heyne, 2000).  For example, Galli 
and Wolffgramm (2004) showed that when rats were given access to water or d-
amphetamine (100, 200, 400mg/L) in the home cage subjects initially showed 
controlled drug intake that was modulated by housing conditions, i.e. subjects 
consumed more d-amphetamine when housed in isolation than when they were 
group housed.  After 40 weeks of access, six of the animals tested showed a 
large increase in drug consumption, while the remaining six animals did not.  
After a 10-week forced abstinence those animals showed an increase and 
subsequently maintained high rates of drug consumption even when the drug 
solutions were adulterated with bitter tasting quinine.  In contrast, those animals 
that did not show increased drug consumption remained flexible in their drug 
intake, i.e. adulteration with quinine reduced intake.  In a comparison group with 
only 16 weeks access to d-amphetamine none of the animals showed increased 
drug consumption, suggesting that length of access to the drug has an impact 
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on the change from “controlled” drug intake to “addicted”.  This result also 
suggests that not all subjects will progress to the point of addiction and some will 
remain in the controlled intake state in perpetuity.  In an earlier study, Heyne 
and Wolffgramm (1998) showed that the ability to choose was important to 
development of the addiction-type profile as rats that were forced to drink d-
amphetamine as the only available solution remained controlled in their drug 
intake and did not show perseverance in the face of quinine challenge as did 
subjects who instead had free choice.      
The following experiment tested MDMA consumption in rats given free access to 
MDMA in the home cage with the intention of comparing intake rates between 
home cage access and future experiments examining the operant delivery of 
reinforcers.  Previous research with iv self-administration indicates that MDMA 
acts as a reinforcer in animal models (see Table 3.1).  Furthermore, ethanol 
intake rates in home cage free-choice drinking paradigms by a range of ethanol-
preferring mice and rats are positively correlated with oral ethanol self-
administration in the same strains, but negatively correlated with conditioned 
taste aversion (Green & Grahame, 2008).  The relationship between home-cage 
free-choice drinking and self-administration would imply that MDMA will provide 
reinforcement in both free-choice and operant paradigms.  The results of 
Reinhard and Wolffgramm (2005, 2006) indicate only low rates of consumption 
of MDMA, however only a single dose of MDMA was tested.  It remains a 
possibility that the single dose used in that study was not sufficient to induce 
substantial central effects of MDMA.  The current study seeks to expand upon 
that research by using a higher dose of MDMA, one that that has been shown to 
maintain high rates of oral self-administration in pilot studies conducted 
previously.  The use of a higher dose may help to promote the MDMA-induced 
reinforcing effects.  In addition, the high rates of responding observed during the 
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pilot study indicate that the dose used in this study is not aversive as response 
rates were roughly equivalent with those seen for vehicle alone (See Experiment 
3.2 for more details).                   
 
Method 
Subjects: 
Subjects were six naïve male Sprague-Dawley rats bred in the Psychology 
Animal Facility at Victoria University of Wellington, housed individually in 
polycarbonate cages with cage tops made of metal grating in the testing room.  
The testing room was maintained on a reversed 12:12 hour light/dark cycle, with 
lights on at 6pm, and maintained at a constant temperature between 19-21°C.  
Animals were maintained at 85% of their free-feeding weights throughout the 
duration of the experiment.  Mean weight at the beginning of the experiment was 
380 grams (SD = 32.66).  Animals were treated in accordance with ethical 
guidelines set forth by the Victoria University of Wellington Animals Ethics 
Committee. 
 
Apparatus/materials:  
Equipment: 
Home cages were modified to allow the attachment two 120ml graduated 
drinking bottles (Habitrail Safari, Living World, Rolf C. Hagen Inc.) with a single 
ball drinking mechanism to the front of each cage.  Brackets for water bottles 
were positioned on the front of the cage 20mm from the side and 30mm from the 
top of the cage.  The brackets were positioned 80mm apart from one another.  
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When bottles were fitted into the brackets the spout protruded 20mm into the 
cage and was positioned 45mm above the cage floor.  
Solutions: 
+/-3,4-methylenedioxymethamphetamine hydrochloride (ESR, Porirua, New 
Zealand) was mixed with tap water at a concentration of 81.25mg/L.  Drug 
weights refer to the salt.  
Procedure: 
Animals were placed on a restricted diet and subsequently reduced to 85% of 
their free feeding weights.  Once baseline weights had stabilised, the standard 
water bottles were removed and replaced with a single graduated sipper bottle 
filled with tap water in either the left of right hand position on the front of the 
cage (alternated across rats).  Animals were acclimatised to the new drinking 
bottles over a 3-day period.  Subsequently a second bottle was filled with MDMA 
solution and placed in the free bracket of each cage. 
Daily measurements of fluid drinking were conducted between 10am and 12pm 
every day.  Briefly, both bottles were removed and the contents measured and 
recorded.  If any bottles needed refilling they were refilled at this time.  
Additionally, the animals were weighed before being placed back into their home 
cages and replacing the sipper bottles.  Animals were fed a restricted diet (85%) 
consisting of Diet 86 pellets (Sharpes, New Zealand). 
The location of the drug and water bottles was alternated after 21 days and data 
collection was continued for a total of 45 days. 
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Results and Discussion 
Daily intake measures for MDMA and water were averaged over successive 
3-day periods for analysis.  Figure 3.1 (top panel) shows the total average liquid 
intake in mls over 3-day time bins for MDMA and water.  Subjects showed a 
clear preference for water over the MDMA-containing solution drinking on 
average 22.75mls (SE = 1.31) of plain water in comparison to 3.70mls (SE = 
0.47) of MDMA.  A two-way repeated measures ANOVA between type of 
solution (water vs. MDMA) and time was performed.  There was a significant 
interaction between type of solution and time (F (14, 70) = 4.827, p < 0.01).  
Paired sample t tests revealed that water intake was significantly greater than 
MDMA (all tests significant, p < 0.05).  In order to examine how intake changed 
over time, paired sample t tests were conducted between only the first and last 
time blocks for both MDMA and water.  MDMA intake was significantly lower (M 
= 3.17, SD = 2.49) during the last time block than it was during the first (M = 
7.72, SD = 2.86).  This difference was significant, t (5) = 4.526, p = 0.008.  In 
contrast, water intake significantly increased (t (5) = -4.235, p = 0.008) from the 
first time block (M = 17.44, SD = 4.66) to the last time block (M = 27.28, SD = 
4.11).  Figure 3.1 (bottom panel) shows the median percentage of liquid intake 
from the drug-containing solution.  During the first 3-day block, subjects 
consumed approximately a quarter of their fluid intake from the MDMA solution 
(Mdn = 23.24, SD = 4.32) though individual subject variation was high with the 
minimum percentage MDMA intake being 7.27% and a maximum percentage 
MDMA intake of 39.09%.  Subsequently percentage intake from the drug 
containing solution decreased to less than 12% of the total fluid intake for the 
remainder of the study. A one-way ANOVA revealed a significant main effect of 
time on the percentage of intake from the drug-containing solution (F (14, 70) = 
2.611, p = 0.04). 
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Figure 3.1: (Top panel) Average liquid intake (mls) for MDMA (open circles) and water 
(closed circles) as a function of 3-day time bins.  (bottom panel) Percentage of daily intake 
consumed from the MDMA bottle averaged across 3-day time bins.  On day 22 the bottle 
of position of drug and water containing solutions was rotated.  Error bars represent 
standard error of the mean.   
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Over the course of the 45 days of study subjects had a mean total intake of 
34.40 mg/kg of MDMA (SE = 5.55, range, 17.82 – 53. 07mg/kg).  Figure 3.2 
shows total MDMA intake summed across successive 3 day periods.  MDMA 
intake was erratic with largest MDMA intake during the first 3-day block, and 
during the 8th block that corresponded with the alternation of the bottle position.  
To examine changes in the pattern of MDMA consumption for individual rats the 
cumulative intake of MDMA (mg/kg) for each individual was plotted as a function 
of the cumulative total of each 3-day time bin.  Figure 3.3 shows that total intake 
varied considerably across rats.  In general, rates of intake of MDMA were 
stable within individuals, with the exception of rat 6 for whom intake increased 
markedly when the bottle position was alternated.  Rat 6 showed a persistent 
 
Figure 3.2: Average daily intake of MDMA plotted as a function of 3-day average 
consumption.  On day 22 bottle position for MDMA and water-containing solutions 
was rotated.  Errors bars represent standard error of the mean.   
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increase in rate of drinking from the drug bottle after the change in 
position.
 
Overall this study showed that subjects had a clear preference for the water-only 
containing bottle.  However, all subjects continued to sample from the drug-
containing solution though subjects consumed less than 20% of their daily fluid 
intake from the drug-containing solution.  Visual inspection of the data revealed 
relatively few instances of an animal consuming no MDMA on a given day.  
Across all six animals no MDMA intake was only recorded in 14 out of a total of 
270 data points, representing approximately 5% of all recorded observances.      
Average MDMA intake was 0.83mg/kg per day (SE = 0.07); considerably less 
than that consumed in operant studies of iv self-administration (see Table 3.1).  
However, this study yielded higher rates of MDMA intake in comparison with the 
Figure 3.3: Cumulative MDMA intake in mg/kg plotted as a function of consecutive 3-day 
averages for 6 rats.  NB. On day 22 bottle position was rotated for all subjects.   
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results of Reinhard and Wolffgramm (2005).  In their study subjects consumed 
an average of 4.433 mg/kg of MDMA across the entire course of the 49 weeks 
of study.  In a comparatively shorter period of time (45 days or 6.4 weeks) 
subjects in this study consumed on average 34.40 mg/kg of MDMA (range = 
17.82 - 53.07).  It remains unclear why there is such a large disparity between 
intake across both studies, however the dose used in the current study was 
approximately 1.6 times stronger than the dose used by Reinhard and 
Wolffgramm.  It is not clear whether the amount of MDMA consumed in the 
current study produced any pharmacological effects because no tests were 
administered during the course of the study.  However, low doses of MDMA in 
rats have been shown to disrupt performance on a number of tasks, for example, 
delayed matching to sample (Harper, Wisnewski, Hunt & Schenk, 2005; LeSage, 
Clark & Poling, 1993) and the radial arm maze (Braida, Pozzi, Cavallini, & Sala, 
2002; Kay, Harper & Hunt, 2010).  In addition low doses of MDMA have been 
shown to produce robust drug discrimination (Oberlender & Nichols, 1988; 
Schechter, 1987, 1991), conditioned place preference (CPP) (Schechter, 1991) 
and reduce the reward threshold for electrical brain stimulation (Hubner, Bird, 
Rassnick & Kornetsky, 1988).  However all of these paradigms use bolus 
injections (ip or sc) that produce relatively rapid effects; this method differs 
markedly from the slow accumulation of MDMA that would occur during the free 
access paradigm.  It is also unclear when (light vs. dark cycle) and how frequent 
visits to the drug bottle were.  It would be beneficial for future studies to use a 
method that would allow for the analysis of drinking bout time as well as bout 
length.         
One factor that may contribute to the drug preference is experience with the 
drug in question.  The following experiment represents a partial replication of 
Experiment 3.1A using MDMA-experienced animals.  Subjects were tested 
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using the free-access choice procedure described in Experiment 3.1A in order to 
test whether previous exposure to oral MDMA consumption would have any 
effect on the concurrent choice between MDMA and water in the home cage.    
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Experiments 3.1B: Effect of prior drug history on drug preference using a two-
bottle free access choice procedure in the home cage  
 
Experienced animals for the current experiment were selected from those 
animals that had previously participated in an operant-based oral self-
administration procedure and had significant exposure to oral doses of MDMA.    
As subjects in the current study were already experienced with oral consumption 
of MDMA it was expected that there should be some transfer of overall intake 
rates from the operant task to the free-access paradigm.  Thus it is hypothesised 
that rats in the current study will consume MDMA via the free-access method 
equivalent to the operant method and that subjects should show higher levels of 
drinking and MDMA consumption than seen in the naïve rats studied in 
Experiment 3.1A. 
 
Method 
Subjects: 
The subjects used in this experiment were 12 male Sprague-Dawley rats 
previously used in Experiment 3.2 who had significant experience with oral 
administration of MDMA via the operant method (for a detailed description of the 
subjects‟ experience see Experiment 3.2).  Subjects were housed individually in 
polycarbonate cages with cage tops made of metal grating in the testing room.  
The testing room was maintained on a reversed 12:12 hour light/dark cycle, with 
lights on at 6pm, and maintained at a constant temperature between 19-21°C.  
Prior to the initiation of the current experiment, animals had been tested on a 21-
hour water deprivation schedule.  This water deprivation scheme was 
discontinued and animals were reduced to 85% of their free feeding weights.  
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Subjects‟ weights ranged between 350 and 530 grams prior to being placed on 
the restricted diet.  Housing conditions remained the same as used previously.  
Research was approved and all animals were treated in accordance with ethical 
guidelines set forth by the Victoria University of Wellington Animals Ethics 
Committee.               
 
Apparatus/materials:  
Equipment: 
See Experiment 3.1A.          
Procedure: 
A single bottle filled with tap water was placed in either the left or right position 
of each cage and rats were allowed to acclimatise themselves to the new water 
bottles for 3-days.  The water bottles were then removed and refilled with water, 
and an identical set of bottles was filled with 81.25mg/L MDMA solution and 
placed in the free bracket on each cage.  Assignment of water/drug bottles to 
the left and right positions was alternated across rats.  Animals had free access 
and choice to both bottles at all times. 
Daily measurements of the volume in each bottle were taken between 
approximately 10:00am and 11:00am each morning.  At this time the rats were 
also weighed and fed based on their 85% free feeding weight and any bottles 
that required filling were refilled.   
Consumption of both drug and water was recorded 7-days a week for a period of 
14 days.  On the eighth day the position of the water and drug bottles was 
reversed in order to take into account any bias effects 
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Results and Discussion 
Total MDMA intake per day was collected and the results are shown in Figure 
3.4.  On the first day of MDMA availability intake was the highest with intake 
decreasing rapidly on the second and subsequent days to a relatively stable 
daily intake of MDMA solution.  The range of intake varied across rats with the 
highest average intake across the 14-day period being 1.2mg/kg/day while the 
lowest intake among all of the subjects being 0.3mg/kg/day (SD = 0.29).  
Examination of the raw data revealed that on occasion some animals would not 
consume any fluid from the MDMA bottle, though these days only happened on 
occasion and only once for more than a single day.   
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Figure 3.4: Average MDMA intake (mg/kg) per day during using a two-bottle (MDMA vs. 
water) free access paradigm for 12 MDMA-experienced rats.  Error bars represent standard 
error of the mean.         
 
Figure 3.5: Average liquid intake in mls from two bottles containing either MDMA (81.25 g/L) 
(filled circles) or water (open circles) for 12 MDMA-experienced rats.  Error bars represent 
standard error of the mean.            
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While MDMA intake appeared to be low, consumption of plain water during the 
experiment was high.  As can be seen in Figure 3.5, MDMA and water intake 
(millilitres) were approximately even during the first day of testing, however, from 
day two onwards water intake began to increase while MDMA intake remained 
low.  Animals‟ could clearly differentiate between the bottles that contained 
water from those that contained the solution including MDMA.  Despite the high 
rates of responding for this dose of MDMA seen in Experiment 3.2A, this did not 
carry over to the free-access situation when plain water was available as an 
alternative.  Clearly animals were able to discriminate between solutions and 
showed a clear preference for the plain solution.  The ability to discriminate the 
solutions was likely the result of taste, though despite the differences in taste 
animals did continue to drink from the MDMA bottle and produced little evidence 
of exclusivity for the plain water bottle.          
After eight days the position of the drug-containing bottles was switched which 
resulted in a noticeable decrease in water intake and a small increase in MDMA 
consumption, though this difference was transitory suggesting that subjects 
rapidly acquired the new location of each of the bottles after an initial period of 
confusion.      
Despite their previous exposure to MDMA solutions the animals in this study 
reduced their intake of MDMA rapidly to a very low level and maintained high 
levels of water intake throughout the experiment.  When an MDMA solution was 
simultaneously available with plain water the water solution was preferred 
despite previous experience with oral reinforcement with MDMA.  The results 
found in this study are comparable with those found by Reinhard and 
Wolffgramm (2006), though animals in the current study showed higher rates of 
intake.  However, this study only lasted for a fraction of the time (2 weeks 
compared with 49 weeks) than that of Reinhard and Wolffgramm‟s study.   
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Despite the fact that rats in this study consumed on average more MDMA per 
day, it is possible that rats in the current study may have completely 
extinguished their MDMA drinking much like those in Reinhard and 
Wolffgramm‟s study did after long-term exposure to the drug.  Additionally, the 
fact that the subjects in the current study were drug experienced may have 
contributed to the higher rates of MDMA intake seen in this study in comparison 
to those of Reinhard and Wolffgramm.   
In contrast to expectations the rats in this study did not show a preference for 
the MDMA containing solution.  In addition, the MDMA-experienced animals did 
not show a significantly greater consumption of MDMA despite extensive 
experience compared with that of the naïve animals tested in Experiment 3.1A 
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Figure 3.6 shows a comparison between the results from Experiment 3.1A using 
naïve animals and Experiment 3.1B using MDMA-experienced animals.  Due to 
differing lengths of each experiment only the first two weeks of Experiment 3.1A 
was including in order to facilitate comparisons.  Surprisingly, rats who were 
naïve to MDMA prior to the beginning of the experiment actually showed greater 
levels of intake for both the first and second weeks of the study.  The rats that 
had prior exposure to MDMA (while participating in Experiment 3.2) showed 
lower levels of MDMA intake than those of the naïve group.  The MDMA-
experienced group showed a smaller decrease in MDMA consumption from 
 
Figure 3.6: Comparison of weekly MDMA intake (mg/kg) across naïve (n = 6) or MDMA-
experienced animals (n = 12).  Error bars represent standard error of the mean.      
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week 1 to week 2 relative to the naïve group, but the overall amount of MDMA 
intake was on average lower for the experienced compared with the naïve 
animals.  It is unclear why the experienced animals consumed less MDMA than 
their naïve counterparts, though the experienced animals had ample time for 
tastes preferences or tolerance to develop that may have had an impact on the 
results of this study.  
Further research is necessary in order to further examine the effects of 
free-access to oral MDMA solutions.  For example, the bitter taste of MDMA 
may promote preference for the plain solution over the drug-solution irrespective 
of the drug effect associated with it.  In addition, only a single dose of MDMA 
was used throughout the course of this study, which prevents any analysis of 
dose-dependent effects on intake.  In order to more fully examine the oral 
reinforcing effects of MDMA, further experiments utilised an operant paradigm in 
order to examine the effects of dose on oral self-administration of MDMA.     
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Experiment 3.2: Operant self-administration of a MDMA/water solution  
 
The literature reviewed previously has focused primarily on measuring MDMA 
self-administration using the iv route of administration.  Those studies indicate 
that MDMA functions as a reinforcer when delivered via the iv route of 
administration in animal subjects.  However, MDMA is primarily consumed as an 
oral drug in humans and thus the iv route of administration may not fully 
replicate the human experience with MDMA use.  It is likely that differences in 
metabolism and absorption will have profound effects on the pharmacological 
profile of orally administered MDMA and these effects may alter the 
effectiveness of MDMA to serve as a reinforcer.  The results of Experiment 2.1 
showed that onset of action for MDMA was delayed when delivered orally as 
measured by locomotor activity.  In addition, the maximal effect of MDMA was 
substantially lower when the drug was tested via the po route than it was when 
delivered ip or sc.  The attenuated response of orally delivered MDMA on 
locomotor activity suggests that there may also be decreases in MDMA‟s 
reinforcing effects when delivered via that route.  This notion is supported by the 
results of Reinhard and Wolffgramm (2005, 2006) that showed that MDMA was 
consumed only at low levels and in a controlled pattern when it was made 
available in drinking water.  The results of Experiment 3.1 also showed that low 
levels of MDMA were consumed using a similar method.   
In the majority of studies MDMA self-administration has been tested using 
instrumental responding under continuous or ratio schedules.  To date, operant 
methods have not been used to test the reinforcing properties of oral 
administration of MDMA.  The absence of this research remains an intriguing 
omission since it is not yet understood if MDMA will produce reinforcing effects 
in animal models that use oral rather than intravenous delivery.  The following 
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experiment presents an initial study using an operant paradigm to test the 
effects of orally delivered MDMA.  The experiment was modelled after those 
studies conducted in our laboratory using iv self-administration and simple 
schedules of reinforcement (e.g. Schenk et al., 2003, 2008).                                   
 
Method 
Subjects: 
Subjects were 12 experimentally naïve male Sprague-Dawley rats bred in the 
School of Psychology Animal Facility at Victoria University of Wellington.  
Subjects were aged approximately eight weeks old at the start of training and 
weighed between 240-285 grams at the beginning of testing.  Subjects were 
housed individually in polycarbonate cages cage tops made of metal grating 
situated in the testing room.  The testing room was maintained on a reversed 
12:12 hour light/dark cycle with lights on at 6pm and maintained at a constant 
temperature between 19-21°C.  Animals were fed ad libitum with food pellets 
(Diet 86, Sharpes, New Zealand) but water access was restricted and only 
available for a 90-minute period subsequent to daily test sessions.  Experimental 
sessions were conducted five days a week, however on days when subjects did 
not have experimental sessions they were given free access to water in the 
home cage.  Restricted access to water was reinstituted approximately 20-hours 
prior to the next week‟s scheduled experimental sessions.   Animals were 
treated in accordance with ethical guidelines set forth by the Victoria University 
of Wellington Animals Ethics Committee. 
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Apparatus/materials:  
Equipment: 
Experimental sessions were conducted in six ENV-008 modular test chambers 
(Med Associates Inc.) equipped with two retractable levers (ENV-112CM, Med 
Associates Inc.) situated at the front of the chamber to either side.  Chambers 
were enclosed in light and sound attenuating cubicles.   
Liquid reinforcers were delivered by a liquid dipper (ENV-202M-UP, Med-
Associates Inc.) in the volume of 0.1 cc per reinforcer.  The liquid dipper for 
presentation of reinforcers was situated in the centre at the front of the chamber 
2 cm from the chamber floor.  The two retractable levers were positioned to the 
left and right 8 cm from the liquid dipper and 3 cm from the sides of the 
chamber.  At the rear of the chamber a house light was positioned 22 cm directly 
above the chamber floor.   
Solutions: 
+/-3,4-methylenedioxymethamphetamine hydrochloride (ESR, Porirua, New 
Zealand) was mixed with tap water at doses ranging between  0.040625mg/ml 
and 0.825mg/ml.  All drug weights refer to the salt.  
 
Procedure: 
Acquisition Phase: 
Water-deprived rats were initially auto-shaped during daily 90-minute sessions 
to lever press and were reinforced with a single dip (0.06cc) of tap water.  Auto-
shaping lasted for approximately five days.  During the auto-shaping procedure 
the right lever would insert into the chamber and the house light would illuminate 
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signalling the availability of reinforcement.  If no response was recorded within 
30-s the lever would retract, the house light would extinguish and the liquid 
dipper would activate providing the subjects with a free reinforcer.  After a 30-s 
timeout a new trial would commence with insertion of the right lever and 
illumination of the house light.  Responses to the lever within 30-s of the lever 
insertion resulted in presentation of the dipper followed by a 5-s ITI after which 
the next trial began.  At the conclusion of each days testing animals were given 
access to water bottles for 90 min resulting in a 21-hour water deprivation 
regime across all conditions.      
Experimental testing began when all rats had successfully acquired lever 
pressing.  At the beginning of each test session the right retractable lever would 
insert into the chamber and the house light would illuminate.  Animals were 
reinforced for responding on the right hand lever on an FR1 schedule of 
reinforcement with a single dip of MDMA solution (dose range: 0.01mg/kg/reinf – 
0.2 mg/kg/reinforcer).  The left-hand retractable lever was never inserted into the 
chamber during test sessions thus had no scheduled consequence.  After 
completion of the response requirement (FR1) the lever was retracted, the 
house light extinguished and the liquid dipper was activated, resulting in 
presentation of the reinforcer.  The liquid dipper was set in the normally up 
position resulting in reinforcers being available for collection until another 
successful response requirement was met (resulting in the loss of any previously 
available, but not collected, reinforcer).  A 10-s ITI preceded the start of the next 
trial.   
After establishing responding at FR1 the response requirement was increased in 
order to promote increased responding during daily test sessions.  Initially the 
fixed ratio was increased to FR2 and later FR4.   
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Testing Phase 
After extensive experience with MDMA-reinforced responding a dose-response 
curve determination was conducted.  Beginning with the largest dose, animals 
were tested on each dose of drug for four consecutive days on an FR4 schedule 
of reinforcement.  The drug doses tested during this experiment in chronological 
order were: 0.2, 0.08, 0.04, 0.02, 0.01mg/kg/reinforcer and vehicle solution 
(H2O).  
Results and Discussion 
For each rat the number of responses made on the FR4 schedule was averaged 
across the four daily sessions of each dose.  Figure 3.7 shows the mean total 
responses across rats at each dose.  This figure shows that animals responded 
in a dose dependent manner, as dose decreased the subjects‟ responding 
increased thus maintaining intake of MDMA at a relatively stable level.  This 
group function was fairly representative of the dose response curves for the 
individual rats (see Figure 3.9).  With the exception of Rat 41 the rats were 
sensitive to changes in dose of MDMA; however, idiosyncratic differences in the 
total rate of responding were apparent.  Subjects 33, 36 and 46 produced more 
step-like dose-response functions where responding decreased sharply with 
increases in dose.   
A one-way ANOVA with repeated measures found a significant main effect of 
dose, F (4, 44) = 30.361, p < 0.001.  Post-hoc contrasts found significant 
differences in responding between doses (all p < 0.05) with the exception of that 
between the 0.08mg/kg and 0.2mg/kg/reinforcer doses (F (1, 11) = 2.745, p = 
0.126).          
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Figure 3.7: Dose-response curve for the oral self-administration of MDMA in a water 
vehicle.  Subjects were reinforced on an FR4 schedule.  Error bars represent standard 
error of the mean.          
 
Figure 3.8: Average daily MDMA consumption in mg/kg plotted as a function of MDMA 
dose.  Error bars represent standard error of the mean.   
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Figure 3.9: Dose-response curves for the oral self-administration for MDMA for 12 rats.  Subjects were reinforced according to an FR4 schedule 
of reinforcement.  Error bars represent standard error of the mean.        
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Figure 3.9: (cont) Dose-response curves for the oral self-administration for MDMA for 12 rats.  Subjects were reinforced according to 
an FR4 schedule of reinforcement.  Error bars represent standard error of the mean.        
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In order to calculate consumption of MDMA by the animals the total number of 
reinforcers was multiplied by the dose and the volume of each reinforcer before 
being divided by each rat‟s body weight on each session. Consumption of 
MDMA was analysed by examining the average amount of drug consumed as a 
function of dose and is displayed in Figure 3.8.  Data were averaged across 
each of the four sessions tested for each dose and the group function 
represents the average of all 12 rats.  Figure 3.8 shows consumption increased 
with increasing dose with the highest consumption of MDMA occurring for the 
highest dose tested.  A one-way ANOVA was conducted and showed a 
significant main effect of dose, F (4, 44) = 20.613, p < 0.001.  Post-hoc paired 
samples t tests were conducted and showed a significant difference between 
0.08 and both the 0.04 (t (11) = -3.302, p = 0.007) and the 0.2mg/kg/reinforcer 
doses (t (11) = -3.893, p = 0.003).  Consumption of MDMA was highest for the 
largest dose 0.2 mg/kg/reinforcer, despite subjects having the lowest response 
rate at that dose.  Note that some responding would be likely due to the 
water-deprivation conditions; hence it is unclear whether the consumption at the 
highest dose was the result of the drug‟s effects or alternatively a result of fluid 
deprivation.  Fluid deprivation seems unlikely as an explanation as the animals 
were exhibiting extremely low rates of reinforcement during the 
0.2mg/kg/reinforcer condition; gaining on average 4 reinforcers per session, or 
the equivalent of only 0.4ml.             
Responses throughout the session were analysed to look at the time-course of 
drug-reinforced responding throughout self-administration sessions.  Figure 3.10 
(top panel) shows the average number of responses throughout the 90-minute 
sessions in 10-minute bins as function of drug dose.  For all conditions the 
highest rate of responding occurred within the first 10-minutes of the session.  
Animals continued to respond at a slower rate during minutes 11-20 but 
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responding had virtually ceased by minutes 21-30.  A two-way repeated 
measures ANOVA showed a significant interaction between dose and bin, F (40, 
440) = 22.725, p < 0.001. There was an inverse relationship between dose and 
rate of responding suggesting that water deprivation was not the sole reason for 
responding.  Lower doses of drug had higher response rates than did higher 
doses of MDMA.  Figure 3.10 (bottom panel) plots the percentage of total 
responding plotted as a function of 10-minute time bins and indicates that the 
majority of responding for each dose (range 58%-64%) occurs during the first 10 
minutes of each session, after which responding sharply decreases during the 
next two time bins before dropping to virtually nothing. 
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Figure 3.10: (Top panel) Timecourse of responding for the oral self-administration of 
MDMA in rats.  Total responses for each rat were binned into 10 min blocks and 
averaged across each day of training for a particular dose.  Data represent averages 
across rats.  Error bars represent standard error of the mean.  (Bottom panel) 
Percentage of total responding for each dose plotted as a function of time bin.            
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In addition to testing different doses of MDMA subjects were also tested with 
water (vehicle) to determine any effects on behaviour potentially caused by 
thirst-activated responding due to the water deprivation.  The results are shown 
in Figure 3.7 and show that total responses in a session for water were higher 
than it was for any of the drug conditions.  A paired sample t test was conducted 
between vehicle and the dose that produced the highest total responding; 
0.01mg/kg/reinforcer.  Responding for vehicle was significantly higher than 
responding for the 0.01mg/kg/reinforcer dose, t (11) = 2.224, p = 0.048.  It was 
hypothesised that rats would show a preference for MDMA-containing solutions, 
but in contrast the highest response rate was for the drug-free vehicle.  Several 
factors may have contributed to this finding.  Firstly, the animals in this study 
were maintained on a rather strict water deprivation regime.  Animals only had 
access to water during the 90-minute sessions followed by a further 90-minute 
period of free access to water in the home cage.  Thus deprivation may have 
contributed to high levels of responding for water.  Animals were clearly able to 
discriminate water from the drug-containing solutions since water produced 
significantly higher responding than each of the five drug doses tested.  
However, it is possible that the discrimination evidenced here is caused by 
differences in the taste of the solutions as opposed to the effect of the drug 
itself.   
Unfortunately taste of the drug-containing solutions causes a potential confound 
that may be a factor in the dose-effect curves produced.  With each reduction in 
dose there is also a reduction in the taste of the solution.  Stronger doses of the 
drug have a stronger taste due to a higher drug concentration and are 
potentially more aversive, thereby suppressing responding at higher 
concentrations.  However, with no adulterant to mask the taste of the drug it is 
unclear whether the increases in responding were the result of the drug dose 
84 
 
manipulations or merely a response to a reduction in the potentially aversive 
taste of the drug-containing solutions.  This may explain why responding was 
highest for the lowest of the drug doses tested, as that solution may have tasted 
more akin to water resulting in a less aversive solution.  Of note here is the 
absence of a typical inverted U-shaped dose-response function consisting of 
both an ascending and descending limb.  It, however, remains possible that the 
ascending limb of the dose response curve is being masked by the high rates of 
responding for the vehicle solution.      
Due to the water deprivation regime used in this study the drug solutions may be 
acting as a compound stimulus consisting of the reinforcing drug properties, in 
addition to the reinforcing properties of the vehicle solution.  Of note here is that 
water deprivation (leading to thirst) may be acting as an establishing operation 
(Michael, 1993) that increases the value of the vehicle component.  Establishing 
operations are environmental events, conditions or states that alter the 
reinforcing effectiveness of a reinforcer either by increasing reinforcing value 
(motivating operations) or decreasing value (abolishing operations) (Tapper, 
2005).  For example, hunger is a motivating operation for food reinforcers; food 
has greater reinforcing value for someone who has not eaten than to someone 
who has.  Similarly, satiety can act as an abolishing operation in that food has 
less reinforcing value when someone has recently eaten.  For example, water 
has more value to a thirsty man in the in middle of the Sahara desert than to 
someone who is visiting a mall.  In addition establishing operations can act to 
increase or decrease goal-directed behaviours related to a given reinforcer 
(Michael, 1993; Tapper, 1995).  For example the thirsty man in the desert will 
expend more of his time searching for water than would the man visiting the 
mall.  In the context of the current experiment thirst would increase the value of 
water as a reinforcer and may contribute greatly to the reinforcing strength of the 
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combined drug-vehicle compound solution.  Generally speaking water is a weak 
reinforcer under conditions of free access, but much stronger under restricted 
conditions (for example see Case, Nichols & Fantino, Experiment 3, 1995).  
Because thirst may enhance the reinforcing properties of the vehicle, in this 
case water, making firm conclusions about the reinforcing properties of the 
actual drug solution independent of the reinforcing value of the vehicle is 
difficult.         
Further testing may have determined the contributions of the reinforcing 
properties of the drug versus the vehicle solution.  If lower doses of MDMA were 
tested and it produced compensatory responding above levels seen for the 
vehicle solution then it would be likely that the drug had at least some 
reinforcing properties.  Alternatively, if as dose decreased, responding 
decreased then it would be evidence for the ascending limb of the dose-
response curve.   
As both taste and water-deprivation have confounding effects preventing clear 
interpretation of the current results a further study was designed in which the 
effects of water-deprivation were removed and palatability of the solution was 
increased by adulterating the solution with sweetened saccharin solution in 
order to ameliorate taste-related factors in the oral self-administration of MDMA.     
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Experiment 3.3: Operant self-administration of an MDMA/saccharin solution  
 
The results of Experiment 3.2 showed that MDMA produced results consistent 
with the descending limb of the dose-response curve.  The results are also 
consistent (at least partially) with dose response curves generated for iv 
administration of MDMA and other drugs of abuse; however, the results of 
Experiment 3.2 are potentially confounded with both tastes and/or with the water 
deprivation conditions under which the animals were tested.  In order to 
overcome these confounding variables a further experiment was conducted to 
reassess the dose-response function in an MDMA solution containing saccharin 
as the vehicle.  Rats respond readily for saccharin solution so it was no longer 
necessary for subjects to be water-deprived prior to experimental sessions.     
Saccharin was chosen over sucrose for its non-caloric nutritional value in order 
to eliminate any confounds produced by the addition of calories to the solution. 
Another concern arising from Experiment 3.2 was that food intake was not 
controlled for in that study.  Though food was not available during testing 
sessions, there was no control over stomach content prior to daily sessions.  
The presence of food in the stomach may alter the efficacy of the drug by 
slowing absorption by delaying the gastric emptying allowing for increased 
metabolism due to a delay in reaching the gastrointestinal tract wherein the 
majority of absorption occurs.  Thus under such circumstances testing the drug 
under conditions that control for stomach content is highly desirable.  To this 
end subjects in the current experiment were tested at 85% of their free feeding 
weights and were fed their normal diet of rat chow post-session in order to 
directly control stomach content during experimental sessions.  
Much like water in the previous experiment, it is expected that saccharin-alone 
will produce relatively high rates of responding.  Of particular interest is whether 
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the MDMA/saccharin solution will produce a typical dose-response function and 
replicate the findings of Experiment 3.2 in non water-deprived animals. 
 
Method 
Subjects: 
This study used the same 12 subjects that had been previously used for 
Experiments 3.2 and 3.1B.  Subjects were 12 male Sprague-Dawley rats who 
had extensive experience with orally delivered MDMA solutions. Subjects were 
approximately ten months old at the beginning of this experiment and weights 
ranged from 395 – 523 grams (M = 452, SD = 34.8)  Animals were maintained 
at 85% of their free feeding weights with post-session feeding (Diet 86, Sharpes, 
New Zealand).  Water was freely available in the home cage.  Subjects were 
housed individually in polycarbonate cages cage tops made of metal grating 
situated in the testing room.  The testing room was maintained on a reversed 
12:12 hour light/dark cycle with lights on at 6pm and maintained at a constant 
temperature between 19-21°C.  Experimental sessions were conducted five 
days a week. 
 
Apparatus/materials: 
Equipment: 
Sessions were run in same chambers as those used during Experiment 3.2.  
However, during this study the dipper cup used to deliver the reinforcers was 
decreased to 0.02cc per reinforcer. 
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Solutions: 
MDMA hydrochloride (ESR, Porirua, New Zealand) was mixed in a vehicle of 
0.2% (w/v) Sodium Saccharin (Sigma-Aldrich, New Zealand) dissolved in tap 
water.  Due to the reduction in reinforcer size caused by the change in dipper 
cup, each drug dose was increased by a factor of five in order to produce an 
equivalent amount of drug in each reinforcer across Experiments 3.2 and 3.3 in 
order to accommodate for direct comparisons between these two studies.  The 
following doses were tested in this study; 0.02; 0.04; 0.08; 0.16mg/kg/reinforcer 
and vehicle-alone (0.2% saccharin solution).  All drug weights refer to the salt.  
 
Procedure: 
Subjects were run five days a week in daily 60-minute sessions.  It was noted 
during Experiment 3.2 that few responses were made in the last third of the 90-
session so session times in this study were decreased accordingly.   
At the beginning of each experimental session the right hand lever was inserted 
into the chamber and the house light illuminated.  Subjects were reinforced on 
an FR4 schedule with a single dip of liquid reinforcer (drug or vehicle).  
Following reinforcement there was a 10-s ITI before starting the next trial that 
was signalled by the insertion of the right-hand retractable lever and illumination 
of the house light.   
Initially subjects were tested with 0.2% saccharin vehicle solution as the 
reinforcer.  Testing for saccharin was continued for 14 days at FR4, with only 
the last five days testing used for subsequent analysis.  Following saccharin 
testing each drug dose was tested for five consecutive sessions (Monday to 
Friday) before examination of the next dose the following Monday.  The order of 
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testing was run in an ascending dose sequence beginning with 0.02, followed by 
0.04, 0.08 and 0.16mg/kg/reinforcer respectively.  Due to data loss caused by a 
computer error during testing of the 0.8mg/kg/reinforcer dose a further five days 
testing was conducted; however only the last five sessions were subsequently 
used in the data analysis.             
 
Results and Discussion 
The mean number of responses per session was calculated across each of the 
five sessions of each dose.  The results can be seen in Figure 3.11.  Results 
show that the mean total numbers of responses was highest for saccharin and 
for the 0.02 mg/kg/reinforcer dose of MDMA.  Lower total responding was 
shown for the 0.04, 0.08, and 0.16mg/kg/reinforcer MDMA doses respectively.  
A one-way repeated measures ANOVA found a significant main effect of Dose, 
F (4, 44) = 14.76, p < 0.001.  Pair-wise comparisons revealed significant 
differences between all MDMA doses (p < 0.01) but no significant difference 
between the lowest dose of MDMA (0.02 mg/kg/ reinforcer) and the saccharin 
vehicle.  
90 
 
 
Overall oral self-administration produced a typical dose-response curve with 
greater responding found for lower doses of drug.  As expected responding for 
the saccharin vehicle remained high, though the lowest dose of MDMA tested 
produced comparable responding.  The dose of MDMA appears to have strong 
control over responding and animals continue to respond for MDMA in a dose-
dependent pattern. 
Data collected from individual subjects are shown in Figure 3.12.  Rats 33, 35, 
36, 42, 44, 45 and 46 all produce typical dose-response curves, while rats 31 
and 34 produce functions that exhibit dose-dependant responding, though to a 
lesser degree.  Rats 32, 41 and 43 did not produce dose-appropriate 
responding, however, these animals also exhibit low response rates during the 
 
Figure 3.11: Dose-response curve for the self-administration of oral MDMA in 0.2% 
saccharin vehicle.  Subjects were reinforced on an FR4 schedule of reinforcement.  
Open circles represent drug-containing solution.  Closed circles represent the 
vehicle-alone condition.   Error bars represent standard error of the mean. 
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vehicle-only condition indicating an overall deficit in responding (data not 
shown). 
Further analysis was conducted to examine the total consumption of MDMA 
across each dose of drug.  The average total consumption of MDMA (mg/kg) is 
shown in Figure 3.13 and did not vary as a function of dose, F (3, 33) = 2.011, 
p = 0.131.  There were no significant differences found between levels of intake 
across doses indicating that animals adjusted their responding according to the 
dose of the drug.  Thus, lower doses of orally administered MDMA exhibited 
higher rates of responding as can be seen in Figure 3.11, while the total amount 
of drug consumed stayed the same across different doses tested.          
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Figure 3.12: Dose-response curve for the oral self-administration of MDMA in 0.2% saccharin solution for 12 rats.  Subjects were reinforced on a 
FR4 schedule of reinforcement.  Error bars represent standard errors of the mean.            
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Figure 3.12: (cont) Dose-response curve for the oral self-administration of MDMA in 0.2% saccharin solution for 12 rats.  Subjects 
were reinforced on a FR4 schedule of reinforcement.  Error bars represent standard errors of the mean.            
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Figure 3.13: Average MDMA consumption plotted as function drug dose (n =12).  Error 
bars represent standard error of the mean.    
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Figure 3.14: Average MDMA intake for individual subjects for water vehicle (black bars, 
Experiment 3.2) and saccharin vehicle (grey bars, Experiment 3.3) conditions.  Error bars 
represent standard error of the mean.   
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Comparison of saccharin vs. water vehicle conditions 
The current experiment used subjects who had already had significant experience 
with oral self-administration of MDMA in both the operant and free-choice 
paradigms (Experiments 3.1B & 3.2).  Both water (Experiment 3.2) and saccharin 
vehicle solutions (current study) were generally indicative of similar responding for 
MDMA as a function of dose.  The results in Experiment 3.3 were compared with 
those found in Experiment 3.2 in order to examine whether similar results were 
found for each vehicle condition (water vs. saccharin).  The dose-response curve 
produced for the animals in Experiment 3.2 was compared with the curve obtained 
from the current study.  Only those doses that were replicated across the 
experiments were included in this analysis.  A two-factor repeated measures 
ANOVA utilising dose (3-levels: 0.2, 0.4 and 0.8mg/kg/inf) and vehicle (2-levels: 
water vs. saccharin) found a significant main effect of dose, F (2, 22) = 20.36, p < 
0.001, but no significant interaction (F (2, 22) = 0.94, ns) or main effect of the 
vehicle (F (2, 22) = 0.03, ns).  Despite the differences in volume of reinforcer and 
vehicle there were no differences found between the dose-response curves for each 
experiment, at least across the common doses tested in these studies.  Further 
analysis was conducted on MDMA intake (mg/kg) across each of the vehicle 
conditions.  The average MDMA intake of each rat was averaged across doses for 
each vehicle and can be seen in Figure 3.14.  The grey bars in Figure 3.14 show 
the average MDMA intake for rats in this study (saccharin vehicle) was 
0.46mg/kg/session (SD = 0.22, range: 0.24 – 0.97mg/kg/session).  There was 
substantial variation between intakes across rats, though generally variation was 
low for a given rat.  Black bars in Figure 3.14 show corresponding intake levels for 
the same rats when water was the vehicle in Experiment 3.2.  Mean intake during 
Experiment 3.2 was 0.53mg/kg/session (SD = 0.21, range: 0.18 – 
0.96mg/kg/session).  Analysis by t test found no significant differences between 
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drug intakes for the water or saccharin vehicle conditions.  Individual analysis of 
each subject revealed that 7 out of 12 animals showed MDMA intake consistent 
across both vehicle conditions.  Of the five remaining subjects, four subjects 
showed substantially higher responding when water was the vehicle, while only one 
subject showed the opposite effect.  It is interesting to note that for those subjects 
that did show a change in intake across vehicle conditions tended to show a 
decrease in intake despite the addition of sweet tasting saccharin.   
The similarities noted between the results for Experiments 3.2 and 3.3 suggest that 
the interpretation of these results as drug-mediated responding is more plausible, 
rather than being due to confounds evident within Experiment 3.2 and noted 
previously.     
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Experiment 3.4: Effect of SCH 23390 on the oral self-administration of MDMA 
 
In light of the results found in Experiments 3.2 and 3.3 oral MDMA appears to 
promote and maintain at least a low level of self-administration behaviour in rats.  
However, it remains unclear how reinforcing the MDMA containing solutions are due 
to the high overall responding found for the vehicle conditions in both experiments 
using water and saccharin vehicles.   
A large body of literature has implicated dopamine in the reinforcing effects of many 
drugs of abuse (Di Chiara & Imperato, 1988; Di Chiara et al., 2004; Self & Nestler, 
1995).  Specifically, Daniela et al. (2004) showed the involvement of dopamine in 
the self-administration of MDMA by finding that pre-treatment with the D1 receptor 
antagonist SCH 23390 shifted the dose-response curve for iv MDMA self-
administration to the right.  In addition, Brennan et al. (2009) showed increased 
responding for MDMA due to partial blockade of post-synaptic DA receptors when 
subjects were administered the D2-like receptor antagonist eticlopride.  Fantegrossi 
et al. (2002) showed attenuation of MDMA self-administration through blockade of 
the 5-HT2 receptor using the antagonists ketanserin and MDL 100907, though this 
result was likely caused by the 5-HT2C receptor‟s ability to downregulate dopamine 
release (Alex & Pehek, 2007).      
The dopamine D1 antagonist SCH 23390 was administered prior to daily self–
administration sessions in order to test the extent to which MDMA contributes (via 
mediation of dopamine release) to the reinforcing properties of the oral solutions 
used in the current studies.  If responding for oral MDMA solutions is mediated by 
dopamine release then administration of the antagonist SCH 23390 should partially 
block dopamine binding and shift the dose response curve for MDMA to the right. 
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Method 
Subjects: 
Twelve naïve male Sprague rats participated in this study.  Animals were 
approximately four months old at the time of testing and weights ranged from 
293 - 337 grams (M = 318, SD = 11.9)   Animals were maintained at 85% of their 
free feeding weights with post-session feeding (Diet 86, Sharpes, New Zealand).  
Subjects were housed individually in polycarbonate cages with cage tops made of 
metal grating situated in the testing room.  The testing room was maintained on a 
reversed 12:12 hour light/dark cycle with lights on at 6pm and maintained at a 
constant temperature between 19-21°C.  Experimental sessions were conducted 
seven days a week.  Research was approved and all animals were treated in 
accordance with ethical guidelines set forth by the Victoria University of Wellington 
Animals Ethics Committee.                
 
Apparatus/materials: 
Equipment: 
Sessions were run in same chambers as those used during Experiments 3.2 
and 3.3.   
Solutions: 
MDMA hydrochloride (ESR, Porirua, New Zealand) was mixed in a vehicle of 0.2% 
Sodium Saccharin (Sigma Aldrich, New Zealand) dissolved in tap water.  The 
following doses were tested in this study; 0.003, 0.006, 0.0125, 0.025 and 0.05 
mg/kg/reinforcer and vehicle (0.2% w/v saccharin solution).  SCH 23390 (Sigma 
Aldrich, New Zealand) was dissolved in a sterile 0.9% saline solution and injected at 
a volume of 1ml/kg.  SCH 23390 was injected at a dose of 0.01mg/kg sc.      
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Procedure: 
Subjects were run seven days a week in daily 60-minute sessions.  At the beginning 
of each experimental session the right hand lever was inserted into the chamber 
and the house light illuminated.  Subjects were reinforced on an FR1 schedule with 
a single dip (0.02cc) of liquid reinforcer (MDMA + saccharin or saccharin-alone).  
Following reinforcement there was a 10-s ITI before the beginning of the next trial 
that was signalled by the insertion of the right hand retractable lever and illumination 
of the house light.   
 Subjects were initially autoshaped during daily sessions using a diluted sweetened 
condensed milk solution.  Once reliable responding was established condensed milk 
was replaced with 0.2% saccharin solution and animals continued daily sessions.  
Daily sessions continued until baseline responding for 0.2% saccharin stabilised 
after which experimental testing began.  Each dose condition consisted of 10 days 
of testing.  Day 1-4 consisted of baseline for the current reinforcer (MDMA + 
saccharin solutions or saccharin-alone).  Day 5-10 consisted of treatment days on 
which subjects received pre-treatment with either SCH 23390 0.01mg/kg or 0.9% 
saline injection administered sc in the homecage 15-min prior to daily sessions.  In 
total each subject received pre-treatment with  SCH 23390 or saline injections for 
three sessions each that were delivered in a pseudorandom order (determined 
individually for each rat by coin flip) such that SCH 23390 or saline were given for a 
maximum of two consecutive sessions.  The saccharin-alone condition was 
conducted first followed by MDMA dose conditions conducted in descending order. 
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Results and Discussion 
Baseline responding for MDMA 
Mean total responding for saline pre-treatment conditions is shown in Figure 3.15.  
Data from the saline condition was analysed in order to examine the dose-response 
function for the oral self-administration of MDMA.  A one-way ANOVA revealed a 
significant main effect of dose, F (5, 55) = 7.409, p < 0.01).  Contrasts revealed that 
all MDMA doses were significantly different from one another (all p < 0.05), but 
there was no significant difference between responding for vehicle alone and the 
0.003 mg/kg/reinforcer dose of MDMA.  This replicates the findings, using naïve 
rats, of significant dose-response relationships found previously in Experiments 3.2 
and 3.3.  However it must be noted that doses used in the current study were lower 
than those used in previous experiments.  Subjects had a mean MDMA intake 
across doses of 0.167 mg/kg (SE = 0.024).  In comparison, subjects in Experiment 
3.3 (which also used a saccharin vehicle) had a mean MDMA intake of 0.46 mg/kg 
(SE = 0.075).  In both experiments, responding for the lowest dose was 
approximately equivalent to saccharin-alone responding despite the dose ranges 
used in each experiment being different.   
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Figure 3.16 simultaneously plots the dose effects curves for both the current 
experiment as well Experiment 3.3 (plotted as reinforcers earned) and suggests that 
subjects in the current experiment appear to be more sensitive to the dose of the 
MDMA as evidenced by a shift in the dose-response curve to the left.  It must be 
noted that subjects in the current study were naïve when experiments began and 
had much less experience with oral MDMA than did subjects in Experiment 3.3.  
This raises the possibility that subjects in Experiment 3.3 had developed a tolerance 
to MDMA due to their extended experience with the drug in prior experiments.  The 
differences in dose-response functions across experiments are suggestive that the 
MDMA-experienced animals used in Experiment 3.3 may be more tolerance to the 
drugs reinforcing properties; however, care must be exercised as subjects in the 
 
Figure 3.15: Dose-response curve for the oral self-administration of MDMA in a 0.2% 
saccharin vehicle solution.  Rats (n = 12) were reinforced according to an FR1 schedule 
of reinforcement.  Error bars represent standard error of the mean.       
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current study received reinforcement under a continuous reinforcement schedule, 
while subjects in the Experiment 3.3 were reinforced on an FR4 schedule.  The 
effects of even subtle changes in ratio requirements have been shown to produce 
robust changes in responding across a range of reinforcers (see Chapter 4 for 
further discussion of this topic).  Furthermore, it remains a possibility that subjects in 
the current study were more sensitive to the bitter taste of the MDMA + saccharin 
solution and that decreases in concentration make the solution more palatable.   
 
 
 
  
 
Figure 3.16: Comparison of the dose-response curves for oral MDMA in 0.2% saccharin 
solution obtained from Experiment 3.3 (open circles, n = 12) and Experiment 3.4 (filled 
circles, n = 12).  Ordinate data represent average number of reinforcers earned during 
daily 1-hr sessions for Experiment 3.3 (FR4) and Experiment 3.4 (FR1).  Error bars 
represent standard error of the mean.     
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Effect of SCH 23390 on oral self-administration of MDMA 
The effect of SCH 23390 pre-treatment on the self-administration of oral MDMA is 
shown in Figure 3.17.  SCH 23390 suppressed responding below baseline levels for 
every dose of MDMA tested.  Pre-treatment with SCH 23390 also results in the 
suppression of responding for the saccharin-alone condition.  A two-way repeated 
measures ANOVA between dose (6 levels) and pre-treatment (saline vs. SCH 
23390) found a significant interaction, F (5, 55) = 7.087, p < 0.001.  Paired-samples 
t test confirmed significant reductions in responding for saccharin-alone, 0.003, 
0.0125, 0.025 and 0.05 mg/kg/reinforcer MDMA doses (all p < 0.05).  However, 
there was no significant difference found for the 0.006 mg/kg/reinforcer MDMA 
dose. 
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Mean intake (mg/kg) for each MDMA dose is presented in Figure 3.18 as a function 
of saline or SCH 23390 pre-treatment.  MDMA intake was higher for larger doses, 
and SCH 23390 decreased MDMA intake for all doses tested.  Two-way repeated 
measures ANOVA revealed a significant interaction between treatment and dose; 
F (4, 44) = 3.369, p = 0.012.  Post-hoc analysis revealed that MDMA intake was 
significantly lower after SCH 23390 pre-treatment for all doses except for the 0.06 
mg/kg/reinforcer dose of MDMA.  Inspection of the individual data revealed that in 
some rare cases while on the 0.06mg/kg/reinforcer dose subjects responded more 
when pre-treated with SCH 23390 than when they were pre-treated with saline.  
 
Figure 3.17: Effect of SCH 23390 (open circles) or saline (filled circles) on the dose-
response curve for the oral self-administration of MDMA in a vehicle of 0.2% saccharin.  
Rats (n = 12) were reinforced according to an FR1 schedule of reinforcement.  Error bars 
represent standard error of the mean.       
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However, this effect was not present in the either of the adjacent doses and is not 
suggestive of potentiated responding due to SCH 23390 pre-treatment, nor is there 
any clear indication of a shift in the dose-response curve for oral self-administration 
of MDMA. 
 
 
 
  
 
Figure 3.18: Average total MDMA intake (mg/kg) per day for saline and SCH 23390 
conditions plotted as a function of dose (n = 12).  Error bars represent standard error of 
the mean.        
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The current study sought to determine whether the reinforcing effects of oral MDMA 
were mediated through dopamine release.  Of primary interest was whether the 
D1-like receptor antagonist, SCH 23390, would shift the dose-response function for 
oral MDMA to the right.  A right-ward shift in the dose-response curve would be 
indicative of a decrease in the potency of MDMA as a result of partial blockade of 
dopamine receptors and suggest that responding for MDMA in this study was 
mediated by dopamine release.  Instead, the current results showed a general 
suppression of operant behaviour across the range of doses tested, including the 
vehicle solution.  It is possible that the decrease in responding noted in this study 
was a result of decreased motor activity due to the SCH 23390 pre-treatment.  
However, this seems unlikely for two reasons.  Firstly, levels of responding were 
actually higher after SCH 23390 pre-treatment for the 0.003 and 0.006 MDMA 
doses than it was for 0.05 MDMA after saline pre-treatment suggesting the 
reduction in responding was not a case of not being able to respond due to a 
locomotor impairment.  Secondly, Daniela et al. (2004) showed no effect of 
SCH 23390 pre-treatment on baseline locomotor activity counts using a 0.02 mg/kg 
dose, a dose that was twice the concentration of the dose used in the current study.  
Though in that study the 0.02mg/kg SCH 23390 attenuated MDMA-induced 
hyperactivity and the 0.01mg/kg dose did not. However, the reduction in responding 
noted in the current study indicates that 0.01mg/kg SCH 23390 is sufficient to cause 
significant decreases in reward-oriented behaviour.  However, administration of 
SCH 23390 in this study resulted in a non-specific deficit in responding for all doses 
and most importantly the vehicle solution.  It is well established that dopamine is 
integral to the rewarding properties of natural rewards, such as food and water 
(Wise, Spindler, De Wit & Gerber, 1978; Wise, 2006a, 2006b).  In this study 
SCH 23390 pre-treatment appears to have decreased the rewarding properties of 
saccharin.  Indeed, Nakajima (1986) found that administration of SCH 23390 dose-
dependently decreased responding for water, food and saccharin.  However, the D2 
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receptor antagonist sulpiride had no effect on the responding for any of the 
reinforcers tested.  Similarly, Shimura, Imaoka and Yamamoto (2006) found that 
micro-injections of SCH 23390 into the ventral pallidum (VP) significantly decreased 
saccharin intake but not that of water or quinine, while the D2 antagonist sulpiride 
had no effect on fluid intake.  The authors suggest that disruption of sweet-tasting 
saccharin, but not water or bitter-tasting quinine implicates D1 receptors in the 
ventral pallidum in the consumption of palatable tastes.  Based on previous studies 
D1 receptors appear to not be an appropriate target for antagonism when dealing 
with oral solutions that combine multiple reinforcing properties together, including 
the saccharin/MDMA combination used in the current study.  Antagonism of the D1 
receptor decreased responding for all conditions which makes interpretation of the 
deficit in responding difficult.  For example, the overall disruption across all doses 
(including saccharin-alone) may have been related to effects of SCH 23390 on 
saccharin responding and not on MDMA-mediated dopamine release as was 
intended.  Further doses of SCH 23390 were not administered due to the complex 
interaction between saccharin-intake and antagonism of the D1 receptor which 
presented a confound that was unlikely to be resolved regardless of the doses 
tested.  It remains unclear as to the contribution that MDMA-induced dopamine 
release has on the reinforcing properties of oral MDMA, especially when adulterated 
with saccharin.  Indeed, there is no clear evidence that significant levels of 
dopamine were even being released as a result of oral self-administration of MDMA.  
The complex reinforcing profile of adulterated oral solutions of drugs may prevent 
further analysis using direct pharmacological techniques.  It warrants mentioning 
that even using normally unobtrusive water as the vehicle solution may well also run 
into interpretation difficulties upon pharmacological intervention.  One possibility for 
conducted future antagonist studies with oral MDMA would be using the intragastric 
(ig) method.  By bypassing the mouth and taste buds and administering the drug via 
catheter directly to the stomach, confounds such as taste, would be avoided 
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allowing for more tightly controlled studies.  An alternative approach would be to use 
behavioural (e.g., Behavioural economics or resistance to change) rather than 
pharmacological manipulations in order to delineate the differences between drug-
maintained and vehicle-maintained behaviour.   
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Chapter Discussion 
The previous studies reported in this chapter were designed to test the viability of 
oral methods of delivery of MDMA.  Experiment 3.1 examined the rate of drinking 
MDMA when presented in drinking water.  Rates of free drinking of MDMA in 
drinking water remained low throughout the duration of the study and plain water 
was consistently preferred to MDMA-containing solutions.  Experiments 3.2 and 3.3 
tested the operant self-administration of oral MDMA using either water or saccharin 
as a vehicle solution.  Finally Experiment 3.4 sought to test the pharmacological 
impact of D1-receptor blockade using the antagonist SCH 23390 on the oral self-
administration of MDMA.  Reliable dose-response functions were found in 
Experiments 3.2 and 3.3 consistent with the descending limb of the of the dose-
response curve despite minor differences in procedure and alternative vehicle 
solutions used across those studies.  These results were further replicated in 
Experiment 3.4 with a further group of naïve rats.  
Overall levels of MDMA intake were varied across experiments, with Experiment 3.2 
(water vehicle) producing the highest mean daily intake (M = 0.53mg/kg, SD = 
0.21).  Experiments 3.3 and 3.4 using a sweetened saccharin vehicle solution had 
mean daily MDMA intakes of 0.46mg/kg (SD = 0.23) and 0.17mg/kg (SD = 0.058) 
respectively.   It should be noted that Experiments 3.2 and 3.3 were conducted in 
the same animals and the results showed relatively consistent intakes (see Figure 
3.14) across the two experiments despite different vehicle conditions and minor 
methodological changes between the studies.  The results of Experiment 3.4 
however show a marked reduction in intake compared with the equivalent results for 
Experiment 3.3.  This result may be reflective of the experience of the previous 
subjects and a long history of MDMA intake across Experiments 3.2 and 3.1B prior 
to participating in Experiment 3.3.  The water deprivation conditions of the earlier 
study may have contributed to the higher intakes noted in Experiment 3.3 relative to 
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the drug naïve subjects in Experiment 3.4 who did not have prior exposure to oral 
MDMA.  Subjects in Experiment 3.4 appeared to be more sensitive to MDMA dose 
than those of Experiment 3.3 and this perhaps represents the development of 
tolerance due to long-term exposure to MDMA in the earlier study.  However, the 
development of tolerance in this case is merely speculative as further studies are 
needed to ascertain the extent of which tolerance develops to the reinforcing 
properties of oral MDMA.  It should be noted that the dose-response function as 
assessed during Experiment 3.4 used a range of lower doses in an attempt to 
produce both the ascending and descending limb of the dose-response function.  
However, like the earlier studies further reductions in dose did not reveal the 
ascending portion of the dose-response function as it was potentially obfuscated 
behind relatively high levels of intake for each of the different vehicle conditions.  
That both water and saccharin vehicle solutions both produced reinforcing effects 
may have occluded doses of MDMA that would normally form the ascending limb of 
the dose-response curve.   
Intake levels shown in the previous studies are largely at odds with the range of 
MDMA intake reported across several other rodent studies using the iv route of 
administration.  For example, the current studies showed extremely low levels of 
intake even compared with studies that showed low levels of iv MDMA self-
administration such as those by Ratzenboeck et al. (2001) (3.5 mg/kg), Cornish et 
al. (2003) (7.5 mg/kg), Reveron et al. (2006, 2009) (6.5-6.6 mg/kg), Ball et al. (2007) 
(2.5mg/kg) and De La Garza (2007) (2.7 mg/kg).  The current studies are even 
more at odds with  studies conducted in the present laboratory: Schenk et al. (2003, 
2007, 2008), Daniela et al. (2004, 2006) and Brennan et al. (2009) that have shown 
much higher rates of iv MDMA intake (range 21-24mg/kg).  Unsurprisingly, the 
results of the current studies are most consistent with those of Reinhard and 
Wolffgramm (2005, 2006) who tested MDMA intake via the oral route.  However, 
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intake of MDMA in the current studies was higher than found by Reinhard and 
Wolffgramm, though methodological differences may have contributed to this.  In 
addition, Reinhard and Wolffgramm found decreased consumption of MDMA over 
time, which was not evident in any of the current studies.   
The present results are difficult to reconcile with previous results due to the 
differences between po and iv administration.  Intravenous administration will result 
in a rapid onset of action and little to no metabolism before producing its effect in 
the CNS.  In contrast, the oral route will undergo significant metabolism that will 
significantly decrease both systemic and central bioavailability.  This prevents direct 
comparison of intake levels between the studies conducted using the iv route and 
the current study using the oral route of administration.   
Experiments 3.3 and 3.4 used an adulterated solution in order to make the drug 
more palatable.  However, the effectiveness of oral drugs, most notably alcohol, can 
be affected by either food or liquids taken either before, concurrently with or even 
after drug administration.  The effects of food or liquid are likely to modulate 
changes in a complex system involving absorption, metabolism and gastric 
emptying (Matthews, Overstreet, Rezvani, Devaud & Morrow, 2001).  However, 
saccharin does not appear to play a role in this system, perhaps due to its non-
nutritive nature.  For example, Roberts, Heyser and Koob (1999) showed that 
saccharin plus ethanol produced similar effects on blood alcohol levels as did plain 
ethanol; however a sucrose plus ethanol solution resulted in decreased blood 
alcohol levels despite greater consumption for the sucrose-ethanol rats (Roberts et 
al., 1999).  Matthews et al. (2001) found similar results indicating that blood alcohol 
levels were not reduced by adulteration with saccharin relative to ethanol alone; 
however, in contrast ethanol plus sucrose produced lower blood alcohol levels 
relative to ethanol intake.  The effects of adulteration have not been specifically 
tested for oral doses of MDMA, though the research conducted with ethanol 
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suggests that the combination of MDMA and saccharin should not affect absorption 
or metabolism to any greater extent than using water as a vehicle.   
Meisch (2001) suggests that in order to determine if a drug is reinforcing it must be 
shown that the drug be consumed at levels greater than its vehicle.  Unfortunately, 
for the present experiments that is not the case.  In this case both vehicle conditions 
(water or saccharin) acted as reinforcers in their own right.  Sucrose fading 
procedures (e.g. Samson, 1986) have been used as a way to initiate high levels of 
drinking drug solutions; once established the sucrose concentration is subsequently 
decreased gradually across sessions.  Subjects that undergo similar procedures will 
often maintain high levels of intake even after the sucrose concentration is reduced 
to zero.  This procedure has been used extensively with alcohol, where the drug 
itself is cheap and easily replaced, attenuating any costs involved with wastage etc.  
However the fading procedure is not a viable option when the drug in question is 
more expensive or difficult to obtain (as in the case of the current experiments).  
Hence the present studies were unable to be conducted using a fading procedure 
and thus be tested under conditions whereby the vehicle itself produces minimal 
reinforcing effects.                         
An alternative method by which the reinforcing qualities of MDMA could be tested is 
to use the intragastric (ig) method of self-administration.  This procedure is modelled 
on the iv self-administration procedure.  Instead of intra-jugular catheters the 
catheters are instead inserted through an incision into the stomach.  Intragastric 
administration lacks strong discriminative cues due to a lack of taste factors.  In 
order to overcome this, the operant response is tied to drinking of flavoured 
solutions, rather than lever responding or some other operant (Fidler, Clews & 
Cunningham, 2006).  Testing with intragastric self-administration would build upon 
the results found in the current studies and add to the literature concerning the oral 
reinforcing effects of MDMA.  The ig method is more suitable for testing antagonist 
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and agonist based experiments where the reinforcing properties are not confounded 
with the reinforcing strength of the vehicle such as they were in the current studies.  
However, the ig method, much like iv self-administration, is much less suited to 
long-term testing due to issues of catheter patency.  Regardless the ig method does 
provide numerous advantages such that future research into this method is 
warranted with MDMA.                        
The results of the current study found mixed evidence for the reinforcing properties 
of MDMA in rats when delivered orally.  On the one hand, the current studies 
provided consistent results with regard to dose-response functions for MDMA using 
two distinct vehicle conditions, water and saccharin.  However, high response rates 
for water and saccharin when presented without MDMA preclude any formal 
pronouncement of the reinforcing properties of MDMA itself.  Further analysis of the 
reinforcing effects of MDMA-containing oral solutions is necessary to tease apart 
the relative contributions of MDMA and the vehicle solution.  The analysis of relative 
reinforcer efficacy provides a potential solution to this problem.  Measuring the 
relative reinforcer efficacy of MDMA + vehicle versus the relative reinforcer efficacy 
of the vehicle alone would provide a means to dissociate the reinforcing effects of 
MDMA from that of its vehicle.  In addition, measurement of relative reinforcer 
efficacy forms the basis of a quantitative method of comparing reinforcing strength 
across drugs of abuse.  The following chapter details several procedural and 
analytical approaches towards an analysis of the relative reinforcing efficacy of 
orally administered MDMA.      
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Chapter 4 BEHAVIOURAL ECONOMICS 
 
Traditional self-administration methods only allow us to determine whether a drug 
acts as a reinforcer or not.  The drug is considered be reinforcing if it initiates or 
supports the maintenance of self-administration behaviour (Spealman & Goldberg, 
1978).  In essence the self-administration procedure when tested using continuous 
reinforcement or fixed ratio requirements (i.e., FR1 or FR5) allows only a 
„qualitative‟ measure of a given drug‟s reinforcing properties (Richardson & Roberts, 
1996).  However, these same traditional methods of self-administration do not allow 
us to determine how strong a reinforcer that drug is relative to other reinforcers, 
known as relative reinforcing efficacy.  Different methods must be adopted that can 
instead provide a „quantitative‟ measure of the reinforcing properties of a drug. 
The term relative reinforcing efficacy refers to the behaviour-strengthening or 
behaviour-maintaining effects of drugs of abuse (Bickel, Marsch & Carroll, 2000).  
As relative reinforcer efficacy varies as a function of different drugs of abuse it has 
been used to refer to the rank ordinal relationship between reinforcers based on the 
strength of that reinforcer to maintain operant behaviour (Katz, 1990; Stafford, 
LeSage & Glowa, 1998).  Due to the close correlation between drugs abused by 
humans and preclinical results with animals models (e.g. Schuster & Thompson, 
1969; Griffiths et al., 1980) relative reinforcer efficacy of drugs of abuse has come to 
be analogous with the abuse liability of drugs of abuse in clinical settings and the 
real world.  For the purposes of this thesis the terms relative reinforcer efficacy and 
abuse potential will be used interchangeably.        
Reinforcing efficacy of a drug can be measured by assessing a subjects‟ 
„motivation‟ to consume that drug.  Motivation can be conceptualised as the amount 
of effort or “work” required to gain access to the drug.  By manipulating the amount 
115 
 
of effort required to obtain drug reinforcers we can obtain behavioural measures for 
that drug‟s strength to act as a reinforcer.  For example, a drug that maintains 
higher rates of responding as the difficulty of obtaining that reinforcer increases (e.g. 
increased FR schedules) would be considered a stronger reinforcer than a drug of 
equal potency that produced lower rates of responding.  Hodos (1961) developed a 
procedure called Progressive Ratio (PR) in which motivation to consume reinforcers 
was measured as a function of incrementally increasing response ratios during a 
given session.  Hodos showed that rats were willing to work longer and harder to 
obtain stronger concentrations of sweetened condensed milk and concluded that 
stronger concentrations of the reinforcer represented higher rewarding strength.  
The progressive-ratio procedure was later adopted by pharmacologists and saw 
increasing usage as a means of assessing relative reinforcing efficacy (see 
Richardson & Roberts, 1996; Stafford et al., 1998, for review).              
Progressive Ratio Schedules 
The primary attribute of the PR schedule is that the animal is subject to an 
incrementing FR schedule whereby each successive reinforcer requires an 
incrementally larger number of responses in order to obtain reinforcement.  In a 
typical progressive-ratio experiment the FR requirement will be manipulated within-
session by incrementing the FR after each successive reinforcer is obtained.  In this 
way each reinforcer becomes progressively harder to obtain.  For example, the FR 
may double with each successive reinforcer (e.g. 1, 2, 4, 8, 16) or may be 
incremented in some other incremental pattern (often exponential).  The point at 
which reinforcers are no longer obtained is defined as the „breakpoint‟ (BP), that is 
to say the point at which the subject is no longer willing to expend additional effort in 
order to obtain further reinforcement.  
When drugs of abuse are considered we can potentially use relative reinforcer 
efficacy as a measure of a drug‟s abuse liability or addictiveness.  Though 
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pharmacokinetic, pharmacodynamic and genetic factors are important in the overall 
assessment of abuse liability, drug seeking in the face of increasing costs reflects 
one definitive area with which we can quantify the addictive properties of drugs of 
abuse.                                                 
While it is generally acknowledged that MDMA is a weak reinforcer (at least relative 
to more prominent drugs of abuse such as cocaine or methamphetamine) only a 
small number of studies have attempted to quantify this by assessing MDMA‟s 
relative reinforcing efficacy.   Progressive ratios have been used previously to 
measure relative reinforcing efficacy of MDMA in non-human primates (Lile et al., 
2005; Wang & Woolverton, 2007), mice (Trigo et al., 2006) and rats (Schenk et al., 
2007).  Lile and colleagues compared the relative reinforcing efficacy of cocaine and 
MDMA in rhesus monkeys using a progressive ratio.  They found that both drugs 
maintained higher BPs than saline; however, MDMA maintained lower peak BPs 
across a smaller range of doses than did cocaine.  Similarly, Wang and Woolverton 
(2007) used a progressive ratio to study the relative reinforcing efficacy of 
Methamphetamine (MA), (±)-MDMA and each of its isomers ((+)-MDMA and (-)-
MDMA).  They concluded that MA produced the highest BPs irrespective of the 
potency difference (MA is more potent than MDMA by approximately a factor of ten) 
suggesting that MA is a stronger reinforcer than MDMA.  MDMA showed differences 
in relative reinforcer efficacy as a function of condition, with (+)-MDMA producing 
the highest breakpoints and (-)-MDMA producing the lowest suggesting that the 
primary reinforcing properties are attributable to the (+)-MDMA isomer.  Schenk and 
colleagues used a progressive ratio in MDMA self-administering rats and found that 
BP increased as a function of increasing dose suggesting that higher doses of 
MDMA were more efficacious (Schenk et al., 2007).  Curiously, Trigo et al. (2006) 
found the opposite to be true when a progressive ratio was utilised in MDMA self-
administering mice.  That is, BP values decreased as a function of increased dose.  
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The result found in the Trigo et al. study is suggestive of the mice titrating their 
consumption of MDMA.  It is possible that under high dose conditions, fewer 
responses were enough to satiate the mice, thus they ceased responding.  Thus the 
Trigo et al. study may be confounded by drug satiation such that motivation to 
continue responding in the face of increased response cost is diminished.  One way 
to avoid such a situation is increase the rate at which the ascending FR sequence 
increases such that an animal is never satiated during the course of a progressive 
ratio session.  MDMA may be more susceptible to satiation of this type as its long 
half-life means that blood-levels will remain relatively constant throughout the 
session.  Faster acting drugs such as cocaine tend to promote continued 
responding throughout the experimental session due to its much faster elimination, 
thus animals must return to responding in order to regulate desired drug effect 
levels.  This idea is consistent with the notion that decreases in the interoceptive 
effects during a session (i.e. a dip below the preferred drug effect threshold) of the 
drug acts as a discriminative stimulus signalling it is time to return to responding 
(Panlilio, Thorndike & Schindler, 2008).  In this case responding is under stimulus 
control such that when the animal is sated it signals a time of non-reinforcement.  
However, when the subjective effects drop below threshold level it signals that 
further drug infusions will be reinforcing.   
Progressive ratios represent a relatively rapid method for the determination of 
relative reinforcer efficacy of drugs of abuse.  Indeed as little as two sessions are 
enough to produce enough data with which to compare two different drugs.  
However the within-session determination of break points produces relatively little 
behaviourally relevant data.  Only a single break point value is obtained for each 
session (Arnold & Roberts, 1997).  In addition, the differences in potency and in 
elimination noted for different drugs makes direct comparisons of BP values difficult.  
In the case of long half-life drugs, such as MDMA, it may be more appropriate to 
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study the effects of increased response requirements across sessions rather than 
within a single session.  Measuring behaviour across sessions and response 
requirements is a method commonly used in the field of Behavioural Economics 
which identifies and implements elements of microeconomic theory and applies it to 
the analysis of behaviour.  Behavioural economic theory has provided a popular 
alternative to progressive-ratio schedule for measuring relative reinforcer efficacy. 
         
Economic Concepts for the Analysis of Behaviour:   
I. Price 
In economic terms the number of responses (FR requirement) required to obtain a 
reinforcer can be considered to be analogous to price (Hursh, 1980).  Consider that 
a subject‟s repertoire of behaviour is its own form of currency.  It is able to expend 
that currency in the form of responses or effort.  The more effort I am willing to 
expend to obtain a reinforcer the higher effective price I have paid.  Hursh, Raslear, 
Shurtleff, Bauman and Simmons (1988) suggests that price is not simply a cost-
benefit ratio between the number of responses and the number of reinforcers 
gained, but also takes into account other additional factors.  For example, Hursh et 
al. (1988) manipulated both costs and benefits by changing the FR schedule and 
force required for lever depression (both cost factors) and also by changing the  
number of pellets obtained per ratio and the probability of reinforcement (both 
benefits).  These factors together all contribute to changes in unit price, or “the 
amount of work required per unit of the commodity” (Hursh et al., 1988, pp 419).  
Rachlin (2003) presents a more complex view of price in that an animal subject is 
not a member of a „money economy‟ where money is substitutable with any other 
good, he instead suggests that animals exist in a „barter economy‟ whereby they 
trade leisure time (i.e. time not responding) for access to reinforcers.  In this case, 
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the animal forgoes the ability to do other behaviours (cleaning, sleeping etc.) and 
instead responds on the lever, since lever pressing and leisure are considered 
mutually exclusive.   
The concept of unit price lends itself well to the analysis of drug reinforcers whereby 
researchers manipulate the dose of drug available during self-administration 
sessions.  Changes in dose reflect a change in the magnitude of the reinforcer and 
thus unit price may provide one way in which discrepant results might instead be 
reconciled to a simpler pattern of behaviour.  To examine this concept, Bickel and 
colleagues (Bickel, DeGrandpre, Higgins & Hughes, 1990) re-evaluated past 
literature relating to drug self-administration studies that had manipulated both drug 
dose and schedule of reinforcement with respect to the notion of unit price.  They 
found that of the ten studies they re-evaluated almost all produced data consistent 
with unit price.  That is, when total consumption of drug (mg/kg) was plotted as a 
function of unit price (schedule of reinforcement/dose of drug) different doses of 
drug all conformed to the same positively decelerating function (called a demand 
function).  This pattern of results was shown to be evident across multiple drugs, 
species and routes of administration indicating that unit price provides a convenient 
way of accounting for differences in dose.        
After showing the functional equivalence of different drug doses and response 
requirements to control overall consumption in their earlier re-examination of the 
literature, Bickel and colleagues sought to provide support for unit price using a 
prospective study.  Bickel, DeGrandpre, Hughes and Higgins (1991) tested this 
using human smokers while providing variable numbers of standardized puffs (1, 2 
and 4) on the subjects preferred brand of cigarettes.  In addition, response 
requirement was varied using FR 200, 400 and 1600 in order to produce six distinct 
unit prices.  Of prime interest to the experimenters were those unit prices that were 
replicated across different number of puff and response requirement conditions.  
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This resulted in three distinct unit prices with replications and data showed that 
consumption (number of puffs) was equivocal for 4 out of the 5 subjects tested and 
that consumption was independent of number of puffs and response requirement.  
Similarly, DeGrandpre, Bickel, Hughes and Higgins (1992) reanalysed studies 
testing the nicotine regulation hypothesis using unit price.  DeGrandpre et al. noted 
that studies on nicotine regulation (the changes in smoking behaviour as a result of 
changing nicotine yields) had shown often contrary results in the literature.  
However, when reanalysed using unit price (in this case the inverse of dose) there 
was a consistent positively decelerating function as a function of increasing unit 
price; that is consumption decreased as the unit price increased.  The reanalysis 
conducted by DeGrandpre et al. indicated that unit price and a behavioural 
economic analysis helped to reconcile several sets of discordant data.  The concept 
of unit price serves to integrate two different independent variables (schedule of 
reinforcement and reinforcer magnitude) previously thought to exert independent 
effects on behaviour into one single parsimonious measure that may help clarify 
areas in the literature previously thought to provide contradictory results (Bickel et 
al., 1990; Bickel, March & Carroll, 2000).       
Early researchers (Lea, 1978; Allison, 1979) raised the issue of adopting economic 
concepts for the study of behaviour.  This notion, later expanded upon by Hursh 
(1980, 1984) led to the adoption of several economic conventions such as using 
consumption (reinforcers gained) as the metric rather than the more traditional 
behavioural analytic measure of response rate (Hursh & Silberberg, 2008).  In 
addition to the effects of price, other economic principles such as the effect of 
substitutable and complementary goods, open and closed economies and the 
effects of restrictions on income have been used.  These concepts have all been 
successfully integrated into the field of behaviour analysis as a means of quantifying 
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behaviour and this led to the establishment of the field of Behavioural Economics 
(Hursh, 1980, 1984). 
II. Consumption 
Primarily behavioural economics is concerned with measuring consumption of a 
given commodity in the face of increasing costs (schedule of reinforcement).  This is 
in contrast with „real world‟ microeconomics where the key factor is the purchase of 
the commodity rather than its consumption.  For animal subjects there exists little 
reason to purchase an item other than its consumption or use.  Consumption is thus 
defined as the amount of commodity “X” consumed per day.  Using the term 
consumption, however, can serve to misrepresent its purpose as behavioural 
economics is not just concerned with appetitive reinforcers like food (Hursh et al., 
1988) but also various drugs of abuse (Bickel et al., 1991; Bickel, DeGrandpre & 
Higgins, 1993; Hursh, 1993; Rodefer & Carroll, 1996;  Hursh, Galuska, Winger & 
Woods, 2005), and also for animal welfare issues including such diverse reinforcers 
like access to mates (Patterson-Kane, Hunt & Harper, 2002), and nesting litters or 
dust bathing substrates in hens (Gunnarsson, Matthews, Foster & Temple, 2000).  
A given commodity is usually only obtainable during experimental sessions (i.e. a 
closed economy) such that the number of reinforcers obtained per session is 
equivalent to the consumption of that reinforcer (assuming equal amounts are 
available per reinforcer).  In the case of drug reinforcers the total dose consumed 
per kilogram can also be used and is particularly useful when testing multiple doses 
of the same drug as it allows for the analysis of consumption as a function of unit 
price (e.g. responses per milligram of drug).  In behavioural economics, Price is 
most commonly manipulated by changing FR requirements, higher fixed ratios 
representing higher prices, though any manipulation that increases the „work‟ or 
time required can be use to manipulate price.  Basic economic theory dictates that 
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as price increases consumption of that commodity will decrease. The function 
describing the effects of price on consumption is called a demand curve.     
III. Demand and Elasticity 
Demand for a given commodity can be assessed by plotting total consumption of 
that commodity against a range of prices; the resulting demand curve describes the 
inverse relationship between consumption of that commodity and its cost (Vuchinich 
& Heather, 2003; Hursh et al., 2005).   
Demand curves when plotted in log-log coordinates indicate two things.  Firstly they 
indicate the intensity of responding at a given point, or how much of a commodity is 
consumed at various prices (Bickel, Green & Vuchinich, 1995).  The height of the 
demand curve represents consumption and there is an inverse relation between 
consumption and price.  Secondly, the slope of the demand curve measures how 
sensitive consumption is to changes in price.  When price is low, consumption is at 
its highest and as price increases consumption typically decreases.  In economics 
this is known as the Demand Law (Allison, 1979).  At some point price become too 
high and responding will cease.  The rate at which this change occurs is described 
by the slope of the demand curve.  This sensitivity to changes in price is termed 
elasticity of demand (hereafter abbreviated to elasticity) and represents the ratio of 
proportional changes in consumption to proportional changes in price (Vuchinich & 
Heather, 2003).  When changes in consumption are in direct proportion to changes 
in price this is termed unit elasticity, i.e. a doubling of price results in a halving of 
consumption.  When consumption is defended such that consumption decreases to 
only a small degree with large changes in price this is termed inelastic demand 
(Hursh, 1984).  For example, inelastic demand is evident when increases in price 
are met with near-proportional increases in responding, thus the animals response 
output increases as a function of price while consumption across those prices 
remains fairly stable (Hursh & Winger, 1995; Hursh et al. 2005).  The opposite of 
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inelastic demand is termed elastic demand and represents when consumption 
decreases more than the proportional change in price; that is even small changes in 
price produce a larger than proportional decrease in consumption.  In terms of total 
responses elastic demand produces a decrease in response rate or total 
expenditure as function of increase in price (Hursh, 1984).   
In reality most commodities produce demand curves that span a continuum from 
inelastic to elastic demand; showing inelastic demand when prices are low and 
elastic demand at relatively higher prices (Hursh et al., 2005).  The point at which 
the shift from inelastic to elastic demand occurs is a useful predictor of the strength 
of a given reinforcer analogous to how a break point provides a measure of 
„motivation‟ to respond using progressive ratio schedules.  The point at which 
responding shifts from being inelastic to elastic also corresponds with the peak 
effort of responding.  Hursh (1984) proposes that inelastic demand is evident for 
essential commodities, like food, where the there is no other source of that 
commodity (or an alternative substitute), i.e. a closed economy.  In contrast elastic 
demand is expected for non-essential items or commodities that have an alternative 
available source (an open economy).  In general terms, inelastic demand is 
consistent with the definition of a „need‟ or a necessity, while elastic demand 
represents demand for a „want‟ or a luxury (Hursh, 1980; DeGrandpre et al., 1992).            
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IV. Modelling Demand 
Demand curves can be modelled mathematically in order to quantify changes in 
intensity (level shifts) as well as changes in slope (elasticity of demand) for a given 
commodity.  Hursh et al. (1988, 1989) conducted a series of studies manipulating 
unit price by changing FR, lever weight, number of pellets received and probability 
of reinforcement.  They found that these manipulations of unit price were well 
described by a single unitary demand function.  In addition this demand function 
was well described by Equation 4.1.   
    
                         (4.1) 
 
Equation 4.1 describes the relationship between consumption (Q) and price (P) with 
three free parameters, a, b and L.  The L parameter represents initial demand at a 
minimal price.  In most cases this is the equivalent of responding at FR1, the 
minimum work requirement.  The L parameter will vary as function of reinforcer size 
and is the major determinant of the height or intensity of responding.  For example, 
decreasing food size will result in an increase in consumption and this will affect the 
total number of reinforcers gained per session (consumption).  In the case of drugs 
of abuse a decrease in dose has been shown to result in an increase in 
consumption (reinforcers per session) at low prices due to a decrease in the 
potency of the drug.  This correlates well with increases in responding for drug 
doses on the descending limb of the dose effect curve when testing using single 
schedules of reinforcement.  It has been suggested that when tested using single 
schedules (such as those employed in behavioural economic testing) the L 
parameter can predict choice between commodities in a concurrent schedule task 
(Bickel, Marsch & Carroll, 2000; Johnson & Bickel, 2006).  Commodities that 
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produce higher consumption at low FRs as indicated by the parameter L should be 
the preferred choice when two or more options are concurrently available.  
However, preference does not always stay the same for all commodities as prices 
are increased.  In many cases, such as the classic study by Elsmore et al. (1980), a 
shift in preference from one commodity to another has been shown as a function of 
increasing costs.  In the Elsmore et al. study it was shown that when monkeys had 
many opportunities to gain reinforcers they preferred intravenous injections of 
heroin over food reinforcers; indicating a preference for heroin over food.  However, 
as the number of choices given was decreased by increasing the inter-trial interval, 
subjects instead showed a preference for food over heroin.  That is, demand for 
heroin was more elastic than responding for food despite initially preferring heroin.  
Similar results were found by Bickel, DeGrandpre, Higgins and Hughes (1991) and 
Johnson and Bickel (2006) using cigarette smokers working to obtain cigarette puffs 
or money.  Both studies found preference for money at low FR requirements, but 
also showed a shift in preference to cigarettes at higher prices, indicating that 
demand for money was more elastic than demand for cigarettes.         
Preference between commodities in concurrent schedules has been used as a 
measure of strength of a reinforcer in line with measures of relative reinforcing 
efficacy (Bickel et al., 2000); however, evidence of preference switching as a 
function of price indicates that care must be taken when using preference as 
measure of the abuse liability of drug compounds.  The parametric nature of the 
behavioural economic analysis may reveal more complicated interactions than are 
possible when only limited prices are examined.  The L parameter does however 
present a useful metric for the prediction of preference when two commodities are 
tested under concurrent schedules. 
The b parameter describes the initial slope of the function at a minimal price.  
Because consumption should not theoretically increase as a function of price the b 
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parameter should be negative, that is there should be an initial downward slope to 
the function (Hursh & Silberberg, 2008).  However as this parameter represents an 
infinitely low price the value of the b parameter should be both negative and close to 
zero.  In cases where this is true then changes in elasticity are wholly caused by 
changes in the a parameter which describes the acceleration of the slope of the 
demand curve (Hursh & Silberberg, 2008).  Higher values of the a parameter 
represent a faster acceleration of the downward sloping curvilinear function.  Higher 
a values thus mean that demand is more elastic.                                                   
From Equation 4.1 the point at which demand switches from inelastic to elastic 
demand can also be calculated.  The point at which the slope of the demand 
function is equal to -1 represents unit elasticity where proportional increases in price 
is met with precisely proportional decreases in consumption. Thus slopes shallower 
than -1 represent inelastic demand, while slopes steeper than -1 represent elastic 
demand.  In addition, the point at which the slope of the demand function is equal to 
-1 is also the point at which maximal responding is found, thus this point has been 
termed Pmax or the price yielding maximum output (Hursh et al., 1989).  Pmax values 
can be calculated using Equation 4.2. 
 
 
                      (4.2) 
 
Pmax directly relates to the rate at which elasticity changes, thus it provides a single 
measure with which to compare the elasticity of different demand curves.  A useful 
function of Pmax is that the units are expressed as prices (FR) at which responding 
becomes elastic.  Thus direct comparisons of Pmax are possible even if the range of 
prices used to fit the demand curve is different.  This unique feature of demand 
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curves is a major benefit over studies using break point as a dependent measure as 
break points rely heavily on the range of ratios used and the size of the reinforcer 
being tested.   
By fitting Equation 4.1 and using the calculated parameters to calculate Pmax using 
Equation 4.2 it is possible to compare the relative reinforcing efficacy of multiple 
different commodities.  Commodities with higher values of Pmax are considered to be 
stronger or more efficacious reinforcers because the subject is willing to work longer 
or harder in order to obtain that reinforcer.        
In addition to measures of consumption, behavioural economics can also be used to 
analyse total response output.  Output function curves are typically bitonic and show 
increases in total responding as a function of increases in price followed by 
decreases in total responses at higher price values.  The peak of the response 
output function represents the price at which maximal output is found and 
corresponds with the value of Pmax.  Best-fit non-linear regression using Equation 
4.3 as proposed by Hursh et al. (1988, 1989) produces a bitonic function of 
responding and price.  Omax is the predicted peak response output value at the point 
of Pmax and is calculated using the parameters obtained by fitting Equation 4.1 to 
consumption data and then substituting those values into Equation 4.3 and 
substituting the calculated value of Pmax for P.   
 
         (4.3) 
 
V. Behavioural Economics and Drugs of Abuse    
Behavioural economics has proven to be a useful tool in the study of drugs of abuse 
with principles from behavioural economics applied to areas such as measuring 
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abuse liability, examining complex interactions between drugs and other reinforcers 
and environmental conditions (such as open or closed economies), treatments for 
drug abuse (including agonist and antagonists therapies) and informing public policy 
(Hursh, 1991; Hursh, 1993; Bickel et al., 1993; Hursh et al., 2005).  Behavioural 
economics, much like progressive ratio schedules, offers a way in which to measure 
„motivation‟ to consume drugs of abuse.  The study of abuse liability has become a 
popular field with increasing numbers of novel pharmacological compounds being 
abused every year.  Thus having rigorous a framework in which different drugs of 
abuse can be characterised and empirically tested for their abuse liability is useful.  
Behavioural economics has proved useful for the study of the abuse potential of 
drugs of abuse and therefore it should not be considered strange that the vast 
majority of recent papers concerning behavioural economics belong in the 
behavioural pharmacology domain. 
Central to a behavioural-economic approach to understanding abuse potential is 
that in humans drugs of abuse are often preferred in choice situations even when 
there are adverse effects from making those choices, including costs, withdrawal, 
addiction or other societal factors.  The underlying assumption being that more than 
just acting as reinforcers, drugs of abuse promote maintenance of drug-taking 
through the process of addiction.  One way to think of drugs of abuse in a 
behavioural economic context is that drugs are inelastic commodities.  That is, 
either through extremely positively rewarding aspects of drugs of abuse, or through 
addiction mechanisms, many drugs of abuse fall would into the „necessity‟ category 
typified by inelastic demand.  Under this assumption access to drugs of abuse will 
be defended highly promoting increased responding in order to maintain levels of 
drug intake.  However, not all drugs are created equal and thus different drugs of 
abuse with greater abuse potential should also promote inelastic responding to 
higher prices, consistent with high abuse potential drugs producing higher break 
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points under progressive ratio schedules.  Behavioural economics allows for the 
quantification of abuse potential by measuring a drug‟s consumption in the face of 
rising costs.  Like all commodities elasticity for a drug of abuse lies on continuum 
such at some point response rate ceases to increase as a function of price and thus 
consumption begins to decrease.  Pmax can thus serve as a quantitative measure of 
the abuse potential of a given drug of abuse.  Research into unit price has indicated 
that the demand for drug reinforcers is independent of the individual replicable Pmax 
value allowing for comparisons across drugs (Bickel et al., 1990; Hursh & Winger, 
1995).       
One potential pitfall in using Pmax as a quantitative measure of abuse liability is that 
different drugs differ in their overall potency, and these differences confound any 
interpretations of the reinforcing strength of the drug.  While manipulations of unit 
price aid in making within-drug comparisons, it does not allow for comparisons 
across different types of drugs or classes when potency is unequal.  Consider a 
drug that produces very high level of initial consumption (high L), but is extremely 
elastic (elasticity < -1) in that consumption decreases rapidly with increased price.  
Then compare that drug with one with low initial consumption (low L) and relatively 
inelastic responding (elasticity > -1).  According to behavioural economic theory, the 
latter is the more reinforcing compound because strength of the reinforcer is derived 
from its slope and not its intensity.  It is possible for the first compound to produce a 
higher Pmax value by virtue of a larger number of reinforcers consumed, despite it 
being more sensitive to changes in price.  In order to eliminate this confound, Hursh 
and Winger (1995) proposed an alternative method whereby obtained data can be 
normalized for baseline consumption and each dose is presented as a percentage 
of consumption at FR1.  This procedure has the advantage of eliminating intensity 
changes across commodities such that all demand curves begin at 100 (i.e. 
responding at FR1 is equivalent to 100% of baseline responding).  In the case of 
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drug reinforcement this means that potency and dose no longer factor into the 
demand curve analysis (Hursh & Winger, 1995).  Both consumption and price are 
calculated as a function of q, the normalized dose calculated using Equation 4.4 as 
previously reported by Hursh and Winger (1995) where d is the dose and B is 
average number of reinforcers gained at FR1; the cancelling out of the dose 
parameter (d) leaves the following simple equation for normalizing data, q = B/100.  
Thus price and consumption are normalized as a function of q where P = FR ÷ q 
and Q = Rq (Hursh & Winger, 1995). 
 
         (4.4) 
 
Hursh and Winger (1995) reanalysed unit price data from two previous papers 
measuring demand for the stimulants, cocaine and methohexital (Winger, 1993) and 
the opioids alfentanil and nalbuphine (Winger, Woods & Hursh, 1996) in order to 
test the validity of the normalization procedure.  Of note is that when fitting 
normalized data using Equation 4.1 the L parameter does not vary and is instead 
replaced by the constant value of 100, as that is the starting point for all normalized 
demand curves (Hursh & Winger, 1995).  Hursh and Winger found that the 
normalization procedure accounted for more variance for alfentanil, similar R2 
values for nalbuphine and methohexital but poorer fits for cocaine.  All of the drugs 
tested produced unitary demand functions using both the unit price and 
normalization procedures; with the exception of cocaine which was better described 
by multiple demand curves due to changes in demand as a function of dose (the 
lowest dose tested appeared more elastic compared with that of the other two 
doses tested).  Pmax values were calculated for each drug and indicated that 
alfentanil showed higher Pmax values and thus more inelasticity than cocaine, 
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followed by a large decrease to nalbuphine and methohexital respectively.  The 
normalization procedure thus allows for the assessment of the abuse liability across 
potency of drug but also across classes of drugs as shown by Hursh and Winger‟s 
analysis of both stimulants and opioids using the same procedure.  When demand 
curves are normalized they are not confounded by the potency of the drug tested 
allowing for the direct comparisons of the elasticity of various compounds; this 
allows direct comparison of different drugs by using Pmax, or the point that 
responding changes from inelastic to elastic responding as a quantitative measures 
of the abuse liability of drugs of abuse.  However, it should also be noted that the 
normalization procedure can be used in the assessment of demand curves for all 
types of commodities and is not restricted to testing demand for drugs of abuse.      
Behavioural economics, among other uses, has primarily been used for measuring 
the strength of a reinforcer or the „motivation‟ to consume said reinforcer.  However, 
the models that are used for this purpose, while providing appropriate fits to the 
data, are often abstracted such that the free parameters do not themselves 
represent the strength of reinforcement (Hursh & Silberberg, 2008).  Recently, 
Hursh and Silberberg (2008) have published a new model based on using an 
exponential function to fit demand curves.  The authors suggest that the exponential 
model shown in Equation 4.5 can be used as a method for measuring what they call 
„essential value‟ or the strength of the reinforcer.  Utilizing the normalization 
procedure referred to above, the exponential model has only a single free 
parameter, α which describes the rate of change of the exponential function.  The 
value of Q0 refers to the starting value or maximal level of consumption at minimum 
price (similar to L from Equation 4.1) and the parameter k is a constant that 
describes the range of the data and is set to the same value across comparisons.  
Price is normalized by default allowing for comparisons across commodities by the 
addition of Q0 x C, representing the independent variable C, or price, and 
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normalizing it in relation to Q0, the maximum level of consumption at minimum price.   
This results in a single parameter that can be used to compare the demand for 
different commodities, α, representing the rate constant of the exponential.  The 
parameter, α, is inversely related to elasticity, such that steeper functions 
representing more elastic commodities will have higher α values, conversely 
inelastic demand is represented by lower α values (Christensen, Silberberg, Hursh, 
Huntsberry & Riley (2008).  Hursh and Silberberg applied the new exponential 
model to previously published data from a variety of sources and found reliable fits 
across almost all of the data tested (R2 > 0.95).     
  
   
                 (4.5)  
 
Christensen et al. (2008) tested the new exponential equation using cocaine and 
food as reinforcers.  In Experiment 1 of their study rats responded for both 
intravenous cocaine and food pellets during experimental sessions, though sessions 
arranged in blocks such that access was only available to a single commodity at a 
time.  The results of this experiment produced larger α values when modelled using 
the exponential model for cocaine than for food, showing that the rats defended 
their access to food more readily than cocaine.  However, when cocaine 
consumption was modelled alone (no access to food) α values were lower than 
when cocaine and food were available in the same session, indicating some 
interaction between the two commodities.  However the opposite was true when 
food was tested alone as α values were smaller.  This suggests that food acts as a 
complement for cocaine consumption, but cocaine acts as a substitute for food.  
Christensen et al. was the first prospective study to utilise the exponential model of 
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demand and in general fits obtained by the model were excellent, (mean group R2 > 
0.95) apart from the slight tendency for the exponential model to underestimate 
cocaine consumption when both food and drug were available. 
So far the exponential model has been used in few studies and those studies have 
examined a range of phenomena and subjects.  For example, Christensen, Kohut, 
Handler, Silberberg and Riley (2009) tested strain differences between Fischer and 
Lewis rats on demand for both cocaine and food using the exponential model.  The 
authors found that Lewis rats demonstrated higher essential value for food than did 
Fischer rats, however this relationship was reversed when the commodity was 
changed to intravenous cocaine.  Overall both strains of rats defended their access 
to food (in a closed economy) significantly more than they did for cocaine 
suggesting that food has higher essential value than cocaine.  The authors suggest 
that the reversal of essential value for food and cocaine as a function of strain 
represents that the exponential model is sensitive to genetic factors that maybe be 
related to drug abuse.  Two studies have used the exponential model of demand to 
test effects of history of exposure to cocaine and have shown that different histories 
of drug consumption lead to changes in the essential value of cocaine (Christensen, 
Silberberg, Hursh, Roma & Riley, 2008; Oleson & Roberts 2009).  Foster and 
colleagues have recently used the exponential model to test the food preferences in 
hens across a range of three qualitatively different foods (Foster, Sumpter, Temple, 
Flevill & Poling, 2009).  In addition to animal subjects the exponential model of 
demand has also been successfully used to measure relative reinforcing efficacy in 
humans.  Murphy, MacKillop, Skidmore and Pederson (2009) used the exponential 
model to test the validity of an Alcohol Purchase Task in a college student sample 
as a measure of relative reinforcer efficacy.  In all of these studies the exponential 
model of demand generally provided good fits to the data and was deemed suitable 
for measuring demand in all cases.  
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More prospective studies of the exponential model need to be completed in order to 
further test the predictions of the model and test the reliability of the α parameter as 
a measure of „essential value‟ or relative reinforcer efficacy.  As such, it remains 
prudent to test predictions of the linear-elasticity model (Hursh et al., 1988, 1989) 
and the exponential model concurrently.  It stands to reason that should the 
predictions of the exponential model hold up in the face of further testing then the 
exponential model will provide the more parsimonious model for measuring or 
ranking the relative reinforcer efficacy of commodities due to it having only a single 
free parameter. 
The current study 
The following experiment has been designed to assess demand curves for MDMA 
when tested using the oral-self administration procedure presented previously (see 
Chapter 3).  Obtained behavioural data will be used to test various behavioural 
economic models that have previously been used as a means of quantifying abuse 
potential or relative reinforcing efficacy.  Data gathered will be analysed using two 
methods of equating drug dose, namely unit price and normalization of drug 
demand.  In addition two models of demand will be utilised, the Linear-Elasticity 
model of Hursh et al. (1988, 1989) and the Exponential Model of Demand (Hursh & 
Silberberg, 2008).  Model fits will be compared in order to assess the utility of both 
approaches and its relation to measuring relative reinforcer efficacy and abuse 
liability.  As taste is a prominent factor in the oral self-administration of drugs of 
abuse, drug solutions will be a mixture of a sweetened saccharin solution and 
MDMA.  Concordant with behavioural economic theory it is expected that as price 
increases consumption of both drug and vehicle solutions will decrease in a 
positively decelerating function describing the change from inelastic to elastic 
demand.  It is expected that the MDMA-containing drug solutions will show more 
inelastic responding than the saccharin-vehicle condition indicating that the drug 
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containing solutions are stronger reinforcers than the vehicle alone providing 
support for MDMA‟s effectiveness as an oral reinforcer.              
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Experiment 4.1: Behavioural Economic Analysis of Oral Self-administration of 
MDMA 
 
Method 
Subjects: 
Subjects were 11 male Sprague-Dawley rats who had extensive experience with 
orally delivered MDMA solutions.  Subjects in this study had prior experience with 
oral MDMA though participation in Experiments 3.2 (self-administration in water 
vehicle), 3.1B (free access choice in the homecage) and 3.3 (self-administration in 
saccharin vehicle).  Animals were aged approximately 12 months old at the 
beginning of testing and weights ranged from 388 – 510 grams (M = 435, SD = 
33.7).  Animals remained at 85% of their free-feeding weights throughout the 
duration of the experiment and water was freely available in the home cage.  
Subjects were housed individually in polycarbonate cages with cage tops made of 
metal grating situated in the testing room.  The testing room was maintained on a 
reversed 12:12 hour light/dark cycle with lights on at 7pm.  Animals were treated in 
accordance with ethical guidelines set forth by the Victoria University of Wellington 
Animals Ethics Committee. 
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Apparatus/materials:  
Equipment: 
Experimental sessions were conducted using the same equipment, housing and 
procedures as outlined previously for Experiment 3.3.      
Solutions: 
+/-3,4-methylenedioxymethamphetamine hydrochloride (ESR, Porirua, New 
Zealand) was mixed with tap water at the following doses; 1.624mg/ml, 0.812mg/ml 
and 0.40625mg/ml. 
Procedure: 
Immediately following the conclusion of Experiment 3.3 the procedure was modified 
to allow for daily manipulations of the FR value for each animal.  An across session 
methodology was used to assess demand for oral MDMA self-administration such 
that each day animals‟ were subject to a different FR schedule of reinforcement.  
Each dose of drug was first tested using an ascending sequence of FR 
requirements in order to establish a suitable endpoint for each dose (highest FR 
ratio reached).  The ascending sequence consisted of seven individual FR 
requirements that increased each day beginning at FR1 and continuing to double 
until a ratio was reached when no reinforcers were obtained.  The arranged FR 
schedules used in this study were 1, 2, 4, 8, 16, 32, and 64.  In some cases animals 
continued to respond at FR64 so an additional eighth FR schedule (FR96) was 
added to the sequence for those animals.  After completion of the first ascending 
sequence each sequence was replicated twice more, however on the second and 
subsequent replications FR ratios were presented in a random order (individually for 
each rat) to produce a non-predictable sequence of ratios.  
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Demand curves were obtained in the following order for vehicle (0.2% saccharin), 
0.02mg/kg/reinforcer, 0.04mg/kg/reinforcer and 0.08mg/kg/reinforcer MDMA 
solutions corresponding to the 0.40625, 0.812 and 1.624 mg/ml doses respectively.  
Reinforcers were delivered in 0.02cc dipper cups.   
 
Results 
Dose-effect Analysis 
Figure 4.1 shows the average number of reinforcers obtained per day 
(consumption) plotted as a function of the FR requirement at which it was obtained 
for three doses of MDMA and the vehicle-alone (top panel).  The same data is 
plotted in the bottom panel of Figure 4.1 using a log x-axis in order to more clearly 
differentiate the results.  All subjects showed the highest average consumption of 
the saccharin vehicle at low and moderate FR requirements.  Consumption of 
saccharin and, indeed MDMA for all doses, decreased as a function of increasing 
FR requirements.  A two-way ANOVA using dose and FR requirement as factors 
found a significant interaction between both factors (F (18, 162) = 18.214, p < 
0.001).  Contrasts revealed significant differences between each of the three doses 
of MDMA and vehicle in the order of highest to lowest consumption: saccharin, 0.02, 
0.04 followed by 0.08mg/kg/reinforcer MDMA.  This pattern is consistent with the 
analysis of dose-response functions from earlier experiments in Chapter 3 with the 
exception that responding for saccharin was significantly higher than all doses of 
MDMA in the current experiment. In the previous experiments this was not the case 
and responding for saccharin was not significantly different from the lowest dose of 
MDMA tested (though it was significantly different from the other doses).            
Total responding for MDMA and vehicle was analysed as a function of the FR 
requirements and are shown in Figure 4.2.  In correspondence with the reinforcer 
139 
 
data total responding was highest for saccharin at all doses tested.  There was a 
bitonic relationship between vehicle responding and FR requirement that peaked at 
FR8 before declining as a function of increasing FR.  Responding for MDMA doses 
was inversely related to dose in that the lowest dose, 0.02 mg/kg/reinforcer, 
produced the highest responding followed by the 0.04 and 0.08 mg/kg/reinforcer 
MDMA dose.  Peak responding for MDMA was not as marked as it was for the 
vehicle condition; however the peak responding for all three doses of MDMA was 
situated at FR16 which was higher than the peak responding for saccharin alone.  
Despite peak responding for saccharin being lower than that of MDMA the vehicle 
condition still produced more total responding at FR16 (the MDMA peak) than did 
any of the MDMA doses.  The shift in the function to the right for MDMA suggests 
that MDMA responding might be less sensitive to changes in FR requirement than 
the saccharin was by itself which may be indicative of less elastic demand for 
MDMA relative to saccharin. 
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Figure 4.1:  Group function (n= 11) for the oral self-administration of MDMA showing 
average reinforcers earned (consumption) of oral MDMA or vehicle as a function of FR 
requirement (top panel) or the same data presented on semi log-axes (bottom panel).  
Error bars represent standard errors of the mean.         
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Figure 4.2: Group function (n= 11) for the oral self-administration of MDMA showing 
average total responding for oral MDMA or vehicle as a function of FR requirement (top 
panel) or the same data presented on semi log-axes (bottom panel).  Error bars represent 
standard errors of the mean.         
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Economic Analysis 
In order to test differences in the sensitivity to price between MDMA-containing and 
vehicle solutions a behavioural economic analysis was conducted by fitting Equation 
4.1 to the obtained number of reinforcers earned (consumption) as a function of the 
FR schedule (price).  The resulting demand curves plot consumption as a function 
of price for each dose of MDMA and the vehicle-alone and are shown in Figure 4.3.  
As expected all doses of MDMA and the vehicle-alone show decreased responding 
as a function of increased price.  Initially level of demand was highest for the 
vehicle-alone as evidenced by higher consumption at FR1.  In addition, fits of the 
model described by Equation 4.1 show a higher L value (initial demand at minimum 
price) for vehicle-alone condition than for each of the drug doses.  The demand 
curves for MDMA conditions reveal decreased values of L as a function of 
increasing dose, that is the highest L values were found for the lowest dose (0.02) 
followed by the 0.04 and 0.08 mg/kg/reinforcer MDMA dose respectively.  
Parameter estimates for the model are shown in Table 4.1.          
When plotted on log-log coordinates the slope of the function describes the 
commodities elasticity or it‟s sensitivity to changes in price.  Within the model 
elasticity is described by the a and b parameters that measure the rate of change 
and the initial slope of the curvilinear function respectively.  By substituting the a 
and b parameters into Equation 4.2 the value of Pmax can be calculated which 
corresponds to the price at which the slope of the function equals -1 and indicates 
the point at which responding changes from inelastic to elastic responding.  Pmax 
values are indicated on Figure 4.3 as bisecting vertical lines and are also reported in 
Table 4.1.  Pmax values for the low and medium doses were comparable producing 
values of 15.48 and 15.21 respectively indicating that both doses produced similar 
elasticity despite the lower dose producing a higher overall level of demand.  The 
high dose MDMA condition produced a slightly lower Pmax value (Pmax (0.08) = 12.28) 
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that was comparable to the vehicle-alone condition (Pmax (saccharin) = 11.91).  A one-
way ANOVA revealed no significant differences between the Pmax values for any of 
the conditions (F (3, 30) = 0.408, p = 0.91). 
The model was fit to data from individual subjects and resulting demand curves and 
parameter estimates can be seen in Figure 4.4 and Table 4.1 respectively.  One 
subject, Rat 44, suffered significant weight loss during the course of the experiment 
and was removed before completing all three doses of MDMA.   Generally individual 
results mirror the group results with saccharin producing the highest overall level of 
demand followed by the low, medium and high MDMA doses respectively.  Peak 
Pmax values were varied with 5 of 11 animals showing the highest Pmax value for the 
low dose condition, 3 for the medium MDMA dose condition and 3 for the high dose 
condition.  No animals produced their highest Pmax value in the vehicle-alone 
condition, nor did it always produce the lowest Pmax value as that was only the case 
for 4 out of 11 animals.  Rats 32 (saccharin) and 33 (0.08 MDMA) produced 
negative values for Pmax indicating that consumption was elastic even at a minimum 
FR for those conditions. Variance accounted for was generally high indicating that 
the model described the data well.  The average R2 value for all fits was M = 0.89, 
SE = 0.025.  While some fits of the model produced acceptable R2 values there 
were a number of fits that did not produce standard curvilinear demand functions 
generally as a function of variable data and a low number of data points.  In 
particular, Rats‟ 32, 33 and 34 and produced atypical model fits and this occurred 
most often with the 0.08 mg/kg/reinforcer dose.  Rat 41 produced atypical fits for the 
0.02 and 0.04 mg/kg/reinforcer doses.        
While MDMA doses were well described by the model several authors (e.g. Bickel 
et al., 1990; Hursh et al., 1988) have suggested that reinforcers with scalar 
properties such as drug dose can be described using a single demand function 
when consumption is plotted as function of unit price.  Further analysis with unit 
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price will be presented below in order to assess if oral MDMA self-administration 
can also be described by a single demand function by utilising a unit price analysis.        
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Figure 4.3: Demand for oral administration of 3 doses of MDMA and vehicle (0.2% 
saccharin).  Demand curves represent consumption (average reinforcers earned) plotted 
as a function of price (FR ratio) on log-log axes.  Best-fit functions were obtained by 
fitting Equation 4.1 to the data.  Bisecting vertical lines represent Pmax values for 3 doses 
of MDMA and vehicle-alone conditions and were calculated by inputting parameter 
estimates into Equation 4.2 for each condition.         
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Figure 4.4: Demand for the oral self-administration for 3 doses of MDMA in 0.2% saccharin and vehicle-alone plotting consumption expressed as average 
reinforcers earned per day as a function of Price (FR) plotted in log-log coordinates.  Panel 1 represents the group mean of all animals (n = 11).  
Successive panels represent individual subjects.  Lines of best fit were calculated using Equation 4.1 for each condition.  Bisecting vertical lines represent 
Pmax values and were calculated by substituting parameter estimates into Equation 4.2.   Figure continues next page.           
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Figure 4.4 (cont):  Demand for the oral self-administration for 3 doses of MDMA in 0.2% saccharin and vehicle-alone plotting consumption expressed as 
average reinforcers earned per day as a function of Price (FR) plotted in log-log coordinates.  Panel 1 represents the group mean of all animals (n = 11).  
Successive panels represent individual subjects.  Lines of best fit were calculated using Equation 4.1 for each condition.  Bisecting vertical lines represent 
Pmax values and were calculated by substituting parameter estimates into Equation 4.2.          
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Table 4.1:  Parameter fits for demand curves for the oral self-administration of MDMA in 
0.2% saccharin.  Demand curves are expressed in terms of consumption (average 
reinforcers earned) as a function of unit price in log-log coordinates.  Parameters were 
obtained through fits of Equation 4.1.  Pmax values were obtained by fitting Equation 4.2 to 
estimated parameters.      
Subject Dose 
(mg/kg/reinforcer) 
a b L Pmax R
2
 
Group 0.02 0.0412 -0.3614 22.52 15.48 0.99 
 0.04 0.0405 -0.3835 17.83 15.21 0.98 
 0.08 0.0583 -0.2836 9.45 12.28 0.96 
 vehicle 0.0448 -0.4659 68.00 11.91 0.98 
32 0.02 0.0342 -0.7822 19.17 6.36 0.98 
 0.04 0.2359 -0.0645 16.54 3.97 0.75 
 0.08 -0.1157 -1.3148 2.43 2.72 0.87 
 vehicle 0.0611 -1.1434 27.80 -2.35 0.98 
33 0.02 0.1132 0.1008 18.44 9.73 0.93 
 0.04 0.0157 -0.6220 15.76 24.14 0.89 
 0.08 -0.0258 -0.3365 2.11 -25.73 0.09 
 vehicle 0.0988 -0.3845 99.24 6.23 0.95 
34 0.02 0.0237 -0.5703 21.71 18.17 0.95 
 0.04 0.1086 -0.1194 16.36 8.11 0.92 
 0.08 -0.0422 -1.2092 17.27 4.95 0.96 
 vehicle 0.0588 -0.5443 80.21 7.75 0.82 
35 0.02 0.0450 0.1206 11.27 24.93 0.74 
 0.04 0.0307 -0.2844 9.16 23.31 0.96 
 0.08 0.0615 0.1051 3.18 17.98 0.66 
 vehicle 0.0482 -0.0365 33.59 19.98 0.97 
36 0.02 0.0724 -0.2521 19.37 10.33 0.87 
 0.04 0.0245 -0.5311 15.11 19.16 0.98 
 0.08 -0.0105 -1.2819 8.94 26.83 1.00 
 vehicle 0.0486 -0.3561 105.09 13.24 0.84 
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Table 4.1 (cont): 
 
  
Subject Dose 
(mg/kg/reinforcer) 
a b L Pmax R
2
 
41 0.02 -0.0602 -1.7889 22.39 13.10 1.00 
 0.04 -0.1979 -2.1467 18.97 5.79 0.99 
 0.08 -0.0004 -1.3636 11.26 830.79 1.00 
 vehicle 0.2582 -0.2534 38.36 2.89 0.81 
42 0.02 0.0512 -0.2081 22.76 15.47 0.93 
 0.04 0.0157 -0.4780 19.34 33.24 0.91 
 0.08 0.0451 -0.1344 20.06 19.21 0.89 
 vehicle 0.0476 -0.2436 77.00 15.89 0.98 
43 0.02 0.0345 -0.4482 21.98 15.98 0.96 
 0.04 0.0257 -0.2630 11.09 28.70 0.57 
 0.08 0.1109 -0.1909 8.27 7.30 0.60 
 vehicle 0.0202 -0.7714 38.57 11.33 0.95 
44 0.02 0.0467 -0.2558 21.50 15.95 1.00 
 0.04 0.0546 -0.5187 33.93 8.82 0.97 
 0.08 - - - - - 
 vehicle 0.0310 -0.5475 80.80 14.61 0.95 
45 0.02 0.0171 -0.4712 38.44 30.84 0.97 
 0.04 0.0509 -0.0571 23.22 18.53 0.97 
 0.08 0.0082 -0.4022 12.54 72.80 0.96 
 vehicle 0.0564 -0.3424 105.83 11.65 0.96 
46 0.02 0.0543 -0.3031 31.38 12.85 0.83 
 0.04 0.0901 -0.1755 22.08 9.15 0.99 
 0.08 0.0921 -0.2439 14.13 8.21 0.94 
 vehicle 0.1393 -0.2720 58.00 5.23 0.98 
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Unit Price Demand Curve Analysis 
A unit price analysis was conducted by examining demand curves for the oral 
administration of MDMA by plotting average daily intake (mg/kg/day) of MDMA 
against unit price (response requirement/reinforcer magnitude) and plotted in log-log 
coordinates.  Equation 4.1 was fitted to the obtained data.  Several dose/FR 
requirement combinations resulted in replication of a given unit price and these 
were treated as additional data points within the analysis.  Figure 4.5 shows that 
consumption of oral MDMA decreased as a function of increases in unit price.  
Despite multiple doses of MDMA being tested they were generally described well by 
the same demand function (R2 = 0.92) fitted using Equation 4.1.  However, the 
function best described the data when unit price was low to moderate and variability 
was small.  The largest dose (0.8 mg/kg/reinforcer) of MDMA in particular appeared 
to be more elastic than the other doses of MDMA as it produced lower consumption 
at higher unit prices relative to the other two doses.  Pmax for the unit price analysis 
for the group function was 650.68.  Pmax values ranged from a minimum of 475.87 to 
a maximum of 1516.18 for the individual subjects (see Table 4.2 for parameter 
estimates for individual subjects).  Individual demand functions for the consumption 
of MDMA for each animal are shown in Figure 4.6.  All subjects‟ data is 
representative of the group function.  Fits of the model to individual subject data 
produced generally good fits with 7 out of 11 animals producing fits greater than 
R2 = 0.75, (M = 0.74, SE = 0.056, min = 0.35, max = 0.96).          
Using a unit price analysis precludes a comparison with the vehicle-alone condition.  
An MDMA dose of 0.0 for the vehicle-alone condition is undefinable when converted 
to unit price.  However, unit price analysis is a useful metric because it eliminates 
dose as a variable in the demand for a given drug commodity.  The results for the 
unit price analysis of the self-administration of MDMA reported here show that 
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MDMA produces a single unitary demand function that was well described by 
Hursh‟s linear elasticity model (Equation 4.1).   
 
 
 
 
 
Figure 4.5: Demand for oral administration of 3 doses of MDMA in 0.2% saccharin 
vehicle.  Demand curves represent consumption expressed in mg/kg/day plotted as 
a function unit price.  Best fit functions were obtained by fitting Equation 4.1 to 
pooled data across MDMA doses.  Bisecting vertical lines represent Pmax values.       
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Figure 4.6: Demand for the oral self-administration for 3 doses of MDMA in a 0.2% saccharin vehicle plotting consumption expressed as mg/kg/session as 
a function of Unit Price.  Panel 1 represents the group mean of all animals (n = 11).  Successive panels represent individual subjects.  Demand curves   
Lines of best fit were calculated using Equation 4.1 using pooled data across doses.  All figures are plotted on log-log axis.  Bisecting vertical lines 
represent Pmax values.   Figure continues next page. 
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Figure 4.6 (cont): Demand for the oral self-administration for 3 doses of MDMA in a 0.2% saccharin vehicle plotting consumption expressed as 
mg/kg/session as a function of Unit Price.  Panel 1 represents the group mean of all animals (n = 11).  Successive panels represent individual subjects.  
Demand curves   Lines of best fit were calculated using Equation 4.1 using pooled data across doses.  All figures are plotted on log-log axis.  Bisecting 
vertical lines represent Pmax values.           
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Table 4.2:  Parameter fits for demand curves for the oral self-administration of MDMA in 
0.2% saccharin.  Demand curves are expressed in terms of consumption (mg/kg/day) as a 
function of unit price in log-log coordinates.  Parameters were obtained through fits of 
Equation 4.1.  Pmax values were obtained by fitting Equation 4.2 to estimated parameters.    
 
  
Subject condition a b L Pmax R
2
 
Group MDMA 0.0005 -0.6654 5.83 650.68 0.92 
32 MDMA 0.0011 -0.4847 1.11 475.87 0.34 
33  MDMA 
 
0.0018 0.0246 0.23 559.92 0.50 
34 MDMA 
 
0.0002 -0.7742 8.69 1282.37 0.96 
35 MDMA 
 
0.0005 -0.2530 0.64 1516.18 0.63 
36 MDMA 
 
0.0010 -0.3804 1.37 605.10 0.75 
41 MDMA 
 
-0.0002 -1.1490 20.16 701.89 0.80 
42 MDMA 
 
0.0008 -0.5095 5.31 638.23 0.79 
43 MDMA 
 
0.0007 -0.3879 1.59 899.22 0.70 
44 MDMA 
 
0.0003 -0.7105 11.24 897.66 0.89 
45 MDMA 
 
0.0004 -0.4405 3.83 1452.10 0.89 
46 MDMA 
 
0.0004 -0.6793 7.93 912.76 0.87 
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Normalized Demand Curve Analysis 
Data was normalized using Equation 4.4 per the method of Hursh and Winger 
(1995).  Each dose was normalized according to the number of reinforcers obtained 
at FR1 by multiplying consumption and dividing price by the scaling parameter q 
where   q = B/100, where B is the average number of reinforcers obtained at FR1.  
When scaled using q initial consumption values at FR1 are equal to 100.  Thus fits 
of the linear-elasticity model substitute the constant 100 for the free parameter L in 
Equation 4.1 as shown in Equation 4.6.    
          
 
         (4.6) 
 
Normalized demand curves were obtained for group data (n = 11) by plotting 
average normalized consumption as a function of normalized price for three doses 
of MDMA (combined) and the vehicle-alone condition and are shown in Figure 4.7.  
Data for the combined drug condition was pooled across doses and Equation 4.6 
was fitted to the resulting pooled group data and the vehicle separately.  In addition, 
the model was fitted to group data for each MDMA dose separately.  Parameter 
estimates for the each individual dose as well as the combined and vehicle 
conditions can be found in Table 4.3.  
Figure 4.7 shows the demand curves for the oral self-administration of MDMA and 
indicates that consumption of MDMA decreased as a function of price.  
Normalization of the data produces a unitary function (R2 = 0.88) of the effects of 
price on the consumption of MDMA.  However Figure 4.7 indicates that the 
vehicle-alone condition produced a shallower demand curve than that of the MDMA 
condition suggesting that subjects treated drug and vehicle-alone conditions 
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differently.  However it appears that saccharin produced more inelastic responding 
than did the drug-containing solutions.  Data for the combined drug condition and 
the vehicle-alone were well described by the model and accounted for 88% 
(R2 = 0.88) and 96% (R2 = 0.96) of the variance respectively.   
Pmax was calculated for each condition by substituting the obtained parameter 
estimates into Equation 4.2.  Pmax was lower for the MDMA (combined) condition 
(Pmax (combined) = 2.74) than it was for the vehicle-alone condition 
(Pmax (vehicle alone) = 6.04) suggesting that responding for saccharin-alone was more 
inelastic than responding for the vehicle-alone condition. 
 
 
Figure 4.7: Normalized demand curves plotted in log-log coordinates for the oral self-
administration for 3 doses of MDMA in 0.2% saccharin vehicle (open symbols) and 
saccharin vehicle alone (closed symbols).  Fitted functions were obtained by fitting Equation 
4.6 to normalized data.  Bisecting vertical lines represent Pmax values for each condition.   
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Analysis of Figure 4.7 indicates that the demand function for the self-administration 
of MDMA appears to overestimate demand for MDMA despite producing a 
reasonable fit of the model (R2 = 0.88).  Specifically the normalization procedure 
sets the initial level of demand (L) to 100 and this value is substituted into the 
Equation 4.1, resulting in the modified form shown in Equation 4.6.  However, when 
fitting Equation 4.6 L is treated as a constant representing consumption at minimum 
price.  In lieu of actual values of initial price at infinitely low price responding at FR1 
is substituted instead.  In the current study q (the normalization parameter) is 
greater than 1 for all conditions, thus normalized demand at minimum price occurs 
at prices lower than 1.  The equation however calculates L as a function of 
normalized FR1 responding which leads to overestimation of consumption at prices 
less than 1.  Note that when q is less than the minimum FR schedule, normalized 
price does not drop below 1 and thus L will accurately represent initial demand 
levels as 100%.  In order to counter this phenomenon the model was refitted to the 
normalized data using Equation 4.1 and all three free parameters were allowed to 
vary; results are shown in Figure 4.8.  Allowing L to vary in the model produced less 
overestimation of the demand for the oral self administration of MDMA.  The 
variance accounted for when fitting normalized data to Equation 4.1 was R2 = 0.88 
and thus resulted in similar levels of R2 when L was free to vary than to when it was 
fixed at a constant value of 100.         
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Normalized demand curves for oral MDMA administration for individual subjects are 
shown in Figure 4.9.  Parameter estimates and R2 values are displayed in Table 4.3.  
As the variance accounted for did not differ between fits of either Equation 4.1 or 4.6 
for the group function the data from individual subjects was analysed using Equation 
4.6 as used by Hursh and Winger (1995) such that the L parameter is entered as a 
constant.  In general, individual subjects showed similar patterns of responding to 
that of the group function; that is all subjects showed decreased responding for 
MDMA and saccharin as a function of increased price.  Like the group function 
saccharin resulted in more inelastic responding (as measured by Pmax) for 8 of 11 
 
Figure 4.8: Normalized demand curves plotted in log-log coordinates for the oral self-
administration for 3 doses of MDMA in 0.2% saccharin vehicle (open symbols) and 
saccharin vehicle alone (closed symbols).  Fitted functions were obtained by fitting Equation 
4.1 to normalized data.  Bisecting vertical lines represent Pmax values for each condition.   
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subjects tested.  Some animals, for example Rats‟ 32, 41, 43 and 46 produced 
equivalent Pmax values across conditions, though Rats‟ 32 and 43 produced (albeit 
marginally) higher Pmax for MDMA than saccharin-alone.  A paired-samples t-test 
revealed that Pmax for saccharin (M = 6.31, SE = 1.36) was significantly higher than 
the Pmax for MDMA (M = 2.68, SE = 0.46), t (10) = -3.113, p = 0.011.  Model fits 
were highly variable across subjects with variance accounted for varying between 
R2 = 0.24 - 0.93, M = 0.59, SE = 0.075) for the MDMA condition.  Variance 
accounted for the saccharin condition was higher with R2 values ranging from 0.72 
to 0.98 (M = 0.92, SE = 0.026).  
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Table 4.3: Parameter fits for normalized demand curves for the oral self-administration of 
MDMA in 0.2% saccharin vehicle.    
Subject        Condition       a    b Pmax R
2 
Group MDMA  0.2909 -0.2026 2.74 0.88 
 vehicle 0.0742 -0.5172 6.51 0.97 
32 MDMA  1.4032 0.3422 0.96 0.24 
 vehicle 1.1558 -0.0538 0.82 0.94 
33 MDMA  0.5387 0.1682 2.17 0.51 
 vehicle 0.1353 -0.2843 5.29 0.97 
34 MDMA  0.6610 0.0588 1.60 0.77 
 vehicle 0.1153 -0.5097 4.25 0.83 
35 MDMA  0.3970 0.0212 2.57 0.54 
 vehicle 0.1525 -0.0483 6.24 0.96 
36 
 
MDMA  0.5419 0.2417 2.29 0.32 
 vehicle 0.0490 -0.3328 13.63 0.85 
41 MDMA  0.9103 0.2764 1.40 0.35 
 vehicle 0.7503 0.0661 1.42 0.72 
42 MDMA  0.2681 -0.0535 3.53 0.81 
 vehicle 0.0666 -0.2465 11.31 0.98 
43 MDMA  0.3456 0.1205 3.24 0.38 
 vehicle 0.1344 -0.6633 2.51 0.96 
44 MDMA  0.3398 -0.0830 2.70 0.93 
 vehicle 0.0394 -0.5934 10.32 0.95 
45 MDMA  0.1053 -0.2941 6.70 0.87 
 vehicle 0.0678 -0.2606 10.90 0.98 
46 MDMA  0.4155 -0.0539 2.28 0.81 
 vehicle 0.2524 -0.3018 2.77 0.98 
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Figure 4.9: Normalized demand curves for the oral self-administration of 3 doses of MDMA in a 0.2% saccharin vehicle.  Demand curves for the combined 
MDMA (open symbols) and vehicle-alone (closed symbols) conditions have been plotted separately.  Panel 1 represent the group mean of all animals (n = 
11).  Successive panels represent individual subjects.  Lines of best fit were calculated using pooled data across doses and fitted using Equation 4.6 plotted 
on log-log axis.  Vertical dotted lines represent values of Pmax fitted using Equation 4.2.  See Table 4.3 for parameter estimates.  Figure continues next page.           
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Figure 4.9 (cont): Normalized demand curves for the oral self-administration of 3 doses of MDMA in a 0.2% saccharin vehicle.  Demand curves for the 
combined MDMA (open symbols) and vehicle-alone (closed symbols) conditions have been plotted separately.  Panel 1 represent the group mean of all 
animals (n = 11).  Successive panels represent individual subjects.  Lines of best fit were calculated using pooled data across doses and fitted using Equation 
4.6 plotted on log-log axis.  Vertical dotted lines represent values of Pmax fitted using Equation 4.2.  See Table 4.3 for parameter estimates.   
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Exponential Model of Demand Curve Analysis 
Further analysis was conducted by fitting the exponential model proposed by Hursh 
and Silberberg (2008) to the data obtained during this experiment.  The model, 
shown in Equation 4.5, uses a single free parameter (α, the rate constant of the 
exponential) to describe differences in what Hursh and Silberberg term „essential 
value‟ which corresponds to differences in elasticity between commodities.  Much 
like the normalized demand model discussed earlier, the exponential model plots 
demand in normalized space in order to facilitate comparisons between 
commodities.  In order to accomplish this, the exponential model uses the 
parameter k in order to constraint the range of the exponential function.  For the 
current analysis k was set to the logarithm of the largest range of consumption for 
each individual fit. 
Demand function and exponential models fits for the group data are shown in Figure 
4.10.  The top panel of Figure 4.10 shows demand for each dose of MDMA and the 
vehicle-alone plotted in log-log coordinates.  Demand for both MDMA and vehicle-
alone decrease as a function of increased price.  Individual exponential functions 
were fit to each dose of MDMA and the results indicate that the 0.02 and 0.04 doses 
of MDMA produced similar functions indicating that those doses produced similar 
essential value for the self-administration of oral MDMA.  This result is confirmed by 
an examination of the α parameters for each condition (see Table 4.4) indicating 
that the 0.02 condition produced an α of 7.95 x 10-4 while 0.04 MDMA condition was 
similar with an α value of 9.97 x 10-4.  In contrast the 0.08 MDMA condition had an α 
value of 2.09 x 10-3 indicating a faster decline in demand as a function of price and 
thus lower essential demand.  The difference in drug conditions was further 
highlighted by Pmax values with 0.02 and 0.04 MDMA doses producing normalized 
Pmax values of 2.26 and 1.80 respectively.  Pmax for the high dose MDMA condition 
(0.08) was 0.86 and overall lower than either of the other MDMA doses.  Of all the 
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conditions however the vehicle alone condition produced the lowest α and highest 
normalized Pmax with α = 3.30 x 10
-4 and Pmax = 5.45.  Overall fits of the exponential 
model to the group data were extremely good with variance accounted for greater 
than 98% for all conditions.     
The bottom panel of Figure 4.10 shows the same data plotted on log-linear axis and 
highlights the differences across conditions where the slope of the exponential 
function indicates sensitivity to price.  Figure 4.10 indicates that subjects defended 
their access to saccharin more strongly than they did for any of the MDMA doses 
tested. 
Exponential model fits to individual subject data are shown in Figure 4.11 (log-log 
plots) and Figure 4.12 (log-linear plots).  Overall fits of the exponential model were 
good with mean R2 = 0.90 (SE = 0.02).  A one-way ANOVA on the α values found a 
significant main effect of dose, F (3, 30) = 10.147, p < 0.001.  Post-hoc contrasts 
revealed significant differences between all doses including the vehicle condition (all 
p < 0.01).  Additionally, a one-way ANOVA on Pmax also revealed an identical 
pattern of results, F (3, 30) = 17.645, p < 0.01).  The results for α and Pmax 
calculated using the exponential model indicates that elasticity decreased 
systematically as a function of increasing dose.  In this case the vehicle condition 
(saccharin alone) produced the most inelastic responding suggesting that subjects 
defended their access to saccharin more so than they did for saccharin containing 
MDMA.  Furthermore both α and Pmax values varied systematically across MDMA 
doses indicating that MDMA consumption was not well characterised by a single 
demand function using the exponential model.  The differences in α values suggest 
that each individual dose of MDMA has a different essential value and as such differ 
in elasticity.                    
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Figure 4.10: Group (n = 11) normalized demand functions for the oral self-administration of 3 
doses of MDMA in a 0.2% saccharin vehicle or vehicle-alone.  Demand curves for each 
MDMA dose (open symbols) and the vehicle-alone (closed symbols) conditions have been 
plotted separately.  The top panel represents data plotted in log-log space while the bottom 
panel represent s the same data plotted on log-linear axes.  Lines of best fit were fitted using 
the exponential equation shown in Equation 4.5. 
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Figure 4.11: Normalized demand curves for the oral self-administration of 3 doses of MDMA in a 0.2% saccharin vehicle.  Demand curves for each MDMA 
dose (open symbols) and vehicle-alone (closed symbols) conditions have been plotted separately.  Panel 1 represent the group mean of all animals (n = 11).  
Successive panels represent individual subjects.  Lines of best fit were fitted using the exponential equation shown in Equation 4.5 and are plotted on log-log 
axes.  Figure continued next page.  
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Figure 4.11 (cont): Normalized demand curves for the oral self-administration of 3 doses of MDMA in a 0.2% saccharin vehicle.  Demand curves for each 
MDMA dose (open symbols) and vehicle-alone (closed symbols) conditions have been plotted separately.  Panel 1 represent the group mean of all animals 
(n = 11).  Successive panels represent individual subjects.  Lines of best fit were fitted using the exponential equation shown in Equation 4.5 and are plotted 
on log-log axes.  
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Figure 4.12: Normalized demand curves for the oral self-administration of 3 doses of MDMA in a 0.2% saccharin vehicle.  Demand curves for each MDMA 
dose (open symbols) and vehicle-alone (closed symbols) conditions have been plotted separately.  Panel 1 represent the group mean of all animals (n = 11).  
Successive panels represent individual subjects.  Lines of best fit were fitted using the exponential equation shown in Equation 4.5 and are plotted on log-
linear axes.  Note: a modified scale was use to plot the data for Rat 36.  Figure continued next page.  
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Figure 4.12 (cont): Normalized demand curves for the oral self-administration of 3 doses of MDMA in a 0.2% saccharin vehicle.  Demand curves for each 
MDMA dose (open symbols) and vehicle-alone (closed symbols) conditions have been plotted separately.  Panel 1 represent the group mean of all animals 
(n = 11).  Successive panels represent individual subjects.  Lines of best fit were fitted using the exponential equation shown in Equation 4.5 and are plotted 
on log-linear axes. 
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Table 4.4: Parameter estimates for exponential model fits to the oral self-administration of 3 
doses of MDMA and 0.2% saccharin vehicle.  Model fits were obtained by fitting Equation 
4.5 to the data for the group mean and to each individual subject.     
     Pmax 
 
 
Subject Condition Q0 k α     C     C x Q0 
    100 
      R
2
 
Group 0.02 19.6 2.902 7.95x10
-04
 11.54 2.26 0.99 
 0.04 14.6 2.902 9.97 x10
-04
 12.32 1.80 0.99 
 0.08 8.9 2.902 2.09 x10
-03
 9.72 0.86 0.98 
 vehicle 58.2 2.902 3.30 x10
-04
 9.36 5.45 0.99 
32 0.02 19.1 2.168 2.88 x10
-03
 4.70 0.90 0.94 
 0.04 21.8 2.168 4.13 x10
-03
 2.87 0.63 0.91 
 0.08 1.7 2.168 1.64 x10
-02
 9.24 0.16 0.70 
 vehicle 48.3 2.168 3.26 x10
-03
 1.64 0.79 0.98 
33 0.02 22.1 2.383 1.22 x10
-03
 8.44 1.86 0.96 
 0.04 11.9 2.383 1.55 x10
-03
 12.37 1.47 0.83 
 0.08 2.1 2.383 6.06 x10
-03
 17.84 0.38 0.27 
 vehicle 114.4 2.383 4.42 x10
-04
 4.50 5.15 0.99 
34 0.02 16.3 2.903 9.77 x10
-04
 11.29 1.84 0.88 
 0.04 17.9 2.903 1.49 x10
-03
 6.77 1.21 0.98 
 0.08 13.9 2.903 2.48 x10
-03
 5.20 0.72 0.82 
 vehicle 79.9 2.903 3.85 x10
-04
 5.85 4.67 0.99 
35 0.02 13.3 1.981 8.24 x10-04 26.81 3.57 0.91 
 0.04 7.8 1.981 2.09 x10
-03
 18.08 1.41 0.92 
 0.08 3.5 1.981 3.88 x10
-03
 21.41 0.76 0.83 
 vehicle 37.5 1.981 4.80 x10
-04
 16.33 6.13 0.97 
36 0.02 18.3 2.506 1.30 x10
-03
 8.98 1.64 0.89 
 0.04 10.9 2.506 1.45 x10
-03
 13.51 1.48 0.94 
 0.08 12.3 2.506 7.77 x10
-03
 2.23 0.28 0.96 
 vehicle 102.0 2.506 2.27 x10
-04
 9.22 9.41 0.97 
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     Pmax 
 
 
Subject Condition Q0 k α     C     C x Q0 
    100 
      R
2
 
41 0.02 73.3 2.744 2.29 x10
-03
 1.14 0.84 0.90 
 0.04 12.8 2.744 3.37 x10
-03
 4.46 0.57 0.64 
 0.08 16.1 2.744 5.98 x10
-03
 1.99 0.32 0.96 
 vehicle 48.2 2.744 1.71 x10
-03
 2.33 1.12 0.90 
42 0.02 21.8 2.380 8.66 x10
-04
 12.08 2.64 0.95 
 0.04 13.5 2.380 8.62 x10
-04
 19.63 2.65 0.85 
 0.08 20.0 2.380 7.29 x10
-04
 15.68 3.13 0.95 
 vehicle 75.8 2.380 2.59 x10
-04
 11.63 8.82 0.99 
43 0.02 17.3 2.380 1.09 x10
-03
 12.05 2.09 0.95 
 0.04 9.6 2.380 1.18 x10
-03
 20.14 1.93 0.56 
 0.08 8.3 2.380 4.03 x10
-03
 6.84 0.57 0.74 
 vehicle 31.9 2.380 9.46 x10
-04
 7.56 2.41 0.97 
44 0.02 19.7 2.373 8.95 x10
-04
 12.99 2.56 0.99 
 0.04 30.7 2.373 1.07 x10
-03
 6.99 2.15 0.98 
 0.08 - - - - - - 
 vehicle 66.8 2.373 3.47 x10
-04
 9.87 6.59 0.98 
45 0.02 26.6 2.568 3.81 x10
-04
 20.48 5.45 0.95 
 0.04 24.4 2.568 5.38 x10
-04
 15.81 3.85 0.98 
 0.08 9.9 2.568 9.84 x10
-04
 21.30 2.11 0.86 
 vehicle 104.6 2.568 2.41 x10
-04
 8.21 8.59 0.99 
46 0.02 28.3 2.852 6.05 x10
-04
 10.71 3.03 0.94 
 0.04 22.7 2.852 1.03 x10
-03
 7.84 1.78 1.00 
 0.08 14.5 2.852 1.84 x10
-03
 6.88 1.00 0.98 
 vehicle 66.9 2.852 6.86 x10
-04
 3.99 2.67 0.97 
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Discussion 
An economic analysis was used in order to ascertain the relative reinforcer efficacy 
of orally self-administered MDMA.  Of interest were three key factors, firstly could 
the responding (and thus reinforcing strength) for MDMA-containing solutions be 
separated from its parent vehicle compound, in this case saccharin solution.  Initial 
studies (see Chapter 3) revealed that responding for the vehicle alone promoted 
higher rates of responding than did the drug-containing solutions thus further 
analysis was necessary to determine whether saccharin represented more a 
desirable commodity than MDMA when a subject was forced to defend access to 
that commodity.  Secondly, of interest was whether the relative reinforcing efficacy 
of orally administered MDMA would conform to a single function of reinforcing 
strength that could be best described by a single demand function.  That is, does 
the relative reinforcing efficacy represent a measurable property of the drug itself 
when factors such as dose and potency are eliminated?  Finally, recent advances in 
the field have led to a novel model of economic demand.  To date few studies have 
tested the suitability of the model, thus a comparison was made between the 
exponential demand model and that of models and analyses used previously in the 
literature.       
Results from Chapter 3 indicated that response rates for saccharin were higher or at 
least comparable to levels of responding for MDMA-containing solutions.  However 
it was expected that when exposed to economic constraint, such as increased FRs 
used in the current experiment, that responding for MDMA would be more resistant 
to increased constraint than would the vehicle alone.  In economic terms, MDMA 
responding should be more inelastic thus animals will defend their access more 
strongly than they would for the drug-free solution.      
Initial analysis of the data revealed that both reinforcers earned, and responses per 
session as a function of dose, were higher for saccharin than they were for any of 
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the MDMA doses.  However, the FR value at which peak responding occurred was 
greater for MDMA than it was for saccharin suggesting that subjects were defending 
their access to MDMA more strongly than saccharin alone.  Economic analyses 
using the linear elasticity model (Equation 4.1) showed that MDMA at the 0.02 and 
0.04 doses did indeed show a higher Pmax than did the vehicle alone, though the 
differences were relatively small and not significant. 
Further analysis was conducted using the normalized demand model (Hursh & 
Winger, 1995) in order to directly compare the elasticity of both MDMA and 
saccharin.  The normalization procedure had been shown to be a robust method for 
comparing elasticity across different commodities.  By eliminating overall level of 
demand and plotting data as a proportion of baseline for that commodity at minimal 
price it allows for the direct comparison of elasticity by using normalized Pmax to 
compare demand functions.  The normalization procedure had been demonstrated 
to facilitate comparison of relative reinforcer efficacy across drugs of differing 
potency as well as drugs of different classes (e.g. stimulants versus opioids) (Hursh 
& Winger, 1995) and to compare demand for qualitatively different foods such as 
normal, puffed and honey puffed wheat in hens (Foster et al., 2009) or food and fat 
in rats (Madden, Smethalls, Ewan & Hursh, 2007).  The current study sought to use 
the normalization procedure to disentangle the reinforcing properties of MDMA from 
the reinforcing properties of the vehicle solution it was presented in.  Doing so would 
add a valuable tool that would further help in studies of oral drugs of abuse where 
drugs are sometimes presented in a compound reinforcer made up of drug and non-
drug components.  Differentiating between the relative contributions of each part of 
this compound reinforcer can sometimes be difficult, so a quantifiable method of 
elucidating these differences would be a promising step. 
It was expected that the addition of MDMA to the saccharin vehicle would increase 
the reinforcing efficacy of the solution and that this increase would manifest as an 
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increase in inelastic demand measured by Pmax, a measure that has been used to 
quantify relative reinforcer efficacy for drugs of abuse previously.  However, 
normalized demand plots analysed using Equation 4.6 showed that saccharin 
produced a higher Pmax than did MDMA indicating that despite predictions to the 
contrary subjects defended their access to saccharin more strongly than they did for 
MDMA.                   
The same data was subsequently analysed with the more recent exponential model 
proposed by Hursh and Silberberg (2008) to the same ends.  Saccharin produced 
higher normalized Pmax values than did each of the MDMA-containing solutions.  
Concordant with the Pmax data, α values (the rate constant of the exponential) were 
lower for saccharin (indicating slower decay) than they were for MDMA.  Much like 
the normalization procedure, the exponential model examines demand as a function 
of normalized space, so it not surprising that the results from fits of Equation 4.6 and 
Equation 4.5 produced similar results. 
Contrary to expectations MDMA produced a lower relative reinforcer efficacy as 
measured by Pmax in the linear-elasticity model and α (Hursh and colleague‟s 
„essential value‟) in the exponential demand model than did saccharin when 
consumption and price were normalized.  Rather than the addition of MDMA to the 
solution increasing demand it instead decreased demand by both decreasing overall 
levels of intake (approximated by L in the linear model and Q0 in the exponential 
model) but also by increasing elasticity.  That is, MDMA-containing solutions 
produced lower overall intake and were also more sensitive to price increases.  A 
decrease in overall levels of intake was somewhat expected due to MDMA-
containing solutions producing drug effects that the vehicle condition did not.  
Evidence from both the current study and Chapter 3 suggested that the animals 
were titrating their intake of MDMA as a function of dose, that is consumption was 
increased as dose was decreased and vice versa.  Titration of MDMA dose was 
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supported by unit price analyses where subjects maintained similar rates of 
consumption of MDMA (mg/kg) such that consumption (mg/kg) plotted as function of 
unit price (price per mg/kg) conformed to a single function.  However, relatively 
more elastic responding evidenced during MDMA conditions compared with vehicle 
was unexpected and difficult to reconcile.  It seems unlikely that aversive drug-
specific consequences are the cause of the increased elasticity as consumption is 
decreased more so at larger FR requirements thus aversive effects of the drug 
would be lower than responding at low FR requirements.  One explanation for 
MDMA‟s lower elasticity may be that rather than the supposed drug effects, subjects 
are in fact responding as a function of taste.  Though the MDMA solutions were 
adulterated with saccharin to ameliorate taste related responding it remains 
plausible that some identifying taste remains.  If the taste of the solutions were 
indeed aversive and this aversiveness changed as a function of concentration of 
MDMA then it would be expected that different doses of MDMA would produce 
distinct demand curves (when normalized) rather than conforming to a single 
function.  There is some evidence to suggest that this may be case with both the 
unit price and normalized demand functions indicating that the 0.08 dose of MDMA 
was generally not as well described by the fitted functions.  However in both cases 
the functions for the 0.02 and 0.04 dose of MDMA were well described by the model 
and seem to produce a single unitary function of demand.  However, inspection of 
demand curves for the exponential analysis reveals that there was a significant 
systematic decrease in Pmax and an increase in α as a function of dose, suggesting 
that as dose increased elasticity also increased.  This systematic change in 
elasticity for dose may be indicative of the animals‟ responding being sensitive to 
the increases in the concentration of MDMA that resulted in a change in the taste 
rather than being sensitivity to the reinforcing effects of MDMA per se.  It must be 
noted that the doses of MDMA used in this study were substantially smaller than 
those used previously so it cannot be confirmed that the drug itself was producing 
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reinforcing effects with the concentrations tested.  Due to the relatively low doses of 
MDMA used in this study it is possible that MDMA intake falls along the ascending 
(rather than the descending) portion of the dose-response curve.  If this were the 
case then MDMA reinforced behaviour could possibly be masked by the saccharin 
when MDMA doses were below threshold for the occurrence of reinforcing effects; 
leaving taste of the resulting solutions as the sole differentiating factor.  However it 
should be noted that a five-fold change in concentration did not appreciably change 
the dose-response curve for oral MDMA between Experiments 3.2 and 3.3 (though 
in the first case MDMA was mixed with water and in the second case MDMA doses 
were adulterated with saccharin that may have aided in palatability despite the 
change in MDMA concentration).  It seems likely that taste would have a larger 
effect during the course of Experiment 3.2 when solutions were not adulterated, yet 
total intake of MDMA stayed relatively constant across each of those experiments.   
An alternative and more likely explanation for the current findings is that oral MDMA 
represents a weak reinforcer and thus does not promote greater inelastic 
responding than saccharin (a reinforcer in its own right) as was predicted.   
The second point of interest for this study was how well each of the behavioural 
economic models would fit the self-administration data for orally delivered MDMA.  
Specifically of interest was whether data from multiple doses could be extrapolated 
and described with a single function which might represent a unitary measure of 
relative reinforcer efficacy for MDMA when delivered orally.  To serve this purpose 
various models and analyses were fitted to the obtained data.  Bickel and 
colleagues (Bickel et al., 1990; DeGrandpre, Bickel, Hughes, Layng & Badger, 
1993) suggest that unit price presents a “useful metric” for studying drugs of abuse 
as it allows for reinforcer magnitude (i.e. dose) to be removed from the equation on 
the assumption that changes in dose (reinforcer magnitude) and changes in 
response requirement are equivalent operations.  Unit price, operationalised in self-
177 
 
administration studies as responses per mg/kg allows for multiple doses of drug to 
be plotted simultaneously as a single demand function.  The advantage of data that 
can be plotted as a single function is that it indicates that all doses of a drug share 
what is effectively the same relative reinforcer efficacy and allows a direct 
quantification of relative reinforcer efficacy for the purposes of comparisons within 
and across other drugs of abuse.        
Obtained data from the oral-self administration of MDMA when transformed into 
average total intake per day and plotted as function of unit price did indeed produce 
a function that was well described by the model (R2 = 0.92) (see Figure 4.5).  
However, unit price represents an absolute measure of the reinforcing efficacy of a 
given commodity and assumes that the commodity is scalar such that the unit price 
model assumes that consumption changes linearly as a function of the scalar 
variable (e.g. drug dose, grams of food, concentration etc.).  For drug doses these 
assumptions only hold true as long the drug being examined is measured in the 
same part of the dose response curve.  For example, it might be expected that drug 
doses measured from the ascending and descending sequences of the 
dose-response curve would produce differing values for reinforcer efficacy that 
might be more appropriately modelled as separate functions.  For example, Winger 
(1993, see also Hursh & Winger, 1995) found that a low dose of iv self-administered 
cocaine produced a unit price demand function that was not consistent with two 
larger doses tested in the same rhesus monkeys.  The current data (see Figure 4.5) 
also provide some support for this as the 0.08 MDMA dose (Pmax (0.08) = 153.51, 
R2 = 0.96) appears to more elastic than the other two doses (Pmax (0.02+0.04) = 659.02, 
R2 = 0.99). 
Unfortunately while unit price presents a nice conceptualisation of the reinforcing 
efficacy of MDMA and other drugs of abuse it is difficult to directly compare the 
elasticity of one drug with another (or other commodity) due to overall differences in 
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potency (level of demand) across drugs.  Hursh and Winger (1995) instead 
proposed a normalization procedure as an alternative to unit price that used 
consumption relative to baseline rather than absolute measures such as unit price.  
By normalizing demand across commodities it provides a way of directly comparing 
elasticity of a drug without potency contributing as a factor.  This allows a direct 
comparison of the sensitivity to changes in price and allows Pmax values to be used 
as a direct measure of relative reinforcer efficacy.   
Much like the unit price analysis the normalization procedure produced a relatively 
good fit (R2 = 0.88) to the obtained oral MDMA self-administration data collected 
during this study and ultimately does a good job of representing the relative 
reinforcing efficacy of oral MDMA when tested under these conditions.          
 
 
             (4.7) 
 
In a recent contribution to the literature Hursh and Silberberg (2008) proposed an 
exponential model as an alternative to the conventional linear elasticity model.  The 
primary advantage according to the authors was that elasticity is described through 
the use of a single free parameter, α.  In contrast, the linear elasticity model uses 
two parameters to describe elasticity as shown in Equation 4.7, the initial slope b 
and the rate of change of the curve, a.  Elasticity changes as linear function of price 
(P) since the parameters a and b are fixed for each demand curve (Hursh & 
Silberberg, 2008).  While the linear elasticity model can be summarised to produce 
a single estimate of elasticity by using Pmax, Hursh and Silberberg suggest that the 
single parameter exponential model fulfils the goal of a producing a more 
parsimonious model with a single measure of elasticity of demand.  This measure, 
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α, is described by Hursh and Silberberg as representing the „essential value‟ of a 
commodity thusly due to its close correlation with other demand measures can be 
substituted as a measure of relative reinforcer efficacy.         
The current study sought to test and compare the linear elasticity and the 
exponential models of demand.  The exponential model produced a good 
description of the data with fits of the group data accounting for at least 98% of the 
variance.  The data was also in accordance with fits of the normalized demand 
model and similarly produced the highest relative reinforcer efficacy for the 
vehicle-alone condition compared with MDMA-containing solutions. 
In fitting the exponential model to the oral MDMA self-administration data k was set 
to the log of the maximum range of consumption for each of the analyses.  The k 
parameter represents a scaling parameter and effectively constrains the asymptotes 
of the exponential function.  In order to allow the direct comparison of each demand 
curve Hursh and colleagues suggest that the k value for those comparisons should 
be the same.  In all cases this resulted in the k value being set to the range of the 
vehicle condition as it possessed the greatest range in consumption as a function of 
price.  While this solution produced adequate fits of the both group and individual 
data it should be noted that variations in the k parameter can have a direct effect on 
the results obtained.  Foster et al. (2009) tested exponential model as a means of 
measuring demand for qualitatively different foods in hens and found that fitting the 
model with a range of k values resulted in changes not only in the α parameter itself  
but also in the orders with which the three commodities were arrayed.  As a 
comparative tool for measuring relative reinforcer efficacy this presents a potential 
problem as fits within studies, and certainly across studies, will vary based on the k 
value with which the functions are fit.  This may prevent α values being directly 
compared across studies which would be a benefit in the process of cataloguing 
relative reinforcer efficacy across a range of drugs and classes (a function 
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potentially more suited to the normalized demand model where no scaling 
parameter is necessary).  Indeed the range of k values used in published studies 
varies widely across studies.  In order to compensate for this potential shortcoming 
it seems prudent that where possible that raw data be published in order to allow for 
subsequent authors to refit analyses with k values appropriate to both new and old 
data sets where comparisons are necessary or warranted.            
Christensen et al. (2008b) present an interesting test of the exponential model of 
demand.  In their study the authors sought to examine cocaine escalation data 
previously reported by Ahmed and Koob (1998).  In Ahmed and Koob‟s study they 
found that rats given 6-hours access to cocaine self-administration (long access) 
produced a markedly different profile of self-administration than those animals that 
had only a 1-hour (short access) daily access to cocaine.  The animals in the long 
access group showed escalation of cocaine intake over the course of training and 
showed an upward shift in the dose-response for cocaine in contrast with those in 
the short access group.  Christensen et al. (2008b) reanalysed Ahmed and Koob‟s 
data within and economic context and found that cocaine produced a higher 
essential value (lower α) in the long access subjects compared with those in the 
short access group.  They further studied this effect by re-determining demand 
curves for food and cocaine for rats who had previous experience from a prior study 
(Christensen et al. 2008a).  Interestingly they found that essential value for cocaine 
increased as a function of the second demand curve analysis while essential 
demand for food remained the same.  This illustrates an interesting approach to the 
disambiguation of the differences between drug reinforcers and biological 
necessities like food.  Within the context of the current study this approach may 
provide a way to further examine the reinforcing effects of MDMA and provide 
support for the reinforcing effects of MDMA independent of the reinforcing effects of 
the vehicle.  Specifically, if replicating the demand analysis resulted in increases in 
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essential value for MDMA, but not the vehicle conditions then those changes would 
be attributable to MDMA‟s effect as drug reinforcer and not to the effects of taste or 
the vehicle solution it was presented in.   
Though still it‟s in infancy, the exponential model provides another robust tool for the 
economic analysis of behaviour.  It appears that the new model shares a strong 
correspondence with the earlier model in that the results and predictions remain 
largely similar across applications of each model.  That the exponential model 
achieves this despite using a single parameter is a distinct advantage of that model 
over previous iterations.  Though desirable it may be too early to tell whether the 
exponential demand model can be repurposed specifically for providing 
rank-ordered and detailed analysis of the relative reinforcing efficacy of multiple 
compounds and across many classes of drugs of abuse.  As recommended by 
Bickel and colleagues (Bickel, Marsch & Carroll, 2000; Johnson & Bickel, 2006)   
adopting behavioural economic models as standard practice for the analysis of the 
relative reinforcer efficacy is worthy and allows for comprehensive testing of the 
abuse liability of drugs of abuse across a variety of dimensions. 
In this chapter behavioural economic analysis was conducted on the oral self-
administration of MDMA.  The analyses revealed that care must be taken when 
conducting economic analyses as different methods and models can provide 
different conclusions and support different interpretations of the data.  Initial analysis 
of the data indicated that MDMA functioned as a stronger reinforcer by supporting 
responding to higher FR requirements than did the saccharin-vehicle alone.  
However, when data was normalized in order to allow direct comparison across 
commodities this effect was instead reversed, suggesting that the vehicle itself 
functioned as a stronger reinforcer.  Further research is necessary to more clearly 
understand the relationship between the reinforcing properties of oral MDMA and 
that of saccharin.  Of particular importance is research investigating demand for 
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MDMA and saccharin when available under concurrent schedules.  Under such 
conditions more conclusive results might be found with regard to the reinforcing 
efficacy of oral MDMA in comparison with the separate schedules method employed 
during the current study.     
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Chapter 5 GENERAL DISCUSSION 
Meisch and Carroll (1987) identify three key factors in determining whether an oral 
drug serves as a positive reinforcer or not.  Firstly, the drug must maintain 
behaviour consistent with that shown under intermittent schedule performance.  
Secondly, the drug should produce orderly dose-response functions.  That is, the 
drug should show evidence of an inverted U dose-response function or at the very 
least evidence of the ascending or descending portions of the dose-response curve.  
Finally, behaviour for the drug solution should exceed that of its component vehicle 
solution.  The current thesis sought to examine MDMA as oral reinforcer and the 
results found herein generally conform to the guidelines outlined by Meisch and 
Carroll. 
The current thesis finds support for intermittent schedule performance in two key 
ways.  Behaviour in all operant experiments was maintained on fixed ratio 
schedules of performance and subjects responded across all conditions tested in 
order to gain access to reinforcers (irrespective of dose).  Crucially, when FR was 
manipulated during Experiment 4.1 subjects produced FR-dependent responding; 
that is, as the FR was increased total session responding increased then decreased 
as a bitonic function of FR as expected.  Overall response rates for the experiments 
tested above were relatively low when tested across the entire session however; in 
general, subjects showed differences in response rate across the course of the daily 
sessions that was both dose- and FR-dependent.  Responding primarily occurred 
during the first part of daily sessions with lower response rates during the latter 
portions of each session (see Figure 3.10).  It might be expected that in Experiment 
3.2 that responding for water-alone would decrease during the course of each 
session due to satiation of thirst-induced responding.  The decrease in responding 
over the latter portions of daily sessions for water-alone suggests that that may 
have occurred.  By the same token it may have been expected that animals in 
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Experiment 3.3 responding for saccharin-alone would continue to respond to 
respond at high rates throughout the session for access to saccharin because 
responding would not be inhibited by accumulation or titration of drug dose in that 
condition.  This was not the case and responding for saccharin-alone decreased 
throughout the session at much the same rate as the 0.02 dose of MDMA (data not 
shown).                 
Meisch and Carroll‟s (1987) second proposition posits that orderly concentration 
response curves must be demonstrated in order firmly conclude that that a given 
oral drug is functioning as a reinforcer.  Experiment 3.2 clearly demonstrated that 
orderly dose-response functions were found for the oral self-administration of 
MDMA.  Group averages (and to a lesser extent individual subject data) produced 
orderly dose response functions indicating increased responding as a function of 
decreases in dose.  Individual-subject data was more variable but generally subjects 
showed orderly functions of dose (with the exception of a single animal who no 
evidence of dose-dependent responding).  The data obtained from Experiment 3.2 
is indicative of titration of drug levels during daily sessions and is representative of 
the descending portion of the dose-response curve.  Experiment 3.2 did not produce 
an inverted U-shaped function of dose and found no evidence representative of the 
ascending portion of the dose-response function.  It is likely that the ascending 
portion of the dose-response function was masked by responding for the vehicle 
condition (water) which remained high due to animals being tested under water-
deprivation conditions.  Hence any further decreases in dose served to make the 
solution more vehicle-like.  Because responding for water-alone was high, lower 
concentration MDMA solutions would be expected to maintain rates similar to those 
seen for the vehicle-alone.  It is likely that the animals would continue to respond for 
access to water component of the solution even as the reinforcing magnitude of 
MDMA is decreased (as would be expected for doses along the ascending portion 
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of the dose-response curve).  A similar pattern of results was found during 
Experiment 3.3 when subjects were instead tested with various doses of MDMA in a 
vehicle of 0.2% saccharin solution.  Again both group averages and individual 
subjects showed orderly dose-response functions indicating increased responding 
as a function of decreases in dose.  Furthermore, MDMA intake as a function of 
dose was highly correlated across Experiment 3.2 and 3.3 for individual subjects (r 
= 0.798, n = 12, p = 0.01) despite a number of fundamental changes in 
experimental procedure.  For example, in Experiment 3.3 subjects responded for 
MDMA in a saccharin vehicle solution whereas Experiment 3.2 used water as the 
vehicle (in water-deprived rats).  The use of a saccharin vehicle allowed for subjects 
to have free access to water in the home cage, removing the necessity of water 
deprivation during the earlier experiment.  In addition, higher dose, but smaller 
magnitude (0.1cc versus 0.02cc) reinforcers were used during Experiment 3.3.  
Despite these fundamental differences subjects showed generally similar MDMA 
intake across the experiments.  Like Experiment 3.2 before it, Experiment 3.3 also 
found orderly dose-response functions representing only the descending portion of 
the dose-response curve.  When tested with low FR values (FR4) it appears that 
saccharin is a highly regarded reinforcer in its own right, thus much like Experiment 
3.2 the saccharin vehicle may have masked the ascending portion of the dose-
response curve.  Experiment 3.4 served two purposes; (1) examine the effect of the 
D1 antagonist SCH23390 on oral MDMA self-administration and (2) test a lower 
range of MDMA doses for oral self-administration in order to more fully examine the 
ascending portion of the dose-response curve.  Daniela et al. (2004) showed that 
pre-treatment with of SCH 23390 shifted the dose-response curve for iv self-
administration to the right.  However, pre-treatment with SCH 23390 to rats orally 
self-administering MDMA instead produced a non-specific decrease in responding 
across all doses, and crucially, the vehicle-alone condition.  Rather than shifting the 
dose-response curve as expected SCH 23390 abolished responding for all doses 
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suggesting that SCH 23390 may have decreased motivation to respond for all 
conditions.  However, pre-treatment with SCH 23390 did demonstrate that 
responding for oral MDMA in saccharin was sensitive to challenge by 
pharmacological and not just behavioural methods.  Experiment 3.4 used a different 
dose range from used in Experiments 3.2 and 3.3.  The purpose was to further 
examine whether oral MDMA in saccharin would demonstrate an inverted U-shaped 
dose-response curve.  Unfortunately, there was still no definitive evidence for the 
ascending portion of the dose-response curve with doses as low as 0.003mg/kg of 
MDMA.  However, Experiment 3.4 did produce data consistent with the descending 
arm of the dose-response curve and indeed consistent with those produced 
previously for Experiments 3.2 and 3.3 despite a different dose range and 
inexperienced animals.                                           
In contrast to the operant self-administration methods, Experiments 3.1A and 3.1B 
used concurrently available water and MDMA during a free-access task.  All 
subjects developed a clear preference for the water-containing bottle over that of 
the MDMA-containing solution.  Though animals continued to sample from the 
MDMA containing solution it is unclear to what extent the taste of the unadulterated 
solution affected this preference.  In addition, only a single dose of MDMA was 
tested in conjunction with plain water, thus no dose-effect evaluations were able to 
be conducted.  An adapted form of the task used in Experiment 3.1 might prove 
useful for demonstrating dose-effect relationships for consumption of oral MDMA in 
the homecage.  Specifically, the procedure should use a three-bottle test rather than 
two.  In one bottle, plain water would be available.  The second bottle would contain 
MDMA solutions in a saccharin vehicle (to aid in palatability).  The final bottle would 
contain plain saccharin and would serve as a control for drinking from the MDMA-
containing solution.  The presence or absence of the third bottle would allow for the 
analysis of changes in MDMA consumption as a function of availability of an 
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alternative reinforcer that may act as a partial substitute.  The key effect of using 
easily flavoured solutions for the drug and alternative reinforcer is that the animal is 
free to consume water necessary for survival independent of the manipulated drug 
solutions.  In addition multiple doses of MDMA should be made available in order to 
measure dose-effect relations for consumption of oral MDMA.           
The final feature key attribute outlined by Meisch and Carroll (1987) is that rates of 
drug maintained behaviour for the drug-containing solutions must exceed that of the 
parent vehicle solution whether presented concurrently (as they were in Experiment 
3.2A & B) or sequentially such as in Experiments 3.2, 3.3, 3.4 and 4.1.  Chapter 3 
provided mixed evidence for this proposition.  In the free-access choice paradigm 
water was always preferred to MDMA; though in that case drinking of water was 
related to survival while drinking of the drug solution was not.  The expectation that 
drinking of drug solutions should be higher in that case would be erroneous.  
Typically the lowest dose of MDMA used in Experiments 3.2, 3.3 and 3.4 
approached but did not exceed the rate of vehicle maintained behaviour and other 
doses produced total responding lower than that of the vehicle-alone.  In all three 
studies the vehicle solution acted as a reinforcer in its own right and maintained 
generally high rates of responding.  On the surface using Meisch and Carroll‟s 
criteria suggest that oral MDMA does not function as a reinforcer under the 
conditions tested during Chapter 3.  Meisch and Carroll‟s third criteria can be 
examined as rather simplistic view of the strength of a reinforcer as studies of the 
overt behaviour can sometimes mask underlying elements that are revealed only 
under conditions of challenge.  In Experiment 4.1 reinforcement with oral MDMA 
and vehicle alone was challenged under economic constraint.  Behavioural 
economic demand functions were fit to data obtained when FR (price) was varied.  
In this way elasticity (sensitivity to changes in price) was used as a measure to 
distinguish between demand for MDMA + saccharin from saccharin-alone.  If indeed 
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MDMA functioned as a reinforcer it was expected that MDMA-containing solutions 
would show more relative elasticity than the vehicle-alone.  However, using a variety 
of analyses and two different behavioural economic models this proposition was 
shown to be tenuous at best.  Though simple forms of analysis revealed that MDMA 
may indeed represent more inelastic demand than saccharin-alone, these effects 
were reversed when data was analysed using normalization procedures.  When 
normalized demand curves were compared for MDMA and saccharin-alone, it was 
the saccharin-alone rather than the MDMA-containing solutions that were defended 
more strongly as a function of increasing price.     
Alternative Approaches and Future Directions 
Concurrent Schedules 
An alternative method not utilised in the current thesis that warrants further 
examination would be the analysis of the effect of economic constraint under 
concurrent schedule performance.  That is study the effect of price increases to 
either or both MDMA and vehicle when both commodities are available during the 
same session. 
To illustrate, we again turn to the classic study of Elsmore et al. (1980).  In their 
study Baboons were given concurrent access to intravenous heroin or food.  Using 
a discrete trials procedure income (number of opportunities to choose between the 
two reinforcers) was manipulated by increasing the inter-trial interval (ITI) between 
choices.  When the ITI was low and income was plentiful subjects chose heroin 
more often than food.  However as the ITI was increased and income was 
decreased subjects responded more for food at the expense of heroin.  In effect the 
subjects showed a preference reversal where the initially favoured alternative 
(heroin) decreased as a function of economic constraint in favour of the other 
alternative (food).  In this case food was more inelastic than heroin.  This study 
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illustrates that the presence of alternative reinforcers can change the elasticity of 
other reinforcers.  Environmental events (including the presence of other 
reinforcers, economy etc.) can thus affect the elasticity of commodity and as such 
elasticity cannot be thought as inherent property of that commodity (Petry & 
Heyman, 1995).  Thus far this thesis has only considered elasticity of demand as a 
function of changes in price for itself, more correctly termed own-price elasticity 
(Allison, 1979; Petry & Heyman, 1995).  However, elasticity can also be measured 
as a function of proportional change in consumption as a function of changes in 
price of an alternative commodity, termed cross-price elasticity (Allison, 1979; 
Hursh, 1980, 1984; Bickel et al., 1995; Petry & Heyman, 1995).  Interactions 
between reinforcers form a continuum spanning three categories: substitutes, 
complements and independents (Bickel et al., 1995).  A commodity that acts as a 
substitute would exhibit increased consumption as function of increased price in the 
alternative commodity while its own price remained fixed.  For example, price 
increases in a commodity (e.g. Coca-cola) would result in an increase in 
consumption for a different alternative (e.g. Pepsi) that provides similar effects 
(Bickel et al., 1995).  Conversely a complement would exhibit decreased 
consumption as a function of increasing price of the alternative reinforcer and vice 
versa.  Finally independent commodities show no changes in consumption as result 
of changes in price of an available alternative.  Note that the relationships between 
concurrently available commodities are not always reciprocal and can produce 
asymmetrical relationships between commodities (Bickel et al., 1995). 
Petry and Heyman (1995) examined the effects of concurrently available ethanol in 
sucrose and sucrose-alone by manipulating the price of either the ethanol mix, 
sucrose or both.  When the price of the ethanol  mix was manipulated by increasing 
the VR schedule subjects evidence of increased responding, suggesting that 
responding for ethanol was inelastic (at least for modest increases in price).  As the 
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price of ethanol increased sucrose intake remained relatively constant suggesting 
that sucrose responding was independent of the price changes for ethanol.  When 
the price of sucrose was manipulated, sucrose responding declined even with 
modest increases in price suggesting sucrose responding was elastic, at the same 
time responding for the fixed price alternative, ethanol, increased suggesting that 
the ethanol mix acted as a substitute for plain sucrose.  When the price of both 
ethanol and sucrose was increased subjects typically showed inelastic demand for 
both commodities at low prices but as price continued to increase responding 
predominantly on the ethanol-associated lever suggesting that the ethanol mix was 
inelastic and responding for sucrose was elastic.  Similarly, Williams and Woods 
(2000) offered concurrent access to ethanol or water in Rhesus monkeys when 
baseline responding for ethanol was either higher (2% EtOH), equal (8% EtOH) or 
lower (32% EtOH) than water-maintained responding.  They found that as price 
increased for both commodities ethanol responding was more resistant to increased 
price than was water for all three conditions.  When baseline ethanol responding 
was lower than baseline water consumption increasing price resulted in a 
preference reversal from water to ethanol.  This highlights the importance of 
measuring preference across a large range of prices as making a single 
measurement at a low fixed price would lead to the assumption that water was more 
reinforcing than ethanol.  However, measuring preference over a higher price range 
revealed that the subjects were more willing to defend their consumption of ethanol 
than water and indicating that in fact ethanol was the more efficacious reinforcer.   
Similar methodology could be utilised to further explore the relationship between 
MDMA and saccharin and may in fact provide support for MDMA‟s function as an 
oral reinforcer in rats.  If it can be shown that price increases for both commodities 
results in a preference reversal from saccharin to MDMA as a function of increased 
economic constraint then it would illustrate that MDMA does provide reinforcing 
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properties over and above that of the vehicle alone.  Additionally, by increasing the 
price of MDMA it can be examined whether saccharin acts as a substitute for 
MDMA and vice versa.  However, use of concurrently available reinforcers 
obfuscates attempts to measure relative reinforcer efficacy across drugs as 
preference reversals make choice procedures inadequate for producing consistent 
and reliable measures of reinforcer value (Madden et al., 2007). 
Resistance to Change   
Resistance to change is an alternate method through which differences in strength 
of reinforcers can be assessed, one which could be further used to examine 
differences in reinforcer strength between MDMA-containing and vehicle solutions.  
Resistance to change is a measure of how insensitive behaviour is to disruption by 
an extraneous source.  Behavioural momentum theory (Nevin, Mandell & Atak, 
1983; Nevin & Grace, 2000) uses the analogy of Newton‟s laws of motion and 
relates momentum to reinforced behaviour whereby baseline response rate is 
analogous to velocity and resistance to change is analogous to mass.  Using this 
analogy, reinforcers that maintain similar response rates can be differentiated in 
strength by instead measuring disruption caused by change (e.g. extinction, non-
contingent reinforcer presentation) relative to baseline response rate.  For example, 
Nevin and Grace (2000) use the analogy of a two concrete walls.  One wall is 
reinforced with steel rods (equivalent to increased mass).  On the surface both walls 
appear as strong as one another (by analogy both have the same velocity); however 
it is not until a disruptive force is applied such as a wrecking ball that the differences 
in strength of the walls become apparent.  The wall that has been reinforced with 
steel is more resistant to the effects of the wrecking ball and thus represents the 
stronger of the two walls.  By further analogy if both walls were reinforced with steel 
the wall that has more steel reinforcing will be more resistant to demolition.  
Behaviours are said to work the same way and “…more frequently or generously 
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reinforced behaviour becomes more resistant to challenge or disruption, and this 
increase in its resistance need not imply an observable increase in the rate or 
probability of currently observed behaviour. Instead, the strengthening effects of 
reinforcement may be evident only when responding is disrupted in some way” 
(Nevin & Grace, pp 75).  Resistance to change is proportional to response strength, 
that is, reinforcers that are more frequent, larger or less delayed produce more 
persistence, or more resistance to disruption.  For example, response strength can 
be increased either as a function of an increase in the rate of reinforcement or by a 
change in the magnitude of reinforcement (Nevin, 1974).   
Results from studies using drugs as reinforcers are consistent with previous 
research on resistance to change.  For example, rats trained to self-administer 
ethanol showed more resistance to extinction in the rich component of a multiple 
schedule than they did in the lean schedule (Jimenez-Gomez & Shahan, 2007).  In 
a related experiment, Shahan and Burke (2004) showed that non-contingent 
presentation of food in one component of a multiple schedule for ethanol self-
administration resulted in decreased response rates, but also an increase in 
resistance to extinction.  Recently, Quick and Shahan (2009) showed that these 
results generalised to iv self-administration of cocaine.   
Resistance to change could be used as a way of distinguishing the strength of 
MDMA from that of the vehicle itself.  If the additive effects of MDMA plus vehicle 
produced a more efficacious reinforcer (i.e. a higher magnitude) than just vehicle-
alone it should be possible to delineate those differences by examining changes in 
persistence after disruption (e.g. extinction).  Traditionally resistance to change is 
measured using multiple schedules where subjects will respond under alternating 
schedules accompanied by unique discriminative stimuli.  In this way response rates 
and reinforcer magnitudes can be varied relative to one another and the presence of 
the disrupter will be equal for both components of the multiple schedules.  However, 
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in order to use resistance to change the current paradigm for the oral self-
administration of MDMA would need to be further adapted.  Traditionally resistance 
to change research has utilised variable interval schedules of reinforcement over 
ratio schedules.  The advantage of variable interval schedules is that reinforcer rate 
is not confounded with response rate as it is in FR schedules (Nevin, 1995).    
Behavioural momentum theory suggests that what is important is not absolute 
changes in response rate, but instead changes in response rate relative to baseline.  
If MDMA solutions had higher response strength it would manifest as a difference in 
the proportional change from baseline responding (for a given drug dose) versus 
response rate during extinction at that given drug dose.  Specifically, if MDMA is 
acting as a reinforcer, then proportion of change (baseline versus extinction) should 
be smaller for higher versus lower doses.  In a comparison between drug-containing 
solutions and vehicle-alone it would be predicted that the addition of the drug to the 
solution would make it a stronger reinforcer than the solution without MDMA.  Thus, 
it would be expected that MDMA would produce higher resistance to change, 
manifesting as higher responding during extinction relative to the vehicle on its own.     
Furthermore, tests of concurrently available solutions including drug/drug and 
drug/vehicle will likely provide stronger evidence for response strength as measured 
by resistance to change.                                         
Conditioned Place Preference 
A large body of literature has used Conditioned Place Preference (CPP) to measure 
the motivational effects of drugs (Tzschentke, 2007), including MDMA (Cole, 
Sumnall, O‟Shea & Marsden, 2003; Meyer et al., 2002; Schechter, 1991).  Briefly, 
CCP has been used to assess the reinforcing properties of drugs of abuse.  Rats 
are given a free choice (preference test) between two sides of a chamber that are 
equipped with unique and distinct environments (contexts) separated by a wall that 
incorporates a removable door.  Each context is then paired several times with 
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either a drug‟s effects (an MDMA injection prior to the conditioning trial for instance) 
or with saline.  The conditioning trials then alternate between drug and saline 
injections with animals always confined to the same compartment for drug pairings 
and the other compartment for saline pairings.   After multiple drug/context pairings 
a further preference test is conducted.  During this test the door is opened and rats 
are free to move between both compartments of the CPP chamber and should 
choose the side of the chamber associated with the most positive effects, in this 
case those of the side paired with exposure to the drug.  Conditioned place 
preference is shown by a shift in preference towards the drug-paired location, such 
that the animal spends more of its time in the compartment that was paired with the 
subjective effects of the drug. 
As part of the data collected for this thesis, CPP was seen as a suitable way to 
directly compare the reinforcing effects of MDMA when delivered across a variety of 
routes of administration.  To this end initial studies were conducted to examine the 
suitability of the task.  Initially, CCP was examined using ip injection and three 
doses of MDMA; 0.25, 5.0 and 10.0mg/kg.  Each drug dose received four pairings 
and saline received an identical number on alternate days in the opposite 
compartment.  The results indicated a dose-dependent decrease in preference as a 
function of MDMA dose.  That is, rather than animals spending more time in the 
drug-paired compartment during the preference test they instead showed less time 
in the drug-paired compartment, i.e. a conditioned place aversion.  It was thought 
that the speed of onset of the ip injection might produce more aversive 
consequences due to the rapid increase in MDMA-plasma levels (see Baumann et 
al., 2009).  CPP for MDMA was further examined by using the sc route of 
administration and comparing it that of the ip route of administration.  MDMA 
5mg/kg administered ip or sc for four conditioning trials each again indicated the 
presence of a conditioned place aversion.  However, in a subsequent preference 
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test subjects were administered with a further dose of MDMA and allowed to freely 
choose between the two compartments.  Administration of MDMA during the 
preference assessment resulted in a preference toward the compartment that had 
previously been paired with MDMA.  Though these results were not consistent with 
the existing literature, the finding of conditioned place aversion after administration 
of MDMA suggests that the subjective drug effects may be aversive, at least under 
some circumstances.  MDMA-induced CPP seems to be extremely sensitive to 
experimental manipulation.  For example, Diller et al. (2007) found significant place 
preference for MDMA at 5.0mg/kg sc, but not 10mg/kg sc.  Meyer et al. (2002) 
showed that MDMA-induced CPP was sensitive to housing conditions such that only 
rats that had been isolated from other rats prior to conditioning showed a significant 
MDMA-induced place preference.             
It is unclear as to why these exploratory CPP tests failed to find evidence of MDMA-
induced place preference.  The failure to replicate previous literature on MDMA-
induced CPP meant that testing the reinforcing properties of oral MDMA via place 
preference was never examined.  However, further examination of CPP using oral 
administration of MDMA is warranted.    
Behavioural Economics and Demand Curve Analysis 
Bickel et al. (2000) suggest that relative reinforcer efficacy is not a homogeneous 
phenomenon and suggest that the heterogeneous elements typically used for 
measuring relative reinforcer efficacy (i.e. breakpoints on PR schedules, peak 
response rates in single schedules and preference in concurrent schedules) can be 
more appropriately modelled by demand curves that encapsulate differences in 
each of these methods for determining relative reinforcer efficacy.  Measures of 
relative reinforcer efficacy as measured by different tasks should ideally produce a 
convergence across tasks; however often times this has not been the case.  Using 
behavioural economics as a framework it can predicted not only when different 
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methods of measuring relative reinforcer efficacy should coincide, but also when 
there should be divergence (Johnson & Bickel, 2006).  Bickel et al. suggest that PR 
breakpoints, peak response rates and preference correspond to Pmax, Omax and 
relative position of demand curves (especially in cases where the demand curves 
cross) respectively. The use of demand curves for analysing drugs of abuse thus 
incorporates features of each of these alternative methods of measuring relative 
reinforcer efficacy and presents the most robust parametric analysis for comparing 
relative reinforcer efficacy by using behavioural economic methods.    
In this thesis several behavioural economic models were compared.  Each model 
tested produced stable demand curves and data that were mostly congruent with 
other analyses.  The linear-elasticity model (Hursh et al., 1988) has been used 
previously for the analysis many behaviours, including measuring relative reinforcer 
efficacy.  The exponential model of demand (Hursh & Silberberg, 2008) provides a 
fresh approach to the analysis of demand.  The exponential model provides a useful 
theoretical addition to the literature by providing a single measure of „essential 
demand‟.  To date few studies have tested the model and conducted valid 
comparisons between various models using the same data set.  This thesis tested 
the predictions of both the linear-elasticity model with that of the exponential model 
and found an overall correspondence between the two.  Essentially the models are 
based on the same theoretical framework and highly utilise obtained and predicted 
parameter in the similar ways.  However, it is notable that the exponential model 
succeeds at doing this while using less free parameters is to its advantage, thus if 
Occam‟s Razor were to decide the victor in this case the exponential would be the 
victor.  Further tested of cross-model comparisons, in addition to testing predictions 
related to the effects of substitutable and complementary goods are necessary.                    
The current study used the behavioural economic framework in order to analyse the 
relative reinforcing efficacy of MDMA.  Oral doses of MDMA were analysed for two 
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reasons.  Firstly, from previous experience it became apparent that within-subject 
parametric analyses of iv self-administration using behavioural economics was 
complicated by issues of catheter patency.  The limited ability to maintain effective 
catheters (at least in rats) for long periods of time prevented effective use of the 
self-administration procedure for this purpose.  Development of rapid methods for 
demand curve analysis for iv self-administration is both enviable and encouraged 
(though somewhat complicated by long–acting drugs such as MDMA).  The benefits 
of oral administration of MDMA (or indeed) other drugs were that issues of catheter 
patency were removed and thus long-term studies are more tenable.  Secondly, 
MDMA is an oral drug of abuse and thus it merits analysis of how its relative 
reinforcing efficacy changes as a function of route of administration.  The current 
studies indicate that MDMA at least when presented orally is a relatively weak 
reinforcer.  Subjects defended access to plain saccharin more so than saccharin 
solutions containing MDMA.  It is unclear to what extent this result is a factor of 
taste of the MDMA containing solutions.  However, rats will readily consume drugs 
such as ethanol despite a relatively strong and aversive taste (Ator & Griffiths, 
2003). 
Although the current study attempted to quantify the relative reinforcing efficacy of 
MDMA it should be noted that no comparisons were made to other abused drugs.  
Though significant advances in quantification of have been made with approaches 
such as behavioural economics, a comparison with a known quantity (such as 
alcohol via the oral route or cocaine via iv) is important with regard to easing the use 
of across study comparisons of relative reinforcer efficacy. 
Also of significant importance is the comparison of relative reinforcer efficacy across 
routes of administrations.  A comparison of the demand curves for iv and orally self-
administered MDMA would give an indication of how differential pharmacokinetics of 
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each route of administration affects relative reinforcing efficacy and thus MDMA‟s 
abuse potential. 
Intravenous versus oral administration of MDMA 
The current results on the assessment of the relative reinforcing efficacy of oral 
MDMA have proven inconclusive and more research is needed to more clearly 
understand the dynamic interaction between oral MDMA and the vehicle in which 
was delivered.  The studies in the current project were designed to replicate those 
of the intravenous self-administration of MDMA in which MDMA has been shown to 
be an effective (if somewhat low efficacy) reinforcer.  In the iv self-administration 
paradigm cumulative small doses are experienced and the resulting cumulative drug 
effects (and associated positive affective effects) are appropriate for modelling the 
pharmacodynamic effects of MDMA in animals.  An important contrast lies in the 
way that human users normally take the drug, which is large oral doses a small 
number of times per session.  Instead of trying to replicate the animal condition with 
regard to patterns of iv consumption it may be that analyses of oral MDMA exposure 
would be more appropriately based on a more human oriented pattern of use.  That 
is provide the animals with fewer, but larger doses that are more likely to result in 
onset of pharmacodynamic processes and less exposed to attenuation due to 
excessive exposure to pharmacokinetic processes involved in oral administration.       
The present studies indicate that taste may have powerful effects that interfere with 
the analysis of the positively reinforcing effects of MDMA.  The doses used in this 
study were chosen by necessity as higher doses supported little to no responding at 
all.  It is possible that the reinforcing subjective effects of MDMA are not apparent at 
the doses used and that analysis of higher doses of MDMA is necessary.  However 
the taste factor prevents testing of higher doses than those used in the current study 
by the methods chosen.  It may be necessary to adopt induction procedures (such 
as SIPs) in order to increase initial drug intake such that the animals fully 
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experience the reinforcing effects of MDMA.  A number of studies have shown that 
behaviour induced in this way is maintained when the inducing manipulation is 
subsequently removed (Falk & Lau, 1995).  Intragastric administration of MDMA 
may provide a promising avenue of research of the oral effects of MDMA not 
confounded by taste.  In a way, the intragastric self-administration more closely 
resembles the human experience as there is no effect of taste involved.  In humans 
swallowing a pill (the most common method of MDMA use) does not generally 
induce a taste response since any aversive taste is removed almost immediately 
and (generally) not repeated throughout the night.  Also in some cases the pills do 
not even invoke an aversive taste either by adulteration of the pills (i.e. the pill are 
sometimes mixed with sugary or sweet adulterants) or by bypassing of the taste 
buds.  Using intragastric self-administration allows for the use of higher doses than 
those used in the procedure used in the current thesis and can be conducted in an 
identical procedure to that of iv self-administration allowing for direct comparisons 
between the two.  However, like iv self-administration the intragastric method would 
likely prove less reliable for long-term studies like those examining behavioural 
economics.      
Final Thoughts          
Despite MDMA being an oral drug in humans relatively little research has focussed 
on the effects of MDMA when delivered orally.  This thesis presents the first use of 
an operant methodology for the study of the reinforcing effects of MDMA in rats.  
While MDMA maintained dose-response functions typical of other drugs of abuse 
delivered both intravenously or orally, it did not engender higher rates of responding 
than the vehicle in which it was presented.  These results suggest that MDMA may 
act a relatively weak reinforcer in rats when delivered orally.   
In addition, this thesis has been the first to examine the reinforcing effects of MDMA 
using a behavioural-economic analysis.  The behavioural-economic framework 
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provides a powerful analytic tool that can be used to assess the relative reinforcing 
efficacy or abuse potential of drugs of abuse.  This robust source of information can 
then be provided to governments in order for them to make relevant decisions on 
the legality of both old and new drugs of abuse (Hursh, 1991).  This thesis provided 
a comprehensive analysis of the reinforcing effects of oral MDMA using both 
established and novel behavioural economic models. 
The multi-analytic approach used in this thesis suggests that oral MDMA represents 
a relatively weak reinforcer in rats.  However, because of notable differences in the 
way humans take and abuse MDMA that differ from the methods used with animals 
in this study, the current results may under represent the abuse potential of MDMA 
in humans.  Further research is still necessary to more clearly define the reinforcing 
effects of oral MDMA and its implications for MDMA‟s addictive potential in humans.   
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